<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for itch in people with advanced chronic kidney disease - Hercz, D - 2020 | Cochrane Library</title> <meta content="Interventions for itch in people with advanced chronic kidney disease - Hercz, D - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011393.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for itch in people with advanced chronic kidney disease - Hercz, D - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011393.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011393.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for itch in people with advanced chronic kidney disease" name="citation_title"/> <meta content="Daniel Hercz" name="citation_author"/> <meta content="Jackson Memorial Hospital / University of Miami" name="citation_author_institution"/> <meta content="daniel.hercz@gmail.com" name="citation_author_email"/> <meta content="Simon H Jiang" name="citation_author"/> <meta content="Canberra Hospital" name="citation_author_institution"/> <meta content="Angela C Webster" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD011393.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/12/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011393.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011393.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011393.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics [*therapeutic use]; Antipruritics [*therapeutic use]; Pruritus [*drug therapy, etiology]; Randomized Controlled Trials as Topic; Renal Dialysis [methods]; Renal Insufficiency, Chronic [*complications, therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011393.pub2&amp;doi=10.1002/14651858.CD011393.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011393\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011393\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ko","th","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011393.pub2",title:"Interventions for itch in people with advanced chronic kidney disease",firstPublishedDate:"Dec 7, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011393.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011393.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011393.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011393.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011393.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011393.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011393.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011393.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011393.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011393.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9384 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011393.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-sec-0126"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-sec-0018"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-sec-0019"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-sec-0120"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/appendices#CD011393-sec-0131"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/table_n/CD011393StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/table_n/CD011393StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for itch in people with advanced chronic kidney disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/information#CD011393-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Daniel Hercz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/information#CD011393-cr-0005">Simon H Jiang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011393.pub2/information#CD011393-cr-0006">Angela C Webster</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/information/en#CD011393-sec-0136">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 December 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011393.pub2">https://doi.org/10.1002/14651858.CD011393.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011393-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011393-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011393-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011393-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011393-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011393-abs-0004">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD011393-abs-0006">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011393-abs-0001" lang="en"> <section id="CD011393-sec-0001"> <h3 class="title" id="CD011393-sec-0001">Background</h3> <p>Itch in patients with chronic kidney disease (CKD) is common, often very distressing and associated with depression, reduced quality of life, and increased death. The most common first‐line treatment has been the use of antihistamines despite the lack of substantial evidence for its use for uraemic itch. Few recommendations and guidelines exist for treatment. </p> </section> <section id="CD011393-sec-0002"> <h3 class="title" id="CD011393-sec-0002">Objectives</h3> <p>We aimed to determine: 1) the benefits and harms (both absolute and relative) of all topical and systemic interventions for the treatment of uraemic itch, either alone or in combination, when compared with placebo or standard care; and, 2) the dose strength or frequency, stage of kidney disease or method of dialysis used (where applicable) in cases where the effects of these interventions vary depending on co‐interventions. </p> </section> <section id="CD011393-sec-0003"> <h3 class="title" id="CD011393-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 17 December 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD011393-sec-0004"> <h3 class="title" id="CD011393-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) in adults with CKD stages 4 or 5 comparing treatments (pharmacological, topical, exposure, dialysis modality) for CKD associated itch to either placebo or other established treatments. </p> </section> <section id="CD011393-sec-0005"> <h3 class="title" id="CD011393-sec-0005">Data collection and analysis</h3> <p>Two authors independently abstracted study data and assessed study quality. Data were analysed using a random effects meta‐analysis design estimating the relative effects of treatment versus placebo. Estimates of the relative effects between treatments are included where possible. For continuous measures of severity of itch up to three months, mean difference (MD) or standardised mean difference (SMD) were used. When reported, adverse effects were tabulated. The certainty of the evidence was estimated using GRADE. </p> </section> <section id="CD011393-sec-0006"> <h3 class="title" id="CD011393-sec-0006">Main results</h3> <p>Ninety‐two RCTs, randomising 4466 participants were included. Fifty‐eight studies (3285 participants) provided sufficient data to be meta‐analysed. Of these, 30 compared an intervention to a placebo or control. The 10 cm Visual Analogue Scale (VAS) was the dominant instrument utilized for itch reporting and the Duo score was used in a minority of studies. </p> <p>GABA analogues including, gabapentin and pregabalin, reduce itch in patients with CKD (5 studies, 297 participants: 4.95 cm reduction, 95% CI 5.46 to 4.44 lower in VAS compared to placebo; high certainty evidence). Kappa opioid agonists, including nalfurafine also reduced itch in this population (6 studies, 661 participants: 1.05 cm reduction, 95% CI 1.40 to 0.71 lower in VAS compared to placebo; high certainty evidence). Ondansetron had little or no effect on itch scores (3 studies, 183 participants: 0.38 cm reduction, 95% CI 1.04 lower to 0.29 higher in VAS compared to placebo; high certainty evidence). Reduction in the severity of itch was reported with oral montelukast, turmeric, zinc sulfate and topical capsaicin. For all other interventions, the certainty of the evidence was low to moderate, and the interventions had uncertain effects on uraemic pruritus. </p> <p>Six studies have disclosed significant financial support from their respective manufacturers, six were affected by lack of blinding, and 11 studies have 15 participants or less. Older, smaller RCTs often failed to follow intention‐to‐treat protocols with unexplained dropouts after randomisation. </p> <p>Adverse effects were generally poorly and inconsistently reported across all RCTs. No severe adverse events were reported for any intervention. </p> </section> <section id="CD011393-sec-0007"> <h3 class="title" id="CD011393-sec-0007">Authors' conclusions</h3> <p>The RCTs of this meta‐analysis contain a large array of interventions with a diverse set of comparators. For many interventions, trials are sparse. This served to make informative meta‐analysis challenging. </p> <p>Of all treatments for uraemic pruritus, gabapentinoids (gabapentin and pregabalin) were the most studied and show the greatest reduction in itch scores. Further RCTs, even of the scale of the largest trials included in this review, are unlikely to significantly change this finding. Kappa‐opioid agonists (mainly nalfurafine) also may reduce itch, but indirect comparison suggests a much more modest effect in comparison to GABA analogues. </p> <p>Evidence for oral montelukast, turmeric, zinc sulfate, and topical capsaicin also showed an itch score reduction. However, these reductions were reported in small studies, and warrant further investigation. Ondansetron did not reduce itch. It is somewhat unlikely that a further study of ondansetron will change this result. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011393-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011393-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011393-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011393-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011393-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011393-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011393-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011393-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD011393-abs-0007">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011393-abs-0002" lang="en"> <h3>What is the best treatment for itch in people with chronic kidney disease?</h3> <p><b>What is the issue?</b> Itch (medical term pruritus) is a common problem for people with chronic kidney disease (CKD). Itch can greatly affect quality of life and may lead to depression or increased risk of death. There are no widely used or agreed upon treatment guidelines for itch associated with CKD. </p> <p><b>What did we do?</b> We found 92 studies involving 4466 people investigating 30 treatments for CKD‐associated itch. The control treatment was either placebo or (less commonly) another treatment for CKD‐associated itch. </p> <p><b>What did we find?</b> One type of drug (gabapentin and pregabalin), an analogue to a common neurotransmitter appear to reduce itch in patients with CKD. Ondansetron, an anti‐nausea drug, was another well studied treatment and appears have no significant association with itch reduction. Kappa‐opioid drugs (nalfurafine) appear to slightly reduce itch. There is too little information on the remaining treatments for any thorough assessment of their efficacy in relieving itch or whether there is any anti‐itch effect at all. </p> <p>The three drugs mentioned above are well studied with higher quality evidence. The other treatments studied are of lower to moderate quality. </p> <p>The studies seldom document a comprehensive list of adverse or side effects incurred during treatment. However, none of the adverse effects documented were severe. Further meaningful assessment on harm cannot be made. </p> <p><b>Conclusions</b> Drugs that work like neurotransmitters (gabapentin and pregabalin) reduce itch in patients with CKD. Other intervention either do not work, do not work as well, or need further study to make a conclusion. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011393-sec-0126" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011393-sec-0126"></div> <h3 class="title" id="CD011393-sec-0127">Implications for practice</h3> <section id="CD011393-sec-0127"> <p>A large number of interventions were examined in this review. Some treatment modalities appear to be effective in the reduction of uraemic itch, others may be of some possible effectiveness, and several appear to have minimal or no effectiveness. </p> <p>Of all treatments for uraemic pruritus GABA analogues have been studies by the greatest number of RCTs and each have been shown to have the greatest effect size versus all other inventions studied. GABA analogues reduce itch in patients with CKD. Within GABA analogues most of the evidence was for gabapentin with the rest for pregabalin. Even with the removal of pregabalin trials, these results remain consistent. A further RCT, even of on the scale of the largest GABA analogue trials included in this review, is unlikely to substantially change this result. </p> <p>There have not been sufficient RCTs using different dosing regimens to give definitive recommendations about dosage. Both scheduled dosing and titrating dosages frequency occur. </p> <p>Evidence in this review show that Kappa opioid agonists slightly reduce itch in patients with CKD. Additionally, indirect comparisons to other interventions suggest a much more modest effect in comparison to GABA analogues. Nalfurafine is the kappa opioid agonist with the largest and highest quality body of evidence. </p> <p>Ondansetron was also well studied in multiple RCTs, bur does not appear to reduce uraemic itch. This was again with high certainty of evidence. </p> <p>Oral montelukast, turmeric, zinc sulfate, and topical capsaicin all probably reduce uraemic pruritus, but additional high quality evidence is required before a decisive conclusion can be made. </p> <p>Guidelines do not often recommend gabapentin as first line treatment in uraemic itch. Many of the included RCTs note that it is often standard practice to prescribe antihistamines initially. Research has shown most medical directors continue to prescribe antihistamines as first line in the majority of cases (<a href="./references#CD011393-bbs2-0181" title="RaynerHC , LarkinaM , WangM , Graham-BrownM , van derVeerSN , EcderT , et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clinical Journal of The American Society of Nephrology: CJASN2017;12(12):2000-7. [MEDLINE: 28923831]">Rayner 2017</a>). Conclusions from this systematic review may influence this policy. </p> <p>This review may also be a guide for a changing role for treatment modalities where evidence was lacking. Erythropoietin, thalidomide, cromolyn, doxepin, nicergoline, cholestyramine, nicotinamide, sodium thiosulfate, and lidocaine are of questionable utility in the treatment of uraemic pruritus. Ondansetron was not efficacious. It is somewhat unlikely the further study on ondansetron will change this result. Currently, there is insufficient data for the other interventions to infer in either direction. </p> </section> <h3 class="title" id="CD011393-sec-0128">Implications for research</h3> <section id="CD011393-sec-0128"> <p>The effectiveness of GABA analogues may guide future study into the underlying mechanisms of uraemic pruritus. GABA analogues may also serve as a target for research in non‐uraemic pruritus which has mostly focused on interventions with unrelated mechanisms of action. While shown to be efficacious, the optimal dosing of gabapentin and pregabalin would benefit from targeted study. Finally, several interventions investigated by this systemic review would benefit from additional appropriately powered RCTs. In particular the interventions turmeric, topical capsaicin, montelukast, high flux or permeability HD, and oral cromolyn have limited, but potentially promising preliminary trials. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011393-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011393-sec-0008"></div> <div class="table" id="CD011393-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Pharmacological interventions versus placebo for the relief of itch in people with advanced chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pharmacological interventions versus placebo for the relief of itch in people with advanced chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> uraemic pruritus </p> <p><b>Settings:</b> outpatient and multi‐centre </p> <p><b>Intervention:</b> pharmacological treatments </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative Effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk of placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk with pharmacological interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GABA analogue</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group ranged from <b>0.8 to 2 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the GABA analogue group was <b>4.95 cm lower</b> (5.46 to 4.44 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p>HIGH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ondansetron</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group ranged from <b>0.1 to 2 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the ondansetron agonist group was <b>0.38 cm lower</b> (1.04 lower to 0.27 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p>HIGH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kappa‐opioid agonist</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group ranged from <b>1.3 to 1.9 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the kappa‐opioid agonist group was <b>1.05 cm lower</b> (1.40 to 0.70 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p>HIGH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mu‐opioid antagonist</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group ranged from <b>0.5 to 1 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the mu‐opioid antagonist group was <b>4.29 cm lower</b> (10.24 lower to 1.66 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nalbuphine</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of the placebo group was <b>3.2 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The <b>mean reduction</b> in VAS score of the nalbuphine group was <b>0.75 cm lower</b> (1.70 lower to 0.20 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cromolyn</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group was <b>3 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the cromolyn group was <b>4.8 cm lower</b> (7.03 to 2.57 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nicotinamide</p> <p><b>VAS</b> <b>(0 to 5 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of the placebo group was <b>1.7 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The <b>mean reduction</b> in VAS score of the nicotinamide group was <b>0.47 cm higher</b> (0.32 lower to 1.26 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPO</p> <p><b>Duo score</b> <b>(0 to 40)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Duo score of the placebo group was <b>1.5 lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The <b>mean reduction</b> in Duo score of the EPO group was <b>14.5 lower</b> (38.78 lower to 9.78 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cholestyramine</p> <p><b>0 to 3 severity scale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean itch score of the placebo group ranged from <b>1.3 to 0.7 lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the cholestyramine group was <b>0.24 higher</b> (0.38 lower to 0.86 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montelukast</p> <p><b>Duo score (0 to 81) and VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Duo score and VAS of the placebo group was <b>7 points and 0.5 cm lower</b> (respectively) than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The<b>SMD reduction</b> of the montelukast group was <b>1.4 lower</b> (1.87 to 0.92 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sertraline</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group was <b>3.7 lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the sertraline group was <b>1.8 cm lower</b> (3.65 lower to 0.05 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lidocaine</p> <p>Itch relief</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>800 per 1000</b><br/>(221 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.80</b><br/>(0.78 to 29.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sodium thalidomide</p> <p>Itch relief</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>133 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>556 per 1000</b><br/>(177 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.17</b><br/>(1.08 to 16.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxepin</p> <p>Itch relief</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>875 per 1000</b> </p> <p>(396 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.20</p> <p>(1.90 to 9.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>The reduction of risk of pharmacological versus placebo (column 3) is the additional risk reduction in addition to the benefit provided by the placebo. "Lower" indicates a reduction or negative numerical change versus baseline. </p> <p><b>CI:</b> Confidence interval; <b>SMD</b> : standardised mean difference; <b>RR:</b> Risk Ratio; <b>VAS</b>: visual analogues scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Evidence of certainty was downgraded one level because of the reliance of the estimated effect on a small number of participants </p> <p><sup>2</sup>Evidence of certainty was downgraded one level because of the imprecise treatment estimate </p> <p><sup>3</sup>Evidence of certainty was downgraded one level because of study risks of bias </p> <p><sup>4</sup>Evidence of certainty was downgraded one level because heterogeneous results utilizing nonvalidated itch scoring methods </p> <p><sup>5</sup>Evidence of certainty was downgraded one level as homogeneity was difficult to assess (due to well validated but different itch scoring methods) and that the analysis would benefit from a greater number of participants </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011393-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical treatments versus placebo for the relief of itch in people with advanced chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Topical treatments versus placebo for the relief of itch in people with advanced chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> uraemic pruritus </p> <p><b>Settings:</b> outpatient and multi‐centre </p> <p><b>Intervention:</b> topical treatments </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk of placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk with topical treatments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capsaicin cream</p> <p><b>VAS and Duo’s score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS and Duo score of this vehicle group was <b>1.7 cm and 13.4 lower</b> (respectively) than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The SMD of the capsaicin group was <b>0.84 lower</b> (1.22 to 0.45 lower) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pramoxine lotion</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this vehicle group was <b>1.4 cm lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the pramoxine lotion group was <b>1.97 lower</b> (6.06 lower to 2.12 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW<sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcineurin inhibitor</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this vehicle group was <b>7.1 cm lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the calcineurin inhibitor group was <b>1.2 higher</b> (0.36 lower to 2.76 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW<sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dead Sea lotion</p> <p><b>1 to 5 severity score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean severity score of this vehicle group was <b>3 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in severity score of the Dead Sea Lotion group was <b>2 lower</b> (4.31 lower to 0.31 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW<sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cromolyn cream</p> <p><b>VAS (0 to 5 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this vehicle group was <b>1.4 cm lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the cromolyn cream group was <b>0.8 cm lower</b> (1.98 lower to 0.38 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baby oil</p> <p><b>Itch Severity Scale</b> <b>(0 to 21)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Itch Severity Scale of this vehicle group was <b>1 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in Itch Severity Scale of the baby oil group was <b>2.36 lower</b> (3.29 to 1.44 lower) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐arginine salve</p> <p><b>0 to 3 severity score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean severity score of this vehicle group was <b>3.4 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in severity score of the L‐arginine salve group was <b>0.58 lower</b> (1.86 lower to 0.7 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polyunsaturated fatty acids</p> <p><b>VAS (0 to 10 cm)</b> </p> <p><b>Duo score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS and Duo score of this vehicle group was <b>1 cm lower and 5 points higher</b> (respectively) than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The SMD of the polyunsaturated fatty acids group was <b>0.91 lower</b> (1.99 lower to 0.17 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>2,6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>The reduction of risk of pharmacological versus placebo (column 3) is the additional risk reduction in addition to the benefit provided by the placebo. "Lower" indicates a reduction or negative numerical change versus baseline. </p> <p><b>CI:</b> Confidence interval; <b>SMD</b> : standardised mean difference; <b>VAS</b>: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Evidence of certainty was downgraded one level as homogeneity was difficult to assess (due to well validated but different itch scoring methods) and that the analysis would benefit from a greater number of participants </p> <p><sup>2</sup>Evidence of certainty was downgraded one level because of the reliance of the estimated effect on a small number of participants </p> <p><sup>3</sup>Evidence of certainty was downgraded one level because of the imprecise treatment estimate </p> <p><sup>4</sup>Evidence of certainty was downgraded one level because of study risks of bias </p> <p><sup>5</sup>Evidence of certainty was downgraded two levels because of study risks of bias and use of a non‐validated itch scoring method. </p> <p><sup>6</sup>Evidence of certainty was downgraded one level because of the imprecise and small treatment estimate </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011393-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Supplements, haemodialysis modalities, and other treatments for the relief of itch in people with advanced chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Supplements, HD modalities, and other treatments for the relief of itch in people with advanced chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> uraemic pruritus </p> <p><b>Settings:</b> outpatient and multi‐centre </p> <p><b>Intervention:</b> supplements, HD modalities, and other treatments </p> <p><b>Comparison:</b> placebo; other HD comparators </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p>A<b>nticipated absolute effects<sup>*</sup> </b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk of comparator</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk with supplements, HD modalities, and other treatments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polyunsaturated fatty acids</p> <p><b>0 to 5</b> <b>severity score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean severity score of this placebo group was <b>1.6% lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in 0 to 5 severity score of the polyunsaturated fatty acids group was <b>11.3% lower</b> (9.0 to 3.6 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine</p> <p><b>VAS (0 to 6 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this placebo group was <b>0.2 higher</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the L‐carnitine group was <b>0.26 lower</b> (2.85 lower to 2.43 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zinc sulfate</p> <p><b>VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS and Duo score of this vehicle group was <b>4.3</b> <b>cm and 6.1 lower</b> (respectively) than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction of the zinc sulfate group was <b>1.77 lower</b> (2.88 to 0.66 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ergocalciferol</p> <p><b>21 point scale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score of this vehicle group was <b>6.1 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the ergocalciferol group was <b>0.4 higher</b> (2.52 lower to 3.32 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turmeric</p> <p><b>Duo score (5 to 40)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Duo’s score of this vehicle group was <b>2 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the turmeric group was <b>6.4 lower*</b> (7.42 to 5.38 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fumaria parviflora</p> <p><b>VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this vehicle group was 2.2<b>lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the Fumaria parviflora group was 3.90<b>lower</b> (5.04 to 2.76 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High flux/permeability</p> <p>dialysis</p> <p><b>VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this control group ranged from <b>0.6 cm to 5.6 cm lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the high flow/permeability group was <b>2.60 cm lower</b> (3.22 to 1.97 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HD with haemoperfusion</p> <p><b>VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this control group was <b>0.6 cm lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the HD with haemoperfusion group was <b>2.37 cm lower</b> (2.89 to 1.85 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐B</p> <p><b>Duo score,</b> </p> <p><b>VAS, and %improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Duo score and VAS of this control group was <b>2.2 points and 0.3 cm lower</b> (respectively) than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The SMD of the UV‐B group was <b>2.49 lower</b> (4.62 to 0.36 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thermal therapy</p> <p><b>VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this control group was <b>5.8 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the thermal therapy group was <b>2.06 lower</b> (6.98 lower to 2.84 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>The reduction of risk of pharmacological versus placebo (column 3) is the additional risk reduction in addition to the benefit provided by the placebo. "Lower" indicates a reduction or negative numerical change versus baseline. </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>SMD</b> : standardised mean difference; <b>VAS</b>: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Evidence of certainty was downgraded one level because of the reliance of the estimated effect on a small number of participants </p> <p><sup>2</sup>Evidence of certainty was downgraded one level because of the imprecise treatment estimate </p> <p><sup>3</sup>Evidence of certainty was downgraded one level because of study risks of bias </p> <p><sup>4</sup>Evidence of certainty was downgraded one level because heterogeneity between studies </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011393-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011393-sec-0009"></div> <section id="CD011393-sec-0010"> <h3 class="title" id="CD011393-sec-0010">Description of the condition</h3> <p>Itch (uraemic pruritus) is a common symptom in people with end‐stage kidney disease (ESKD) and affects 42% to 57% of people on dialysis (<a href="./references#CD011393-bbs2-0172" title="MistikS , UtasS , FerahbasA , TokgozB , UnsalG , SahanH , et al. An epidemiology study of patients with uremic pruritus. Journal of the European Academy of Dermatology &amp; Venereology2006;20(6):672-8. [MEDLINE: 16836494]">Mistik 2006</a>; <a href="./references#CD011393-bbs2-0175" title="PatelTS , FreedmanBI , YosipovitchG . An update on pruritus associated with CKD. American Journal of Kidney Diseases2007;50(1):11-20. [MEDLINE: 17591521]">Patel 2007</a>; <a href="./references#CD011393-bbs2-0177" title="PisoniRL , WikströmB , ElderSJ , AkizawaT , AsanoY , KeenML , et al. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation2006;21(12):3495-505. [MEDLINE: 16968725]">Pisoni 2006</a>; <a href="./references#CD011393-bbs2-0192" title="ZuckerI , YosipovitchG , DavidM , GafterU , BonerG . Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. Journal of the American Academy of Dermatology2003;49(5):842-6. [MEDLINE: 14576662]">Zucker 2003</a>). Itch has significant adverse effects on quality of life (QoL) due to discomfort, disordered sleep, anxiety and depression (<a href="./references#CD011393-bbs2-0174" title="NaritaI , AlchiB , OmoriK , SatoF , AjiroJ , SagaD , et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney International2006;69(9):1626-32. [MEDLINE: 16672924]">Narita 2006</a>; <a href="./references#CD011393-bbs2-0177" title="PisoniRL , WikströmB , ElderSJ , AkizawaT , AsanoY , KeenML , et al. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation2006;21(12):3495-505. [MEDLINE: 16968725]">Pisoni 2006</a>). Despite its high prevalence, mechanisms driving uraemic itch remain poorly understood; two common theories implicate hyperactive and disordered immune (<a href="./references#CD011393-bbs2-0171" title="MettangT , Pauli-MagnusC , AlscherDM . Uraemic pruritus--new perspectives and insights from recent trials. Nephrology Dialysis Transplantation2002;17(9):1558-63. [MEDLINE: 121918205]">Mettang 2002</a>) or opioid systems (<a href="./references#CD011393-bbs2-0064" title="PeerG , KivityS , AgamiO , FiremanE , SilverbergD , BlumM , et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet1996;348(9041):1552-4. [MEDLINE: 8950882]PeerG , SilverbergDS , BlumM , KaplanE , IainaA . Naltrexone (NX) an opiate antagonist relieves pruritus in dialysis patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:560. [CENTRAL: CN-00509406] ">Peer 1996</a>). However, roles have also been proposed for hyperparathyroidism (<a href="./references#CD011393-bbs2-0157" title='HampersCL , KatzAI , WilsonRE , MerrillJP . Disappearance of "uremic" itching after subtotal parathyroidectomy. New England Journal of Medicine1968;279(13):695-7. [MEDLINE: 5670910]'>Hampers 1968</a>; <a href="./references#CD011393-bbs2-0167" title="MassrySG , PopovtzerMM , CoburnJW , MakoffDL , MaxwellMH , KleemanCR . Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. New England Journal of Medicine1968;279(13):697-700. [MEDLINE: 5670911]">Massry 1968</a>), abnormal serum chemistry (<a href="./references#CD011393-bbs2-0014" title="CarmichaelAJ , DickinsonF , McHughMI , MartinAM , FarrowM . Magnesium free dialysis for uraemic pruritus. BMJ1988;297(6663):1584-5. [MEDLINE: 3147085]CarmichaelAJ . Investigation of a low magnesium dialysate in uraemic pruritus [abstract no: 16]. British Journal of Dermatology1988;119(Suppl 33):50. [CENTRAL: CN-00509120] ">Carmichael 1988</a>), mast cell hyperactivity (<a href="./references#CD011393-bbs2-0161" title="KakuH , FujitaY , YagoH , NakaF , KawakuboH , NakanoK , et al. Study on pruritus in hemodialysis patients and the antipruritic effect of neurotropin: plasma levels of substance P, somatostatin, IgE, PTH and histamine. Nihon Jinzo Gakkai Shi [Japanese Journal of Nephrology]1990;32(3):319-26. [MEDLINE: 1693990]">Kaku 1990</a>), and dialysis technique (<a href="./references#CD011393-bbs2-0162" title="KatoA , TakitaT , FuruhashiM , TakahashiT , WatanabeT , MaruyamaY , et al. Polymethylmethacrylate efficacy in reduction of renal itching in hemodialysis patients: crossover study and role of tumor necrosis factor-alpha. Artificial Organs2001;25(6):441-7. [MEDLINE: 11453873]">Kato 2001</a>; <a href="./references#CD011393-bbs2-0188" title="TanJK , HabermanHF , ColdmanAJ . Identifying effective treatments for uremic pruritus. Journal of the American Academy of Dermatology1991;25(5 Pt 1):811-8. [MEDLINE: 1839393]">Tan 1991</a>). </p> </section> <section id="CD011393-sec-0011"> <h3 class="title" id="CD011393-sec-0011">Description of the intervention</h3> <p>Itch has generally been used to refer to a symptom that is an intense sensation of the skin, either local or generalized, which triggers repeated scratching in an attempt to relieve the discomfort. Due to the commonality of itch in general, a formal definition in the context of chronic kidney disease (CKD) has been proposed (<a href="./references#CD011393-bbs2-0192" title="ZuckerI , YosipovitchG , DavidM , GafterU , BonerG . Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. Journal of the American Academy of Dermatology2003;49(5):842-6. [MEDLINE: 14576662]">Zucker 2003</a>). This defines uraemic itch as a) itch appearing shortly before the onset of dialysis, or at any time, without evidence of any other active disease that could explain the itch, b) three or more episodes of itch during a period of less than two weeks, with the symptom appearing a few times a day, lasting at least few minutes, and troubling the patient, and c) appearance of an itch in a regular pattern during a period of six months, but less frequently than listed above. </p> </section> <section id="CD011393-sec-0012"> <h3 class="title" id="CD011393-sec-0012">How the intervention might work</h3> <p>Given the variety of potential mediators in the pathophysiology of uraemic itch, a diverse range of interventions addressing the varied hypotheses has been investigated. These range from topical, symptomatic treatments to systemic treatments aimed at alleged underlying mechanisms. They largely target neurons (thought to be C‐fibres transmitting to the posterior spinothalamic tract and onto the thalamus and somatosensory cortex), their receptors, or their various local inflammatory triggers in the skin. They are presented here by mechanism of action. </p> <section id="CD011393-sec-0013"> <h4 class="title">Opioid receptor mediation</h4> <p>Recent studies have recognised spinal Mu‐receptor agonism as the mechanism of opioid‐associated itch (<a href="./references#CD011393-bbs2-0165" title="LiuXY , LiuZC , SunYG , RossM , KimS , TsaiFF , et al. Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell2011;147(2):447-58. [MEDLINE: 22000021]">Liu 2011</a>), supporting the theory that uraemic itch could represent ‘hyperactivity’ of mu‐receptors. A case report of successful treatment of uraemic itch with naloxone (<a href="./references#CD011393-bbs2-0141" title="AndersenLW , FriedbergM , LokkegaardN . Naloxone in the treatment of uremic pruritus: a case history. Clinical Nephrology1984;21(6):355-6. [MEDLINE: 6467691]">Andersen 1984</a>), a mu‐receptor antagonist, appeared to supported this concept leading to the conduct of several trials to further define this effect (<a href="./references#CD011393-bbs2-0061" title="Pauli-MagnusC , MikusG , AlscherDM , KirschnerT , NagelW , GugelerN , et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. Journal of the American Society of Nephrology2000;11(3):514-9. [MEDLINE: 10703675]">Pauli‐Magnus 2000</a>; <a href="./references#CD011393-bbs2-0064" title="PeerG , KivityS , AgamiO , FiremanE , SilverbergD , BlumM , et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet1996;348(9041):1552-4. [MEDLINE: 8950882]PeerG , SilverbergDS , BlumM , KaplanE , IainaA . Naltrexone (NX) an opiate antagonist relieves pruritus in dialysis patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:560. [CENTRAL: CN-00509406] ">Peer 1996</a>). Mu agonism is typically associated with analgesia. Kappa agonism is typically associated with dysphoria and mu‐antagonism. It has also been suggested that excessive mu‐receptor or inadequate kappa‐receptor activity, with systemic imbalance rather than isolated mu‐receptor hyperactivity, may stimulate itch (<a href="./references#CD011393-bbs2-0036" title="KumagaiH , EbataT , TakamoriK , MiyasatoK , MuramatsuT , NakamotoH , et al. Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. American Journal of Nephrology2012;36(2):175-83. [MEDLINE: 22868684]KumagaiH , EbataT , TakamoriK , MuramatsuT , NakamotoH , SuzukiH . Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrology Dialysis Transplantation2010;25(4):1251-7. [MEDLINE: 19926718]">Kumagai 2010</a>). Thus, kappa‐receptor agonism such a nalfurafine may also be a therapeutic target (<a href="./references#CD011393-bbs2-0036" title="KumagaiH , EbataT , TakamoriK , MiyasatoK , MuramatsuT , NakamotoH , et al. Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. American Journal of Nephrology2012;36(2):175-83. [MEDLINE: 22868684]KumagaiH , EbataT , TakamoriK , MuramatsuT , NakamotoH , SuzukiH . Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrology Dialysis Transplantation2010;25(4):1251-7. [MEDLINE: 19926718]">Kumagai 2010</a>; <a href="./references#CD011393-bbs2-0191" title="WikströmB , GellertR , LadefogedSD , DandaY , AkaiM , IdeK , et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. Journal of the American Society of Nephrology2005;16(12):3742-7. [MEDLINE: 16251241]">Wikstrom 2005a</a>). </p> </section> <section id="CD011393-sec-0014"> <h4 class="title">Anti‐inflammatory immunomodulator mediation</h4> <p>A deregulated pro‐inflammatory immune system has also been implicated in the development of uraemic itch. Histamine is the best‐known immune trigger of pruritus. Preformed histamine is present in large amounts in mast cell granules. For this reason, after mast cell activation, it can be immediately released into the surrounding area where it can induce pruritus via H1 receptors on nerve fibres. Antihistamines act via prevention of the histamine fixation on the surface of the histamine receptors. Doxepin, a tricyclic antidepressant with anti‐H1 receptor effect has been investigated with this presumed mechanism (<a href="./references#CD011393-bbs2-0065" title="Pour-Reza-GholiF , NasrollahiA , FirouzanA , NasliEE , FarrokhiF . Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(1):34-7. [MEDLINE: 19357442]Pour Reza GholiF , Reza NasrollahiA , NafarM , FiroozanA , EsfahaniEN , FarrokhiF . A randomized crossover trial: low-dose doxepin reduces pruritus in dialysis patients [abstract no: MP428]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:374. [CENTRAL: CN-00509425] ">Pour‐Reza‐Gholi 2007</a>). </p> <p>Increased mast cell numbers have been observed in the skin of patients with CKD (<a href="./references#CD011393-bbs2-0148" title="DimkovićN , DjukanovićL , RadmilovićA , BojićP , JuloskiT . Uremic pruritus and skin mast cells. Nephron1992;61(1):5-9. [MEDLINE: 1528340]">Dimkovic 1992</a>; <a href="./references#CD011393-bbs2-0169" title="MatsumotoM , IchimaruK , HorieA . Pruritus and mast cell proliferation of the skin in end stage renal failure. Clinical Nephrology1985;23(6):285-8. [MEDLINE: 4028525]">Matsumoto 1985</a>) leading to speculation that this excess was associated with increased mast cell and histamine activity (<a href="./references#CD011393-bbs2-0187" title="StockenhuberF , Sunder-PlassmannG , BalckeP . Increased plasma histamine levels in chronic renal failure. New England Journal of Medicine1987;317(6):386. [MEDLINE: 3600734]">Stockenhuber 1987</a>). Antagonising histamine or inhibiting mast cell degranulation would block this pathway. Cromolyn sodium is a drug that blocks mast cell degranulation in response to antigens, leading to decreased release of histamine, leukotrienes, and other inflammatory mast cell products. Another purported mechanism of excessive mast cell degranulation is by relative zinc deficiency. By supplementing zinc, degranulation and histamine release may be prevented (<a href="./references#CD011393-bbs2-0166" title="MaroneG , ColumboM , dePaulisA , CirilloR , GiuglianoR , CondorelliM . Physiological concentrations of zinc inhibit the release of histamine from human basophils and lung mast cells. Agents &amp; Actions1986;18(1-2):130-6. [MEDLINE: 2425567]">Marone 1986</a>). Leukotriene antagonists prevent the role of leukotrienes in sustaining the inflammatory response after degranulation. </p> <p>The observation that sun exposure could relieve undifferentiated itch led to trials of ultraviolet radiation in uraemic itch (<a href="./references#CD011393-bbs2-0028" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Relief of uremic pruritus with ultraviolet phototherapy. New England Journal of Medicine1977;297(3):136-8. [MEDLINE: 865585]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1977</a>; <a href="./references#CD011393-bbs2-0035" title="KoMJ , YangJY , WuHY , HuFC , ChenSI , TsaiPJ , et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. British Journal of Dermatology2011;165(3):633-9. [MEDLINE: 21668425]">Ko 2011</a>). Early positive results were eventually attributed to the effect of ultraviolet B radiation in altering T helper subsets (<a href="./references#CD011393-bbs2-0150" title="GarssenJ , VandebrielRJ , De GruijlFR , WolversDA , Van DijkM , FluitmanA , et al. UVB exposure-induced systemic modulation of Th1- and Th2-mediated immune responses. Immunology1999;97(3):506-14. [MEDLINE: 10447774]">Garssen 1999</a>). These conclusions led to several controlled and non‐controlled trials of immunomodulators that could suppress T cell responses, such as tacrolimus, pimecrolimus, and thalidomide. </p> <p>Thalidomide is a drug with anti‐inflammatory properties by modification the immune systems The exact mechanism of action of thalidomide is unknown, but it inhibits TNF‐α, IL‐6, IL‐10 and IL‐12 and other pro‐inflammatory cytokines. It modulates natural killer cell cytotoxicity and also inhibits NF‐κB and COX‐2 activity. </p> <p>Nicotinamide (vitamin B3/niacin), and it is a member of the vitamin B family. It has no side‐effects like its relative, nicotinic acid such as vasodilation or flushing, and it is considered generally safe as a food additive or as a component in cosmetics and medications (<a href="./references#CD011393-bbs2-0174" title="NaritaI , AlchiB , OmoriK , SatoF , AjiroJ , SagaD , et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney International2006;69(9):1626-32. [MEDLINE: 16672924]">Narita 2006</a>). Nicotinamide has been used for a diverse range of conditions, including acne, rosacea, autoimmune bullous dermatoses, photo‐aging and photo immunosuppression by playing a significant role in DNA repair, maintenance of genomic stability and cellular response to injury, including inflammation and apoptosis (<a href="./references#CD011393-bbs2-0018" title="ChoYL , LiuHN , HuangTP , TarngDC . Uremic pruritus: roles of parathyroid hormone and substance P. Journal of the American Academy of Dermatology1997;36(4):538-43. [MEDLINE: 9092738]">Cho 1997</a>). It has been shown to be capable of inhibition of the expression of MHC‐II and the production of IL‐12, TNF‐α and IL‐1 and to be a potent stabilizer of mast cells and leukocytes (<a href="./references#CD011393-bbs2-0173" title="NamaziMR . Nicotinamide: a potential addition to the anti-psoriatic weaponry. FASEB Journal2003;17(11):1377-9. [MEDLINE: 12890690]">Namazi 2003</a>). </p> <p>Erythropoietin (EPO), a hormone produced by the kidneys that stimulates the production of red blood cells. The kidney synthetic function of EPO is impaired in CKD. EPO may have some anti‐itch properties as it is has been shown to reduce plasma histamine concentrations (<a href="./references#CD011393-bbs2-0144" title="Bohlius J SchmidlinK , BrillantC , SchwarzerG , TrelleS , SeidenfeldJ , et al. Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD007303. [DOI: 10.1002/14651858.CD007303.pub2]">Bohlius 2009</a>). </p> <p>Turmeric, a powder of the rhizomes of Curcuma longa L. (Zingiberaceae), commonly used as a dietary spice, is also used in Asian and Iranian medicine ordinarily for treatment of inflammation and skin wounds (<a href="./references#CD011393-bbs2-0143" title="BaligaMS , KatiyarSK . Chemoprevention of photocarcinogenesis by selected dietary botanicals. Photochemical &amp; Photobiological Sciences2006;5(2):243-53. [MEDLINE: 16465310]">Baliga 2006</a>). Curcumin (diferuloylmethane), the most active and non‐toxic component of turmeric, is a polyphenol that has been extensively studied for its therapeutic benefits including anti‐ inflammatory activities (<a href="./references#CD011393-bbs2-0140" title="Aggarwal BB SundaramC , MalaniN , IchikawaH . Curcumin: the Indian solid gold. Advances in Experimental Medicine &amp; Biology2007;595:1-75. [MEDLINE: 17569205]">Aggarwal 2007</a>). </p> </section> <section id="CD011393-sec-0015"> <h4 class="title">Neuronal pathways</h4> <p>Gabapentin and pregabalin are structural analogues of the neurotransmitter gamma‐aminobutyric acid (GABA). The exact mechanisms of their antipruritic effects are not clear but may be related to the hindrance of C‐fibre mediated nociceptive sensations to the brain and thus pruritus (<a href="./references#CD011393-bbs2-0175" title="PatelTS , FreedmanBI , YosipovitchG . An update on pruritus associated with CKD. American Journal of Kidney Diseases2007;50(1):11-20. [MEDLINE: 17591521]">Patel 2007</a>). Gabapentin may be particularly useful in forms of peripheral neuropathic pruritus, itch related to cholestasis, and post‐burn itch in addition to uraemic itch (<a href="./references#CD011393-bbs2-0180" title="RaynerHC . Itching in renal failure: a curse with a cure. Journal of Renal Nursing2013;5(4):75-9. [DOI: 10.12968/jorn.2013.5.4.178]">Rayner 2013</a>). </p> <p>Ondansetron is a 5‐HT3 serotonin receptor antagonist to both the central and peripheral nervous system. 5‐HT3 is known to be an activator of neuronal receptors along the C‐fibre/spinothalamic pathway. The medication’s possible efficacy in uraemic itch has been attributed to this mechanism (<a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a>). </p> <p>Capsaicin has been demonstrated to deplete substance P, a principal neurotransmitter regulating passage of noxious stimuli (<a href="./references#CD011393-bbs2-0146" title="BurksTF , BuckSH , MillerMS . Mechanisms of depletion of substance P by capsaicin. Federation Proceedings1985;44(9):2531-4. [MEDLINE: 2581820]">Burks 1985</a>), and may therefore block transmission of pruritic sensation. </p> <p>Chilled baby oil can also interrupt the transmission of C nerve fibres and can minimize inflammation and chemical stimulation (<a href="./references#CD011393-bbs2-0163" title="KennetJ , HardakerN , HobbsS , SelfeJ . Cooling efficiency of 4 common cryotherapeutic agents. Journal of Athletic Training2007;42(3):343-8. [MEDLINE: 18059988]">Kennet 2007</a>; <a href="./references#CD011393-bbs2-0190" title="WangWY , TangYY , ChuPL , ChaoCM , WangKY . Physiology, pathology and clinical practice in uremic pruritus. Kidney &amp; Dialysis2006;18:99-104.">Wang 2006</a>). This is thought to be mediated by temperature induced vasoconstriction, reduced cell metabolism and nerve transmission speed, and paralysis of neural receptors (<a href="./references#CD011393-bbs2-0147" title="Chiu YLCH , ChuangYF , HsuSP , LaiCF , PaiMF , YangSY , et al. Association of uraemic pruritus with inflammation and hepatitis infection in haemodialysis patients. Nephrology Dialysis Transplantation2008;23(11):3685-9. [MEDLINE: 18515654]">Chiu 2008</a>). </p> </section> <section id="CD011393-sec-0016"> <h4 class="title">Other interventions</h4> <p>Ergocalciferol is a precursor in the local production of active vitamin D in the skin of HD patients after exposure to sunlight. One hypothesis, supported by trials, claims anti‐itch benefit from the positive effect of UVB exposure on uraemic pruritus (<a href="./references#CD011393-bbs2-0070" title="ShirazianS , KlineM , SakhiyaV , SchanlerM , MoledinaD , PatelC , et al. Longitudinal predictors of uremic pruritus. Journal of Renal Nutrition2013;23(6):428-31. [MEDLINE: 24209894]ShirazianS , SchanlerM , DrakakisJ , MiyawakiNB , FishbaneS . The effect of vitamin D insufficiency on uremic pruritis [abstract no: PUB388]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):982A. ShirazianS , SchanlerM , ShastryS , DwivediS , KumarM , RiceK , et al. The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial. Journal of Renal Nutrition2013;23(4):308-14. [MEDLINE: 23453391]">Shirazian 2013</a>). </p> <p>Activated charcoal is an agent that can bind many poisons in the stomach preventing them from being absorbed. Charcoal has been studied for possible effectiveness in uraemic pruritus (<a href="./references#CD011393-bbs2-0151" title="GiovannettiS , BarsottiG , CupistiA , DaniL , BandiniS , AngeliniD , et al. Oral activated charcoal in patients with uremic pruritus. Nephron1995;70(2):193-6. [MEDLINE: 7566302]">Giovannetti 1995</a>). </p> <p>Several agents have also been trialled on an empiric basis with identifiable mechanism. Cholestyramine and lidocaine have been trialled after published RCTs showed benefit with cholestatic itch (<a href="./references#CD011393-bbs2-0189" title="VillamilAG , BandiJC , GaldameOA , GeronaS , Gadano, AC. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. American Journal of Medicine2005;118(10):1160-3. [MEDLINE: 16194649]">Villamil 2005</a>). L‐carnitine has been suspected as the causative agent in other symptoms of uraemia (<a href="./references#CD011393-bbs2-0145" title="BohmerT , BergremH , EiklidK . Carnitine deficiency induced during intermittent haemodialysis for renal failure. Lancet1978;311(8056):126-8. [MEDLINE: 87556]">Bohmer 1978</a>). Pramoxine is a commercially available topical local anaesthetic that has been shown to have antipruritic properties when used both alone and in combination with lactic acid (<a href="./references#CD011393-bbs2-0154" title="GroveG , ZerweckC . An evaluation of the moisturizing and anti-itch effects of a lactic acid and pramoxine hydrochloride cream. Cutis2004;73(2):135-9. [MEDLINE: 15027519]">Grove 2004</a>). L‐arginine ointment, a semi‐essential amino acid, has been shown to improve skin dryness and, in particular, improve pruritus in haemodialysis (HD) patients (<a href="./references#CD011393-bbs2-0021" title="Durrant-FinnU , OstenB , NenoffP . Topical L-arginine hydrochloride ointment improves skin dryness and pruritus in patients under chronic haemodialysis - a vehicle-controlled prospective randomised study [Topisch appliziertes L-argininhydrochlorid verbessert hauttrockenheit und pruritus bei patienten unter chronischer hamodialyse - Eine vehikelkontrollierte prospektive randomisierte studie im halbseitenvergleich]. Aktuelle Dermatologie2008;34(5):175-87. [EMBASE: 2008337532]">Durant‐Finn 2008</a>). Essential fatty acids and their derivatives have a protective function and influence skin structure and physiological characteristics (<a href="./references#CD011393-bbs2-0142" title="AndreassiM , ForleoP , Di LorioA , MasciS , AbateG , AmerioP . Efficacy of gamma-linolenic acid in the treatment of patients with atopic dermatitis. Journal of International Medical Research1997;25(5):266-74. [MEDLINE: 9364289]">Andreassi 1997</a>). </p> </section> </section> <section id="CD011393-sec-0017"> <h3 class="title" id="CD011393-sec-0017">Why it is important to do this review</h3> <p>Itch affects the majority of CKD patients. The majority of patients on HD report itch symptoms. One fifth of all those on HD reported significant sleep disturbances (<a href="./references#CD011393-bbs2-0174" title="NaritaI , AlchiB , OmoriK , SatoF , AjiroJ , SagaD , et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney International2006;69(9):1626-32. [MEDLINE: 16672924]">Narita 2006</a>). Typically, trials investigating itch treatments are single centre studies with small numbers and often have conflicting results. The conclusions from past meta‐analyses were that there was insufficient data to recommend one treatment compared with another, and further rigorous trials were needed. Therefore, it is important that a modern systematic assessment of the existing evidence be conducted to summarise the effect of current studies. The aim of this systematic review is to summarise randomised controlled trials (RCTs) in patients with ESKD comparing any topical or systemic intervention with placebo or usual care in the management of uraemic itch. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011393-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011393-sec-0018"></div> <p>Our objectives are to determine:</p> <p> <ul id="CD011393-list-0001"> <li> <p>the benefits and harms (both absolute and relative) of all topical and systemic interventions for the treatment of uraemic itch, either alone or in combination, when compared with placebo or standard care; and </p> </li> <li> <p>the dose strength or frequency, stage of kidney disease or method of dialysis used (where applicable) in cases where the effects of these interventions vary depending on co‐interventions. </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011393-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011393-sec-0019"></div> <section id="CD011393-sec-0020"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011393-sec-0021"> <h4 class="title">Types of studies</h4> <p>All RCTs and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at evaluating interventions involving uraemic itch. Some studies allocated treatment based only on dialysis schedule (e.g. Monday, Wednesday, Friday) which also represent a systemic change in treatment and environment. These studies have not been included. </p> </section> <section id="CD011393-sec-0022"> <h4 class="title">Types of participants</h4> <section id="CD011393-sec-0023"> <h5 class="title">Inclusion criteria</h5> <p>Patients with advanced CKD defined as CKD stages 4, 5, or 5D were included.</p> </section> <section id="CD011393-sec-0024"> <h5 class="title">Exclusion criteria</h5> <p>Patients with CKD stages 1, 2 and 3 were excluded. In studies before 2002, patients with CKD not on dialysis were excluded. </p> </section> </section> <section id="CD011393-sec-0025"> <h4 class="title">Types of interventions</h4> <p>All interventions, administered by any method (oral, intravenous (IV), topical, or otherwise), in any frequency and at any dose strength are included. Among people undergoing dialysis, the intervention may be administered on dialysis or non‐dialysis days. Complementary interventions (such as acupuncture or massage) were excluded because they are not easily comparable or categorised with other interventions. </p> <p>Participants in included study control arms received no intervention, placebo, a different dose strength or frequency from the experimental intervention, or any other intervention not administered to experimental arm participants. </p> <p>We included studies of the type:</p> <p> <ol id="CD011393-list-0002"> <li> <p>Intervention versus placebo</p> </li> <li> <p>Intervention A versus intervention B</p> </li> <li> <p>Co‐intervention A versus co‐intervention B.</p> </li> </ol> </p> <p>To simplify interpretation, each intervention was assigned a GRADE evidence profile in a summary of findings table (<a href="./references#CD011393-bbs2-0156" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">Guyatt 2011</a>). </p> </section> <section id="CD011393-sec-0026"> <h4 class="title">Types of outcome measures</h4> <p>We assessed outcome measures at the end of the treatment period or up to two weeks post‐treatment, or as reported by investigators. </p> <section id="CD011393-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011393-list-0003"> <li> <p>Post treatment itch</p> <ul id="CD011393-list-0004"> <li> <p>Measured by visual analogue scale (VAS), Duo score or any other validated score for itch </p> </li> <li> <p>Other recognised numerical or categorical itch measurement scores.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD011393-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011393-list-0005"> <li> <p>QoL as measured by any validated QoL scale</p> </li> <li> <p>Death</p> </li> <li> <p>Length of treatment in hospital or outpatient clinic</p> </li> <li> <p>Length of time to itch relief</p> </li> <li> <p>Adverse events</p> <ul id="CD011393-list-0006"> <li> <p>Sleep disturbances</p> </li> <li> <p>Dermatological reactions</p> </li> <li> <p>Other adverse effects (e.g. neurological, gastrointestinal).</p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD011393-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011393-sec-0030"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Specialised Register</a> up to 17 December 2019 through contact with the Information Specialist using search terms relevant to this review. The Cochrane Kidney and Transplant Specialised Register contains studies identified from several sources. </p> <p> <ol id="CD011393-list-0007"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available on the <a href="https://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant website</a>. </p> <p>See <a href="./appendices#CD011393-sec-0132">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD011393-sec-0031"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD011393-list-0008"> <li> <p>Reference lists of review articles, relevant studies, and clinical practice guidelines.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete trials to investigators known to be involved in previous studies. </p> </li> <li> <p>Additional data sources included clinical study reports and direct correspondence with study authors. </p> </li> </ul> </p> </section> </section> <section id="CD011393-sec-0032"> <h3 class="title" id="CD011393-sec-0032">Data collection and analysis</h3> <section id="CD011393-sec-0033"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that were potentially relevant to the review. Two authors independently screened titles and abstracts, and discarded studies that were not applicable; however, studies and reviews that potentially included relevant data or information on studies were initially retained. The two authors independently assessed retrieved abstracts and appropriate full texts of these studies to determine which studies satisfied our inclusion criteria. </p> </section> <section id="CD011393-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>Two authors carried out data extraction independently using standardised data extraction forms. Studies reported in non‐English language journals were translated before assessment. The translators are noted in the acknowledgements. When more than one publication of one study exists, reports were grouped together and the publication with the most complete data was used in the analyses. When relevant outcomes are only published in earlier versions then these data were used. Any discrepancy between published versions were to be noted and there were no significant instances in this meta‐analysis. </p> </section> <section id="CD011393-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items are independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD011393-bbs2-0159" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>) (see <a href="./appendices#CD011393-sec-0133">Appendix 2</a>). </p> <p> <ul id="CD011393-list-0009"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD011393-list-0010"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD011393-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. any itch versus no itch) results were expressed as risk ratios (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (e.g. Duo score or VAS), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales needed to be resolved. </p> <p>Any validated tool for the quantification of itch was used. These included, but were not limited, to VAS and the Duo scoring system, which were the most commonly reported measurement tools for itch. VAS was scored on a 10‐point scale and the Duo scoring system is based on severity, distribution, and sleep disturbance up to a maximum score (usually 45). RCTs with clearly documented, but non‐validated scoring systems were considered as non‐ideal evidence. </p> </section> <section id="CD011393-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of focus was the quantities and qualities affecting a single person. For example, itch episodes/person was preferable to total number of itch episodes affecting an unspecified number of people or time frame. </p> </section> <section id="CD011393-sec-0038"> <h4 class="title">Dealing with missing data</h4> <p>Further information required from the original author was requested by written correspondence (e.g. emailing corresponding author/s) and any relevant information obtained in this manner was included in the review. Evaluation of important numerical data such as screened, randomised patients as well as intention‐to‐treat, as‐treated and per‐protocol population were to be performed. Attrition rates, for example drop‐outs, losses to follow‐up and withdrawals were investigated. </p> <p>For missing data of the second stage of a cross‐over RCT, assuming appropriate data can be acquired from the first (pre‐cross‐over) stage, the second stage was dropped from the analysis. The "first" stage was treated at as a parallel RCT. When all the means and SD for both groups and both periods were available with an incomplete paired data analysis, all measurements from both periods were treated as parallel group studies. If this analysis in consistent with the data provided within the study, we accepted this with the acknowledgement of risk of bias in both the inflation of confidence intervals and study heterogeneity. Finally, if paired data were available (or able to be fully reconstructed) then the generic inverse variance method was used to incorporate the studies into the meta‐analysis. </p> <p>Issues of missing data and imputation methods (for example, last‐observation‐carried‐forward) was critically appraised (<a href="./references#CD011393-bbs2-0159" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD011393-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<a href="./references#CD011393-bbs2-0158" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD011393-sec-0040"> <h4 class="title">Assessment of reporting biases</h4> <p>Given the size and organisation of participants in this review, funnel plots (used to assess for the potential existence of small study bias) were not included. Reporting bias was discussed on an individual study basis (<a href="./references#CD011393-sec-0138" title="">Characteristics of included studies</a>). </p> </section> <section id="CD011393-sec-0041"> <h4 class="title">Data synthesis</h4> <p>Data was pooled using the random‐effects model.</p> </section> <section id="CD011393-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was used to explore possible sources of heterogeneity (e.g. participants, interventions, and study quality). Heterogeneity among participants could be related to age, geography, and stage of CKD. Heterogeneity in treatments could be related to prior agent(s) used and the agent, dose, and duration of therapy (such as increased tolerance after prolonged use of anti‐itch agents). Additionally, cross‐over studies may represent an independent source of bias due to their paired design. Adverse effects have been tabulated and assessed using descriptive techniques, because they are likely to differ among agents used. We planned to calculate the 95% risk difference for each adverse effect. However, due to the variety of interventions used and the inadequate reporting of adverse events, this was not done. </p> </section> <section id="CD011393-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to undertake sensitivity analyses however due the wide variety of interventions this was not performed. </p> </section> <section id="CD011393-sec-0044"> <h4 class="title">Summary of findings' tables</h4> <p>We have presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD011393-bbs2-0183" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD011393-bbs2-0153" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD011393-bbs2-0155" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">Guyatt 2008</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD011393-bbs2-0184" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD011393-list-0011"> <li> <p>Itch severity: a patient's subjective rating of their sensation of itch. Severity is measured on a continuous scale or as a binary response. The most common itch scales included were the VAS and Duo score. Few studies included their own holistic scale based on varying degrees of validated evidence. </p> </li> <li> <p>VAS: a 0 to 10 cm rating using the horizontal or vertical numeric rating scale for subjective characteristics or attitudes that cannot be directly measured. It was developed originally to assess the intensity of pain, but subsequently it was also adopted for pruritus evaluation. A number of studies dealing with itch have demonstrated that VAS is a reliable method of pruritus severity measurement (<a href="./references#CD011393-bbs2-0182" title="ReichA , HeisigM , PhanNQ , TanedaK , TakamoriK , TakeuchiS , et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Dermato-Venereologica2012;92(5):497-501. [MEDLINE: 22102095]">Reich 2012</a>) </p> </li> <li> <p>Duo score: a numerical measure of itching scoring according to severity, frequency, and distribution with roughly equal contributions from each category. Originally proposed by <a href="./references#CD011393-bbs2-0149" title="DuoLJ . Electrical needle therapy of uremic pruritus. Nephron1987;47(3):179-83. [MEDLINE: 3500424]">Duo 1987</a>, modified by <a href="./references#CD011393-bbs2-0170" title="MettangT , FritzP , WeberJ , MachleidtC , HubelE , KuhlmannU . Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells. Clinical Nephrology1990;34(3):136-41. [MEDLINE: 1699691]">Mettang 1990</a>, and again by (<a href="./references#CD011393-bbs2-0160" title="HiroshigeK , KabashimaN , TakasugiM , KuroiwaA . Optimal dialysis improves uremic pruritus. American Journal of Kidney Diseases1995;25(3):413-9. [MEDLINE: 7872318]">Hiroshige 1995</a>), the structure has remained consistent, while the range of score has varied from 0 to 10 to 3 to 81. </p> </li> <li> <p>Adverse events: adverse effects were poorly and inconsistently reported across all studies. These have been documented in the results section and 'additional tables' (<a href="#CD011393-tbl-0004">Table 1</a>; <a href="#CD011393-tbl-0005">Table 2</a>; <a href="#CD011393-tbl-0006">Table 3</a>; <a href="#CD011393-tbl-0007">Table 4</a>; <a href="#CD011393-tbl-0008">Table 5</a>). Further meaningful assessments on harm could not be made and were not included in the 'Summary of findings' tables. </p> </li> </ul> </p> <div class="table" id="CD011393-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events: pharmacological interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Route/dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GABA analogue</p> <p>(pregabalin or</p> <p>gabapentin) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pregabalin</p> <p>(a) Oral: 75 mg, twice/week</p> <p>Gabapentin</p> <p>(b) Oral: 400 mg, twice/week</p> <p>(c) Oral: 300 mg, 3 times/week</p> <p>(d) Oral: 300 mg/day</p> <p>(e) Oral: dose not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0031" title="GunalAI , OzalpG , YoldasTK , GunalSY , KircimanE , CelikerH . Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrology Dialysis Transplantation2004;19(12):3137-9. [MEDLINE: 15575002]">Gunal 2004</a> (c): somnolence, dizziness, fatigue </p> <p><a href="./references#CD011393-bbs2-0050" title="NaghibiM , NazemianF , Mohammad-PoorA , Morovat-DarZ , Javidi-Dasht-BayazA , AzmoodehH . The effect of gabapentin on uremic pruritus in hemodialysis patients [abstract no: FP479]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi181. ">Naghibi 2007</a> (e): somnolence </p> <p><a href="./references#CD011393-bbs2-0051" title="NainiAE , HarandiAA , KhanbabapourS , ShahidiS , SeirafiyanS , MohseniM . Gabapentin: a promising drug for the treatment of uremic pruritus. Saudi Journal of Kidney Diseases &amp; Transplantation2007;18(3):378-81. [MEDLINE: 17679749]NainiAE , ShahidiS , SeirafianS , AtapoorA , KhanbabapoorS , HarandiAA , et al. Gabapentin: a promising treatment for uremic pruritus [abstract no: SP471]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv174. ">Naini 2007</a> (b): somnolence, dizziness, nausea </p> <p><a href="./references#CD011393-bbs2-0055" title="NofalE , FaragF , NofalA , EldesoukyF , AlkotR , AbdelkhalikZ . Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2016;27(6):515-9. [MEDLINE: 27043168]SolakB , SolakY . Reply to: Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2017;28(3):280. [MEDLINE: 27687138]">Nofal 2016</a> (d): somnolence (9/27), dizziness (5/27) </p> <p><a href="./references#CD011393-bbs2-0084" title="TolH , AtalayH , GuneyI , GokbelH , AltintepeL , BuyukbasS , et al. The effects of gabapentin therapy on pruritus, quality of life, depression and sleep quality in pruritic hemodialysis patients. Trakya Universitesi Tip Fakultesi Dergisi2010;27(1):1-5. [EMBASE: 2010207038]">Tol 2010</a> (c): not reported </p> <p><a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a> (a): somnolence (3/67), loss of balance (2/67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0031" title="GunalAI , OzalpG , YoldasTK , GunalSY , KircimanE , CelikerH . Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrology Dialysis Transplantation2004;19(12):3137-9. [MEDLINE: 15575002]">Gunal 2004</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0050" title="NaghibiM , NazemianF , Mohammad-PoorA , Morovat-DarZ , Javidi-Dasht-BayazA , AzmoodehH . The effect of gabapentin on uremic pruritus in hemodialysis patients [abstract no: FP479]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi181. ">Naghibi 2007</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0051" title="NainiAE , HarandiAA , KhanbabapourS , ShahidiS , SeirafiyanS , MohseniM . Gabapentin: a promising drug for the treatment of uremic pruritus. Saudi Journal of Kidney Diseases &amp; Transplantation2007;18(3):378-81. [MEDLINE: 17679749]NainiAE , ShahidiS , SeirafianS , AtapoorA , KhanbabapoorS , HarandiAA , et al. Gabapentin: a promising treatment for uremic pruritus [abstract no: SP471]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv174. ">Naini 2007</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0055" title="NofalE , FaragF , NofalA , EldesoukyF , AlkotR , AbdelkhalikZ . Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2016;27(6):515-9. [MEDLINE: 27043168]SolakB , SolakY . Reply to: Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2017;28(3):280. [MEDLINE: 27687138]">Nofal 2016</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0084" title="TolH , AtalayH , GuneyI , GokbelH , AltintepeL , BuyukbasS , et al. The effects of gabapentin therapy on pruritus, quality of life, depression and sleep quality in pruritic hemodialysis patients. Trakya Universitesi Tip Fakultesi Dergisi2010;27(1):1-5. [EMBASE: 2010207038]">Tol 2010</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ondansetron versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>161 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) Oral: 8 mg, 3 times/day</p> <p>(b) Oral: 8 mg, once/day</p> <p>(c) Oral: 8 mg, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0006" title="AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uraemic pruritus in maintenance haemodialysis patients [abstract]. In: 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy. 1998:223. [CENTRAL: CN-00483053] AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uremic pruritus in hemodialysis patients. American Journal of Kidney Diseases2000;35(5):827-31. [MEDLINE: 10793015]">Ashmore 2000</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0049" title="MurphyM , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. British Journal of Dermatology2003;148(2):314-7. [MEDLINE: 12588385]MurphyMD , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch [abstract]. British Journal of Dermatology2001;145(Suppl 59):20-1. [CENTRAL: CN-00509373] ">Murphy 2003</a> (b): constipation (1/14), ischaemic stroke (1/18), line sepsis (1/17) </p> <p><a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a> (c): nausea and vomiting (2/64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0006" title="AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uraemic pruritus in maintenance haemodialysis patients [abstract]. In: 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy. 1998:223. [CENTRAL: CN-00483053] AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uremic pruritus in hemodialysis patients. American Journal of Kidney Diseases2000;35(5):827-31. [MEDLINE: 10793015]">Ashmore 2000</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0049" title="MurphyM , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. British Journal of Dermatology2003;148(2):314-7. [MEDLINE: 12588385]MurphyMD , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch [abstract]. British Journal of Dermatology2001;145(Suppl 59):20-1. [CENTRAL: CN-00509373] ">Murphy 2003</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kappa opioid agonists versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>626 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nalfurafine</p> <p>(a) Oral: 2.5 µg once/day</p> <p>(b) Oral: 5 µg once/day</p> <p>(c) IV: 5 µg, 3 times/week</p> <p>(d) IV: 2.5, 5 µg with dialysis</p> <p>CR845</p> <p>(e) IV: 0.5 to 1.5 µg/kg with dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0036" title="KumagaiH , EbataT , TakamoriK , MiyasatoK , MuramatsuT , NakamotoH , et al. Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. American Journal of Nephrology2012;36(2):175-83. [MEDLINE: 22868684]KumagaiH , EbataT , TakamoriK , MuramatsuT , NakamotoH , SuzukiH . Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrology Dialysis Transplantation2010;25(4):1251-7. [MEDLINE: 19926718]">Kumagai 2010</a> (a, b) </p> <p>2.5 µg (oral): somnolence (4.5%); insomnia (7.1%), diarrhoea (4.5%), nasopharyngitis (8.0%) </p> <p>5 µg (oral): constipation (7.9%), somnolence (3.5%), insomnia (14.9%), nasopharyngitis (12.3%) </p> <p><a href="./references#CD011393-bbs2-0075" title="MathurVS , SpencerRH , IllidgeJ , StaufferJW , MuneraC , MenzaghiF . Improvement of quality of life in hemodialysis patients with uremic pruritus as measured by the skindex-10 questionnaire: effect of a novel kappa opiod receptor agonist, CR845 [abstract no: TH-PO1040]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):338A. SpencerR , MathurVS , TumlinJA , StaufferJW , MenzaghiF . CR845, a novel kappa opiod receptor agonist reduces moderate-to-severe pruritus and improves quality of life in chronic kidney disease patients undergoing hemodialysis [abstract no: SA-PO1117]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B9. ">Spencer 2015</a> (e): not reported </p> <p><a href="./references#CD011393-bbs2-0076" title="MenzaghiF , MuneraC , OberdickMS , StaufferJW , SpencerRH . Randomized, placebo-controlled study on the efficacy of CR845 in improving the quality of life of hemodialysis patients with CKD- associated pruritus [abstract no: SA-OR032]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):80. MuneraC , VernonMK , StaufferJW , SpencerRH , MenzaghiF . Psychometric validation and meaningful change threshold of the worst itching intensity numerical rating scale for use in hemodialysis patients with pruritus [abstract]. Journal of Investigative Dermatology2018;138(5 Suppl 1):S99. [EMBASE: 622252595]SpencerRH , MuneraC , OberdickMS , StaufferJW , MenzaghiF . Randomized, placebo-controlled study on the efficacy of CR845 in reducing CKD- associated pruritus in hemodialysis patients [abstract no: FR-PO875]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):629. SpencerRH , MuneraC , VernonMK , StaufferJW , MenzaghiF . Clinically meaningful itch reduction by CR845 an 8-week randomized, placebo-controlled study in hemodialysis patients [abstract no: 280]. American Journal of Kidney Diseases2018;71(4):585. [EMBASE: 621596159]">Spencer 2017</a> (e) (0.5 to 1.5 µg/kg): somnolence (9/129), dizziness (12/129), headache (5/129), diarrhoea (16/129), nausea (11/129) </p> <p><a href="./references#CD011393-bbs2-0010" title="BhaduriS , MathurV , FellmannJ , RosenD , UenoK , UenoY . Nalfurafine (TRK-820) as a treatment for uremic pruritus (UP): patients are responsive independent of baseline itch - data from a multicenter, randomized, placebo controlled trial [abstract no: SA-PO1014]. Journal of the American Society of Nephrology2006;17(Abstracts):787A. BhaduriS , MathurV , FellmannJ , RosenD , UenoK , UenoY . Nalfurafine (TRK-820) as a treatment for uremic pruritus (UP): persistence of effect on dialytic and non-dialytic days - data from a multicenter, randomized, placebo controlled trial [abstract no: SA-PO1015]. Journal of the American Society of Nephrology2006;17(Abstracts):787A. ">Bhaduri 2006</a> (d): not reported </p> <p><a href="./references#CD011393-bbs2-0088" title="WikstromB , GellertR , LadefogedSD , DandaY , AkaiM , IdeK , et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. Journal of the American Society of Nephrology2005;16(12):3742-7. [MEDLINE: 16251241]">Wikstrom 2005</a> (c): headache (3/26), nausea (3/26), vomiting (2/26), insomnia (2/26), vertigo (2/26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0036" title="KumagaiH , EbataT , TakamoriK , MiyasatoK , MuramatsuT , NakamotoH , et al. Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. American Journal of Nephrology2012;36(2):175-83. [MEDLINE: 22868684]KumagaiH , EbataT , TakamoriK , MuramatsuT , NakamotoH , SuzukiH . Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrology Dialysis Transplantation2010;25(4):1251-7. [MEDLINE: 19926718]">Kumagai 2010</a>: nasopharyngitis (17.1%), headache (3.6%), vomiting (3.6%) </p> <p><a href="./references#CD011393-bbs2-0075" title="MathurVS , SpencerRH , IllidgeJ , StaufferJW , MuneraC , MenzaghiF . Improvement of quality of life in hemodialysis patients with uremic pruritus as measured by the skindex-10 questionnaire: effect of a novel kappa opiod receptor agonist, CR845 [abstract no: TH-PO1040]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):338A. SpencerR , MathurVS , TumlinJA , StaufferJW , MenzaghiF . CR845, a novel kappa opiod receptor agonist reduces moderate-to-severe pruritus and improves quality of life in chronic kidney disease patients undergoing hemodialysis [abstract no: SA-PO1117]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B9. ">Spencer 2015</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0076" title="MenzaghiF , MuneraC , OberdickMS , StaufferJW , SpencerRH . Randomized, placebo-controlled study on the efficacy of CR845 in improving the quality of life of hemodialysis patients with CKD- associated pruritus [abstract no: SA-OR032]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):80. MuneraC , VernonMK , StaufferJW , SpencerRH , MenzaghiF . Psychometric validation and meaningful change threshold of the worst itching intensity numerical rating scale for use in hemodialysis patients with pruritus [abstract]. Journal of Investigative Dermatology2018;138(5 Suppl 1):S99. [EMBASE: 622252595]SpencerRH , MuneraC , OberdickMS , StaufferJW , MenzaghiF . Randomized, placebo-controlled study on the efficacy of CR845 in reducing CKD- associated pruritus in hemodialysis patients [abstract no: FR-PO875]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):629. SpencerRH , MuneraC , VernonMK , StaufferJW , MenzaghiF . Clinically meaningful itch reduction by CR845 an 8-week randomized, placebo-controlled study in hemodialysis patients [abstract no: 280]. American Journal of Kidney Diseases2018;71(4):585. [EMBASE: 621596159]">Spencer 2017</a>: somnolence (1/45), dizziness (2/45), headache (1/45), diarrhoea (0/45) </p> <p><a href="./references#CD011393-bbs2-0088" title="WikstromB , GellertR , LadefogedSD , DandaY , AkaiM , IdeK , et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. Journal of the American Society of Nephrology2005;16(12):3742-7. [MEDLINE: 16251241]">Wikstrom 2005</a>: 13/25 (type not reported) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mu opioid antagonists versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 50 mg once/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0061" title="Pauli-MagnusC , MikusG , AlscherDM , KirschnerT , NagelW , GugelerN , et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. Journal of the American Society of Nephrology2000;11(3):514-9. [MEDLINE: 10703675]">Pauli‐Magnus 2000</a>: loss of appetite and nausea (9) </p> <p><a href="./references#CD011393-bbs2-0064" title="PeerG , KivityS , AgamiO , FiremanE , SilverbergD , BlumM , et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet1996;348(9041):1552-4. [MEDLINE: 8950882]PeerG , SilverbergDS , BlumM , KaplanE , IainaA . Naltrexone (NX) an opiate antagonist relieves pruritus in dialysis patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:560. [CENTRAL: CN-00509406] ">Peer 1996</a>: heartburn (2), abdominal discomfort (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0061" title="Pauli-MagnusC , MikusG , AlscherDM , KirschnerT , NagelW , GugelerN , et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. Journal of the American Society of Nephrology2000;11(3):514-9. [MEDLINE: 10703675]">Pauli‐Magnus 2000</a>: nausea (1) </p> <p><a href="./references#CD011393-bbs2-0064" title="PeerG , KivityS , AgamiO , FiremanE , SilverbergD , BlumM , et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet1996;348(9041):1552-4. [MEDLINE: 8950882]PeerG , SilverbergDS , BlumM , KaplanE , IainaA . Naltrexone (NX) an opiate antagonist relieves pruritus in dialysis patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:560. [CENTRAL: CN-00509406] ">Peer 1996</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nalbuphine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>373 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 60 or 120 mg, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0085" title="KumarJ , CrawfordP , MathurV , SciasciaT . Nalbuphine ER tablets in hemodialysis patients with severe uremic pruritus: multicenter, randomized, double-blind, placebo-controlled trial [abstract no: 185]. American Journal of Kidney Diseases2016;67(5):A65. [EMBASE: 72313488]MathurVS , GermainMJ , DuncanR , SciasciaT . The rationale for and design of TREVITR02: a multicenter randomized, double-blind, placebo-controlled trial of nalbuphine ER for the treatment of uremic pruritus in hemodialysis patients [abstract no: PUB113]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):912A. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT , TR02 Study Investigators. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. American Journal of Nephrology2017;46(6):450-8. [MEDLINE: 29253847]MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . A multicenter, phase2/3 randomized, double-blind, placebo-controlled tiral of nalbuphine ER tablets for the treatment of uremic pruritus: baseline population characteristics [abstract no: TH-PO956]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):316a. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . Randomized, double-blind, placebo-controlled, parallel, 3-arm study of safety and anti-pruritic efficacy of nalbuphine HCI ER tablets in hemodialysis patients with uremic pruritus [abstract no: HI-OR07]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2. ">TREVITR02 2017</a> </p> <p>60 mg: serious adverse events (12.7%), adverse events leading to discontinuation (33/128)</p> <p>120 mg: serious adverse events (6.7%), adverse events leading to discontinuation (27/120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0085" title="KumarJ , CrawfordP , MathurV , SciasciaT . Nalbuphine ER tablets in hemodialysis patients with severe uremic pruritus: multicenter, randomized, double-blind, placebo-controlled trial [abstract no: 185]. American Journal of Kidney Diseases2016;67(5):A65. [EMBASE: 72313488]MathurVS , GermainMJ , DuncanR , SciasciaT . The rationale for and design of TREVITR02: a multicenter randomized, double-blind, placebo-controlled trial of nalbuphine ER for the treatment of uremic pruritus in hemodialysis patients [abstract no: PUB113]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):912A. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT , TR02 Study Investigators. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. American Journal of Nephrology2017;46(6):450-8. [MEDLINE: 29253847]MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . A multicenter, phase2/3 randomized, double-blind, placebo-controlled tiral of nalbuphine ER tablets for the treatment of uremic pruritus: baseline population characteristics [abstract no: TH-PO956]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):316a. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . Randomized, double-blind, placebo-controlled, parallel, 3-arm study of safety and anti-pruritic efficacy of nalbuphine HCI ER tablets in hemodialysis patients with uremic pruritus [abstract no: HI-OR07]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2. ">TREVITR02 2017</a>: serious adverse events (15.4%), adverse events leading to discontinuation (7/123) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPO versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) IV: 36 U/kg/dialysis</p> <p>(b) SC: 2000 IU twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0019" title="De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Effect of erythropoietin therapy on uraemic pruritus [abstract]. Nephrology Dialysis Transplantation1992;7(7):767. [CENTRAL: CN-00260739] De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. New England Journal of Medicine1992;326(15):969-74. [MEDLINE: 1545849]">De Marchi 1992</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0073" title="Sja'baniM , AsdieAH . Effect of erythropoietin on pruritus, anemia and quality of life, in chronic hemodialyzed end stage renal disease patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:501. [CENTRAL: CN-00509480] Sja'baniM , AsdieAH . Effect of erythropoietin on pruritus and quality of life in chronic hemodialyzed end stage renal disease patients [abstract]. Journal of Clinical Epidemiology1997;50(Suppl 1):10S. [CENTRAL: CN-00550491] ">Sja'bani 1997</a> (b): not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0019" title="De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Effect of erythropoietin therapy on uraemic pruritus [abstract]. Nephrology Dialysis Transplantation1992;7(7):767. [CENTRAL: CN-00260739] De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. New England Journal of Medicine1992;326(15):969-74. [MEDLINE: 1545849]">De Marchi 1992</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0073" title="Sja'baniM , AsdieAH . Effect of erythropoietin on pruritus, anemia and quality of life, in chronic hemodialyzed end stage renal disease patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:501. [CENTRAL: CN-00509480] Sja'baniM , AsdieAH . Effect of erythropoietin on pruritus and quality of life in chronic hemodialyzed end stage renal disease patients [abstract]. Journal of Clinical Epidemiology1997;50(Suppl 1):10S. [CENTRAL: CN-00550491] ">Sja'bani 1997</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nicotinamide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 500 mg twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0057" title="OmidianM , KhazaneeA , YaghoobiR , GhorbaniAR , PazyarN , BeladimousaviSS , et al. Therapeutic effect of oral nicotinamide on refractory uremic pruritus: a randomized, double-blind study. Saudi Journal of Kidney Diseases &amp; Transplantation2013;24(5):995-9. [MEDLINE: 24029269]">Omidian 2013</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0057" title="OmidianM , KhazaneeA , YaghoobiR , GhorbaniAR , PazyarN , BeladimousaviSS , et al. Therapeutic effect of oral nicotinamide on refractory uremic pruritus: a randomized, double-blind study. Saudi Journal of Kidney Diseases &amp; Transplantation2013;24(5):995-9. [MEDLINE: 24029269]">Omidian 2013</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lidocaine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV: 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0081" title="TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReidenbergMM , et al. Pruritus in dialysis patients treated with parenteral lidocaine. New England Journal of Medicine1977;296(5):261-2. [MEDLINE: 831109]TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReindenbergMM , et al. Treatment of pruritus in dialysis patients with parenteral lidocaine [abstract]. Kidney International1976;10(6):527. [CENTRAL: CN-00583216] ">Tapia 1977</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0081" title="TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReidenbergMM , et al. Pruritus in dialysis patients treated with parenteral lidocaine. New England Journal of Medicine1977;296(5):261-2. [MEDLINE: 831109]TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReindenbergMM , et al. Treatment of pruritus in dialysis patients with parenteral lidocaine [abstract]. Kidney International1976;10(6):527. [CENTRAL: CN-00583216] ">Tapia 1977</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholestyramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 5 mg, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0072" title="SilverbergDS , IainaA , ReisinE , RotzakR , EliahouHE . Cholestyramine in uraemic pruritus. BMJ1977;1(6063):752-3. [MEDLINE: 322794]">Silverberg 1977</a>: constipation (1/5), nausea (1/5) </p> <p><a href="./references#CD011393-bbs2-0086" title="vanLeusenR , Kutsch LojengaJC , RubenAT . Is cholestyramine helpful in uraemic pruritus?British Medical Journal1978;1(6117):918-9. [MEDLINE: 346150]">van Leusen 1978</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0072" title="SilverbergDS , IainaA , ReisinE , RotzakR , EliahouHE . Cholestyramine in uraemic pruritus. BMJ1977;1(6063):752-3. [MEDLINE: 322794]">Silverberg 1977</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0086" title="vanLeusenR , Kutsch LojengaJC , RubenAT . Is cholestyramine helpful in uraemic pruritus?British Medical Journal1978;1(6117):918-9. [MEDLINE: 346150]">van Leusen 1978</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Montelukast versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0041" title="MahmudpourM , RouzbehJ , JalaliQA , PakfetratM , ZadeganSE , SaghebMM . Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients. Iranian Journal of Kidney Diseases2017;11(1):50-5. [MEDLINE: 28174353]">Mahmudpour 2017</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0054" title="NasrollahiAR , MiladipourA , GhaneiE , YavariP , HaghverdiF . Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(2):73-7. [MEDLINE: 19363280]">Nasrollahi 2007</a>: myelodysplastic syndrome (1/8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0041" title="MahmudpourM , RouzbehJ , JalaliQA , PakfetratM , ZadeganSE , SaghebMM . Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients. Iranian Journal of Kidney Diseases2017;11(1):50-5. [MEDLINE: 28174353]">Mahmudpour 2017</a>: Not reported </p> <p><a href="./references#CD011393-bbs2-0054" title="NasrollahiAR , MiladipourA , GhaneiE , YavariP , HaghverdiF . Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(2):73-7. [MEDLINE: 19363280]">Nasrollahi 2007</a>: myocardial infarction (1/8) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sertraline versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 50 mg twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0060" title="PakfetratM , MalekmakanL , HashemiN , TadayonT . Sertraline can reduce the uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran. Hemodialysis International2018;22(1):103-9. [MEDLINE: 28263039]">Pakfetrat 2018</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0060" title="PakfetratM , MalekmakanL , HashemiN , TadayonT . Sertraline can reduce the uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran. Hemodialysis International2018;22(1):103-9. [MEDLINE: 28263039]">Pakfetrat 2018</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sodium thiosulfate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV: 12.5 mg/dialysis session</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0047" title="MohamedWA , ZakiFM , BekhitWH , SherifIS . Sodium thiosulfate (STS): a new option for hemodialysis patients with uremic pruritus [abstract no: SAP598]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii511-2. [EMBASE: 70766834]">Mohamed 2012</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0047" title="MohamedWA , ZakiFM , BekhitWH , SherifIS . Sodium thiosulfate (STS): a new option for hemodialysis patients with uremic pruritus [abstract no: SAP598]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii511-2. [EMBASE: 70766834]">Mohamed 2012</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxepin versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 10 mg, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0065" title="Pour-Reza-GholiF , NasrollahiA , FirouzanA , NasliEE , FarrokhiF . Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(1):34-7. [MEDLINE: 19357442]Pour Reza GholiF , Reza NasrollahiA , NafarM , FiroozanA , EsfahaniEN , FarrokhiF . A randomized crossover trial: low-dose doxepin reduces pruritus in dialysis patients [abstract no: MP428]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:374. [CENTRAL: CN-00509425] ">Pour‐Reza‐Gholi 2007</a>: drowsiness (12/24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0065" title="Pour-Reza-GholiF , NasrollahiA , FirouzanA , NasliEE , FarrokhiF . Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(1):34-7. [MEDLINE: 19357442]Pour Reza GholiF , Reza NasrollahiA , NafarM , FiroozanA , EsfahaniEN , FarrokhiF . A randomized crossover trial: low-dose doxepin reduces pruritus in dialysis patients [abstract no: MP428]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:374. [CENTRAL: CN-00509425] ">Pour‐Reza‐Gholi 2007</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thalidomide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0071" title="LugonJR , SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF . Thalidomide (TH) as a new perspective for the treatment of uremic pruritus (UP): a crossed randomized double-blind trial [abstract no: 14P]. Journal of the American Society of Nephrology1992;3(3):377. [CENTRAL: CN-00461215] SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF , LugonJR . Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron1994;67(3):270-3. [MEDLINE: 7936015]">Silva 1994</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0071" title="LugonJR , SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF . Thalidomide (TH) as a new perspective for the treatment of uremic pruritus (UP): a crossed randomized double-blind trial [abstract no: 14P]. Journal of the American Society of Nephrology1992;3(3):377. [CENTRAL: CN-00461215] SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF , LugonJR . Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron1994;67(3):270-3. [MEDLINE: 7936015]">Silva 1994</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cimetidine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 600 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0007" title="AubiaJ , AguileraJ , LlorachI , GarciaC , RiusE , LLoverasJ , et al. Dialysis pruritus: effect of cimetidine. Journal of Dialysis1980;4(4):141-5. [MEDLINE: 7204712]">Aubia 1980</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0007" title="AubiaJ , AguileraJ , LlorachI , GarciaC , RiusE , LLoverasJ , et al. Dialysis pruritus: effect of cimetidine. Journal of Dialysis1980;4(4):141-5. [MEDLINE: 7204712]">Aubia 1980</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cromolyn versus</p> <p>placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 135 mg, 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0087" title="VessalG , SaghebMM , ShilianS , JafariP , SamaniSM . Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. Nephrology Dialysis Transplantation2010;25(5):1541-7. [MEDLINE: 20007756]">Vessal 2010</a>: flatulence (1/32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0087" title="VessalG , SaghebMM , ShilianS , JafariP , SamaniSM . Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. Nephrology Dialysis Transplantation2010;25(5):1541-7. [MEDLINE: 20007756]">Vessal 2010</a>: nausea (5/30), diarrhoea (4/30) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gabapentin versus pregabalin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral gabapentin (300 mg, once/day) versus oral pregabalin (75 mg, once/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0074" title="AtalayH , SolakY , BiyikZ , GaipovA , GuneyF , TurkS . Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clinical Drug Investigation2013;33(6):401-8. [MEDLINE: 23572323]BiyikZ , SolakY , AtalayH , GaipovA , GuneyF , TurkS . Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. International Urology &amp; Nephrology2013;45(3):831-7. [MEDLINE: 22644743]SolakY , BiyikZ , AtalayH , GaipovA , GuneyF , TurkS , et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology2012;17(8):710-7. [MEDLINE: 22909343]">Solak 2012</a> </p> <p>Gabapentin: not reported</p> <p>Pregabalin: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GADA versus ondansetron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral pregabalin (75 mg twice/week) versus oral ondansetron (8 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a> </p> <p>Pregabalin: somnolence (3/67), loss of balance (2/67)</p> <p>Ondansetron: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GABA analogue versus doxepin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral pregabalin (50 mg every other night) versus oral doxepin (10 mg/night)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0024" title="ForoutanN , EtminanA , NikvarzN , Shojai Shahrokh AbadiM . Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial. Hemodialysis International2017;21(1):63-71. [MEDLINE: 27397522]">Foroutan 2017</a> </p> <p>Pregabalin: intolerable adverse events (3/46), somnolence (6/37), oedema (3/37), drowsiness (3/27), imbalance (1/37), numbness (1/37) </p> <p>Doxepin: intolerable adverse events (1/44), nervousness (1/35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GABA analogue versus antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>212 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) Oral gabapentin (100 mg/day) versus oral ketotifen (1 mg, twice/day)</p> <p>(b) Oral gabapentin (300 mg, 3 times/week) versus oral dexchlorpheniramine (6 mg, 3 times/week) </p> <p>(c) Oral gabapentin (300 mg/day) versus oral loratadine (10 mg/day)</p> <p>(d) Oral gabapentin (100 to 200 mg/day) versus oral hydroxyzine (10 mg/day)</p> <p>(e) Oral gabapentin (100 mg/day) versus oral hydroxyzine (10 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0004" title="AmirkhanlouS , RashediA , TaherianJ , HafeziAA , ParsaeiS . Comparison of gabapentin and ketotifen in treatment of uremic pruritus in hemodialysis patients. Pakistan Journal of Medical Sciences2016;32(1):22-6. [MEDLINE: 27022338]">Amirkhanlou 2016</a> (a) </p> <p>Gabapentin: drowsiness (4/26), dizziness (1/26)</p> <p>Ketotifen: drowsiness (4/26), dizziness (1/26)</p> <p><a href="./references#CD011393-bbs2-0030" title="Gobo-OliveiraM , PigariVG , OgataMS , MiotHA , PonceD , AbbadeLP . Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial. European Journal of Dermatology2018;28(4):488-95. [MEDLINE: 29976533]">Gobo‐Oliveira 2018</a> (b) </p> <p>Gabapentin: total (11/30), drowsiness (17%)</p> <p>Dexchlorpheniramine: total (8/30), drowsiness (1/30)</p> <p><a href="./references#CD011393-bbs2-0044" title="MarinAR . Gabapentin therapy for pruritus in automated peritoneal dialysis patients: a randomized controlled trial [abstract no: SA-PO936]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):841A. ">Marin 2013</a> (c) </p> <p>Gabapentin: somnolence (8/30)</p> <p>Loratadine: none reported</p> <p><a href="./references#CD011393-bbs2-0056" title="NoshadH . Comparison of gabapentin and antihistamins in treatment of uremic pruritus and its psychological problems [abstract no: P209]. Iranian Journal of Kidney Diseases2011;5(Suppl 2):27-8. [EMBASE: 70673855]">Noshad 2011</a> (d) </p> <p>Gabapentin: complications (7/20)</p> <p>Hydroxyzine: complications (10/20)</p> <p><a href="./references#CD011393-bbs2-0078" title="SuwanpidokkulP , ChaiprasertA , SupasyndhO , ChoovichianP , LuesuthiviboonL . Effects of gabanpentin and loratadine on uremic pruritus in hemodialysis patients: a randomized controlled trial [abstract no: F-PO896]. Journal of the American Society of Nephrology2007;18(Abstracts):300A. ">Suwanpidokkul 2007</a> (e) </p> <p>Gabapentin: (9/18)</p> <p>Loratadine: (4/16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mu opioid antagonists versus antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral naltrexone (50 mg/day) versus oral loratadine (10 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0038" title="Legroux-CrespelE , CledesJ , MiseryL . A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology2004;208(4):326-30. [MEDLINE: 15178915]">Legroux‐Crespel 2004</a> </p> <p>Naltrexone (26): vomiting (2), nausea (9), anorexia (1), abdominal distention (1), malaise (1), cramps (2), sleep disturbances (5), vertigo (5), headache (2), somnolence (1), paraesthesia (1), withdrawn (10) </p> <p>Loratadine (26): vomiting (2), malaise (1), withdrawn from study (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ondansetron versus antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) Ondansetron tablet (8 mg/day) versus cyproheptadine</p> <p>syrup (8 mg/day)</p> <p>(b) "3 doses ondansetron 8mg" versus "diphenhydramine 25mg"</p> <p>(c) Oral ondansetron (8 mg, 3 times/day) versus oral loratadine (10 mg twice/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0058" title="OzaykanS , MansurT , GunduzS , GuneyO . Comparison of ondansetron and cyproheptadine in treatment of uremic pruritus [Uremi kasintisi olan hastalarda ondansetron ve siproheptadinin etkinliginin karsilastirilmasi]. Turkderm Deri Hastaliklari Ve Frengi Arsivi2001;35(2):130-4. [EMBASE: 2001415704]">Ozaykan 2001</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0077" title="SubachRA , RadabaughRS , WilliamsDK , MarxMA . Ondansetron versus diphenhydramine versus placebo for hemodialysis-associated itching [abstract no: A1790]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):348A. [CENTRAL: CN-00447890] ">Subach 2001</a> (b): not reported </p> <p><a href="./references#CD011393-bbs2-0046" title="MirnezamiM . Effect of ondasetron on pruritus in hemodialysis patients. Arak Medical University Journal (AMUJ)2013;16(3):80-4. ">Mirnezami 2013</a> (c): not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*when reported</p> <p>GABA ‐ gamma‐aminobutyric acid</p> </div> </div> <div class="table" id="CD011393-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events: topical interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Route/dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cromolyn cream versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4% cream</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0023" title="FeilyA , DormaneshB , GhorbaniAR , MoosaviZ , KouchakM , CheraghianB , et al. Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients.[Erratum in: Int J Clin Pharmacol Ther. 2013 Nov;51(11):910]. International Journal of Clinical Pharmacology &amp; Therapeutics2012;50(7):510-3. [MEDLINE: 22732382]">Feily 2012</a>: burning sensation (6/30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0023" title="FeilyA , DormaneshB , GhorbaniAR , MoosaviZ , KouchakM , CheraghianB , et al. Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients.[Erratum in: Int J Clin Pharmacol Ther. 2013 Nov;51(11):910]. International Journal of Clinical Pharmacology &amp; Therapeutics2012;50(7):510-3. [MEDLINE: 22732382]">Feily 2012</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capsaicin cream versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) 0.025%, 4 times/day</p> <p>(b) 0.03%, 4 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0013" title="BrenemanDL , CardoneJS , BlumsackRF , LatherRM , SearleEA , PollackVE . Topical capsaicin for treatment of hemodialysis-related pruritus. Journal of the American Academy of Dermatology1992;26(1):91-4. [MEDLINE: 1732343]">Breneman 1992</a> (a): burning and stinging sensation (5), decrease in xerosis (3), dryness (2) </p> <p><a href="./references#CD011393-bbs2-0018" title="ChoYL , LiuHN , HuangTP , TarngDC . Uremic pruritus: roles of parathyroid hormone and substance P. Journal of the American Academy of Dermatology1997;36(4):538-43. [MEDLINE: 9092738]">Cho 1997</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0042" title="MakhloughA , AlaS , Haj-HeydariZ , KashiZ , BariA . Topical capsaicin therapy for uremic pruritus in patients on hemodialysis.[Erratum in: Iran J Kidney Dis. 2010 Jul;4(3):273 Note: Ala, Shahram [added]; Haj-Heydari, Zohreh [added]; Kashi, Zahra [added]; Bari, Alireza [added]]. Iranian Journal of Kidney Diseases2010;4(2):137-40. [MEDLINE: 20404425]">Makhlough 2010</a> (b): skin burning </p> <p><a href="./references#CD011393-bbs2-0082" title="TarngDC , ChoYL , LiuHN , HuangTP . Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron1996;72(4):617-22. [MEDLINE: 8730431]">Tarng 1996</a> (a): local burning and/or stinging sensations </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0013" title="BrenemanDL , CardoneJS , BlumsackRF , LatherRM , SearleEA , PollackVE . Topical capsaicin for treatment of hemodialysis-related pruritus. Journal of the American Academy of Dermatology1992;26(1):91-4. [MEDLINE: 1732343]">Breneman 1992</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0018" title="ChoYL , LiuHN , HuangTP , TarngDC . Uremic pruritus: roles of parathyroid hormone and substance P. Journal of the American Academy of Dermatology1997;36(4):538-43. [MEDLINE: 9092738]">Cho 1997</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0042" title="MakhloughA , AlaS , Haj-HeydariZ , KashiZ , BariA . Topical capsaicin therapy for uremic pruritus in patients on hemodialysis.[Erratum in: Iran J Kidney Dis. 2010 Jul;4(3):273 Note: Ala, Shahram [added]; Haj-Heydari, Zohreh [added]; Kashi, Zahra [added]; Bari, Alireza [added]]. Iranian Journal of Kidney Diseases2010;4(2):137-40. [MEDLINE: 20404425]">Makhlough 2010</a>: none </p> <p><a href="./references#CD011393-bbs2-0082" title="TarngDC , ChoYL , LiuHN , HuangTP . Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron1996;72(4):617-22. [MEDLINE: 8730431]">Tarng 1996</a>: local burning and/or stinging sensations </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pramoxine lotion versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0% twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0090" title="FleischerAB , KaurM , ClarkA , YosipovitchG . A controlled comparative study of the efficacy of 1% pramoxine hydrochloride lotion for the treatment of uremic pruritus in adult hemodialysis patients [abstract no: P591]. Journal of the American Academy of Dermatology2007;56(2):AB63. [CENTRAL: CN-00615966] YoungTA , PatelTS , CamachoF , ClarkA , FreedmanBI , KaurM , et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. Journal of Dermatological Treatment2009;20(2):76-81. [MEDLINE: 18821119]">Young 2009</a>: none </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0090" title="FleischerAB , KaurM , ClarkA , YosipovitchG . A controlled comparative study of the efficacy of 1% pramoxine hydrochloride lotion for the treatment of uremic pruritus in adult hemodialysis patients [abstract no: P591]. Journal of the American Academy of Dermatology2007;56(2):AB63. [CENTRAL: CN-00615966] YoungTA , PatelTS , CamachoF , ClarkA , FreedmanBI , KaurM , et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. Journal of Dermatological Treatment2009;20(2):76-81. [MEDLINE: 18821119]">Young 2009</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baby oil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chilled and unchilled 15 min application at least once/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0040" title="LinTC , LaiYH , GuoSE , LiuCF , TsaiJC , GuoHR , et al. Baby oil therapy for uremic pruritus in haemodialysis patients. Journal of Clinical Nursing2012;21(1-2):139-48. [MEDLINE: 22093006]">Lin 2012</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0040" title="LinTC , LaiYH , GuoSE , LiuCF , TsaiJC , GuoHR , et al. Baby oil therapy for uremic pruritus in haemodialysis patients. Journal of Clinical Nursing2012;21(1-2):139-48. [MEDLINE: 22093006]">Lin 2012</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dead Sea lotion versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Entire body, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0012" title="BoazM , ShtendikL , OronM , Portugal-CohenM , KohenR , BiroA , et al. A randomized controlled clinical trial comparing the efficacy of dead sea mineral-enriched body lotion versus two types of placebo in the treatment of cutaneous dryness, itching, peeling and tightness in hemodialysis patients (EDIT). Nephron2009;113(3):c169-76. [MEDLINE: 19672115]">Boaz 2009</a>: total adverse events (2/25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0012" title="BoazM , ShtendikL , OronM , Portugal-CohenM , KohenR , BiroA , et al. A randomized controlled clinical trial comparing the efficacy of dead sea mineral-enriched body lotion versus two types of placebo in the treatment of cutaneous dryness, itching, peeling and tightness in hemodialysis patients (EDIT). Nephron2009;113(3):c169-76. [MEDLINE: 19672115]">Boaz 2009</a>: total adverse events (3/25) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sericin cream versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 g, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0005" title="AramwitP , KeongamaroonO , SiritientongT , BangN , SupasyndhO . Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study. BMC Nephrology2012;13:119. [MEDLINE: 23006933]">Aramwit 2012a</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0005" title="AramwitP , KeongamaroonO , SiritientongT , BangN , SupasyndhO . Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study. BMC Nephrology2012;13:119. [MEDLINE: 23006933]">Aramwit 2012a</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐arginine salve versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 µg/2.5 cm<sup>2</sup> twice/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0021" title="Durrant-FinnU , OstenB , NenoffP . Topical L-arginine hydrochloride ointment improves skin dryness and pruritus in patients under chronic haemodialysis - a vehicle-controlled prospective randomised study [Topisch appliziertes L-argininhydrochlorid verbessert hauttrockenheit und pruritus bei patienten unter chronischer hamodialyse - Eine vehikelkontrollierte prospektive randomisierte studie im halbseitenvergleich]. Aktuelle Dermatologie2008;34(5):175-87. [EMBASE: 2008337532]">Durant‐Finn 2008</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0021" title="Durrant-FinnU , OstenB , NenoffP . Topical L-arginine hydrochloride ointment improves skin dryness and pruritus in patients under chronic haemodialysis - a vehicle-controlled prospective randomised study [Topisch appliziertes L-argininhydrochlorid verbessert hauttrockenheit und pruritus bei patienten unter chronischer hamodialyse - Eine vehikelkontrollierte prospektive randomisierte studie im halbseitenvergleich]. Aktuelle Dermatologie2008;34(5):175-87. [EMBASE: 2008337532]">Durant‐Finn 2008</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcineurin inhibitors versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TAC: 0.1% twice/day</p> <p>Pimecrolimus: 1.0% twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0020" title="DuqueMI , YosipovitchG , Fleischer AB Jr, WillardJ , FreedmanBI . Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. Journal of the American Academy of Dermatology2005;52(3 Pt 1):519-21. [MEDLINE: 15761435]">Duque 2005</a>: warmth sensation (6/12) </p> <p><a href="./references#CD011393-bbs2-0026" title="GhorbaniAR , FeilyA , KhaliliA , DormaneshB . Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients. Dermatitis2012;22(3):167-8. [MEDLINE: 21569748]">Ghorbani 2012a</a>: burning sensation which disappeared by the end of 8 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0020" title="DuqueMI , YosipovitchG , Fleischer AB Jr, WillardJ , FreedmanBI . Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. Journal of the American Academy of Dermatology2005;52(3 Pt 1):519-21. [MEDLINE: 15761435]">Duque 2005</a>: warmth sensation (3/8) </p> <p><a href="./references#CD011393-bbs2-0026" title="GhorbaniAR , FeilyA , KhaliliA , DormaneshB . Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients. Dermatitis2012;22(3):167-8. [MEDLINE: 21569748]">Ghorbani 2012a</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweet almond oil versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0001" title="AfrasiabifarA , MehriZ , HosseiniN . Efficacy of topical application of sweet almond oil on reducing uremic pruritus in hemodialysis patients: A randomized clinical trial study. Iranian Red Crescent Medical Journal2017;19(2):e34695. [EMBASE: 614585273]">Afrasiabifar 2017</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0001" title="AfrasiabifarA , MehriZ , HosseiniN . Efficacy of topical application of sweet almond oil on reducing uremic pruritus in hemodialysis patients: A randomized clinical trial study. Iranian Red Crescent Medical Journal2017;19(2):e34695. [EMBASE: 614585273]">Afrasiabifar 2017</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gamma‐linoleic acid versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2%, 30 mL/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0016" title="ChenYC , ChiuWT , WuMS . Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. American Journal of Kidney Diseases2006;48(1):69-76. [MEDLINE: 16797388]">Chen 2006e</a>: allergic reaction (1/8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0016" title="ChenYC , ChiuWT , WuMS . Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. American Journal of Kidney Diseases2006;48(1):69-76. [MEDLINE: 16797388]">Chen 2006e</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcineurin inhibitors versus cromolyn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pimecrolimus: 2% twice/day</p> <p>Cromolyn: 4%, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0027" title="Ghorbani BirganiAR , KhaliliA , ZamaniL . A comparison between the effect of cromolyn sodium gel 4% and pimecrolimus cream 1% in treatment of pruritus of patients with end stage renal disease. Avicenna Journal of Nursing &amp; Midwifery Care2011;19(2):11-22. ">Ghorbani Birgani 2011</a>: unknown </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0027" title="Ghorbani BirganiAR , KhaliliA , ZamaniL . A comparison between the effect of cromolyn sodium gel 4% and pimecrolimus cream 1% in treatment of pruritus of patients with end stage renal disease. Avicenna Journal of Nursing &amp; Midwifery Care2011;19(2):11-22. ">Ghorbani Birgani 2011</a>: unknown </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avena sativa versus diluted vinegar versus hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avena sativa: variable dose, twice/day</p> <p>Dilute vinegar: 30 mL twice/day</p> <p>Oral hydroxyzine: 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0053" title="NakhaeeS , NasiriA , WagheiY , MorshediJ . Comparison of Avena sativa, vinegar, and hydroxyzine for uremic pruritus of hemodialysis patients: a crossover randomized clinical trial. Iranian Journal of Kidney Diseases2015;9(4):316-22. [MEDLINE: 26174460]">Nakhaee 2015</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sarna versus eurax</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sarna: 0.5% each of camphor, menthol, and phenol "as required" for 7 days</p> <p>Eurax: 10% crotamiton "as required" for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0080" title="TanCC , WongKS , ThirumoorthyT , LeeE , WooK . A randomized, crossover trial of sarna and eurax lotions in the treatment of haemodialysis patients with uraemic pruritus. Journal of Dermatological Treatment1990;1(5):235-8. [EMBASE: 1991052418]">Tan 1990</a> </p> <p>Sarna: none</p> <p>Eurax: rash (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*when reported</p> </div> </div> <div class="table" id="CD011393-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: oral and IV supplements</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose/route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polyunsaturated fatty acids versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fish oil</p> <p>(a) Oral: 6 g/day</p> <p>(b) Oral: 3 g/day</p> <p>Omega‐3 fatty acids</p> <p>(c) Oral: 3 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0009" title="BegumR , BeluryMA , BurgessJR , PeckLW . Supplementation with n-3 and n-6 polyunsaturated fatty acids: effects on lipoxygenase activity and clinical symptoms of pruritus in hemodialysis patients. Journal of Renal Nutrition2004;14(4):233-41. [MEDLINE: 15483784]">Begum 2004</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0025" title="GhaneiE , ZeinaliJ , BorgheiM , HomayouniM . Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial. Iranian Red Crescent Medical Journal2012;14(9):515-22. [MEDLINE: 23115713]">Ghanei 2012</a> (c): not reported </p> <p><a href="./references#CD011393-bbs2-0048" title="MojganM , MasoudM , ShahrzadS , ZahraPH , FirouzehM , JinoosZ , et al. Pruritus-reducing effects of omega-3 fatty acids in hemodialysis patients [abstract no: P106]. Iranian Journal of Kidney Diseases2017;11(Suppl 1):7-8. [EMBASE: 616611409]">Mojgan 2017</a> (b): not reported </p> <p><a href="./references#CD011393-bbs2-0062" title="PeckLW , MonsenER , AhmadS . Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. American Journal of Clinical Nutrition1996;64(2):210-4. [MEDLINE: 8694022]">Peck 1996</a> (a): not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0009" title="BegumR , BeluryMA , BurgessJR , PeckLW . Supplementation with n-3 and n-6 polyunsaturated fatty acids: effects on lipoxygenase activity and clinical symptoms of pruritus in hemodialysis patients. Journal of Renal Nutrition2004;14(4):233-41. [MEDLINE: 15483784]">Begum 2004</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0025" title="GhaneiE , ZeinaliJ , BorgheiM , HomayouniM . Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial. Iranian Red Crescent Medical Journal2012;14(9):515-22. [MEDLINE: 23115713]">Ghanei 2012</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0048" title="MojganM , MasoudM , ShahrzadS , ZahraPH , FirouzehM , JinoosZ , et al. Pruritus-reducing effects of omega-3 fatty acids in hemodialysis patients [abstract no: P106]. Iranian Journal of Kidney Diseases2017;11(Suppl 1):7-8. [EMBASE: 616611409]">Mojgan 2017</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0062" title="PeckLW , MonsenER , AhmadS . Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. American Journal of Clinical Nutrition1996;64(2):210-4. [MEDLINE: 8694022]">Peck 1996</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV: 10 mg/kg, once/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0045" title="MettangT , ThomasS , KuhlmannU . L-carnitine does not alleviate uremic pruritus in hemodialysis patients. Nephron1997;75(3):372. [MEDLINE: 9069470]ThomasS , FischerFP , MettangT , Pauli-MagnusC , WeberJ , KuhlmannU . Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: a double-blind randomized trial. American Journal of Kidney Diseases1999;34(4):678-87. [MEDLINE: 10516349]">Mettang 1997</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0045" title="MettangT , ThomasS , KuhlmannU . L-carnitine does not alleviate uremic pruritus in hemodialysis patients. Nephron1997;75(3):372. [MEDLINE: 9069470]ThomasS , FischerFP , MettangT , Pauli-MagnusC , WeberJ , KuhlmannU . Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: a double-blind randomized trial. American Journal of Kidney Diseases1999;34(4):678-87. [MEDLINE: 10516349]">Mettang 1997</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zinc sulfate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) Oral: 220 mg/day</p> <p>(b) Oral: 200 mg twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0043" title="MaparMA , PazyarN , SiahpooshA , LatifiSM , Beladi MousaviSS , KhazaneeA . Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: a pilot randomized, triple-blind study. Giornale Italiano di Dermatologia e Venereologia2015;150(4):351-5. [MEDLINE: 24825404]">Mapar 2015</a> (a): none </p> <p><a href="./references#CD011393-bbs2-0052" title="MortazaviM , FaghihiG , NaeiniAE , MonghadM , HosseiniSM . Zinc sulfate for the relief of pruritus in patients on maintenance hemodialysis [abstract no: SA590]. NDT Plus2010;3(Suppl 3):iii241. [EMBASE: 70484056]NajafabadiMM , FaghihiG , EmamiA , MonghadM , MoeenzadehF , SharifN , et al. Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis. Therapeutic Apheresis &amp; Dialysis2012;16(2):142-5. [MEDLINE: 22458392]">Najafabadi 2012</a> (b): none “attributable to zinc sulfate” </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0043" title="MaparMA , PazyarN , SiahpooshA , LatifiSM , Beladi MousaviSS , KhazaneeA . Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: a pilot randomized, triple-blind study. Giornale Italiano di Dermatologia e Venereologia2015;150(4):351-5. [MEDLINE: 24825404]">Mapar 2015</a>: vomiting (1/20) </p> <p><a href="./references#CD011393-bbs2-0052" title="MortazaviM , FaghihiG , NaeiniAE , MonghadM , HosseiniSM . Zinc sulfate for the relief of pruritus in patients on maintenance hemodialysis [abstract no: SA590]. NDT Plus2010;3(Suppl 3):iii241. [EMBASE: 70484056]NajafabadiMM , FaghihiG , EmamiA , MonghadM , MoeenzadehF , SharifN , et al. Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis. Therapeutic Apheresis &amp; Dialysis2012;16(2):142-5. [MEDLINE: 22458392]">Najafabadi 2012</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ergocalciferol versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 50,000 IU/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0070" title="ShirazianS , KlineM , SakhiyaV , SchanlerM , MoledinaD , PatelC , et al. Longitudinal predictors of uremic pruritus. Journal of Renal Nutrition2013;23(6):428-31. [MEDLINE: 24209894]ShirazianS , SchanlerM , DrakakisJ , MiyawakiNB , FishbaneS . The effect of vitamin D insufficiency on uremic pruritis [abstract no: PUB388]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):982A. ShirazianS , SchanlerM , ShastryS , DwivediS , KumarM , RiceK , et al. The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial. Journal of Renal Nutrition2013;23(4):308-14. [MEDLINE: 23453391]">Shirazian 2013</a>: none </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0070" title="ShirazianS , KlineM , SakhiyaV , SchanlerM , MoledinaD , PatelC , et al. Longitudinal predictors of uremic pruritus. Journal of Renal Nutrition2013;23(6):428-31. [MEDLINE: 24209894]ShirazianS , SchanlerM , DrakakisJ , MiyawakiNB , FishbaneS . The effect of vitamin D insufficiency on uremic pruritis [abstract no: PUB388]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):982A. ShirazianS , SchanlerM , ShastryS , DwivediS , KumarM , RiceK , et al. The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial. Journal of Renal Nutrition2013;23(4):308-14. [MEDLINE: 23453391]">Shirazian 2013</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turmeric (curcumin) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 500 mg (22.1 mg), 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0059" title="PakfetratM , BasiriF , MalekmakanL , RoozbehJ . Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. Journal of Nephrology2014;27(2):203-7. [EMBASE: 2014347658]">Pakfetrat 2014</a>: none </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0059" title="PakfetratM , BasiriF , MalekmakanL , RoozbehJ . Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. Journal of Nephrology2014;27(2):203-7. [EMBASE: 2014347658]">Pakfetrat 2014</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fumaria parviflora versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 1000 mg, 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0002" title="AkramiR , HashempurMH , TavakoliA , NimrouziM , SayadiM , RoodakiM , et al. Effects of Fumaria parviflora L on uremic pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled trial. Jundishapur Journal of Natural Pharmaceutical Products2017;12(3 Suppl):e39744. [EMBASE: 621978284]">Akrami 2017</a>: Gastric pain (4/39), rash (1/39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0002" title="AkramiR , HashempurMH , TavakoliA , NimrouziM , SayadiM , RoodakiM , et al. Effects of Fumaria parviflora L on uremic pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled trial. Jundishapur Journal of Natural Pharmaceutical Products2017;12(3 Suppl):e39744. [EMBASE: 621978284]">Akrami 2017</a>: abdominal pain (1/40), constipation (1/40) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Senna versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: dose and frequency not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0022" title="FallahzadehMK , FaridiP , SarvestaniAK , SaghebMM , BlondinJ , MohagheghzadehA , et al. Effect of senna on reduction of uremic pruritus in hemodialysis patients: a randomized double-blind placebo-controlled trial [abstract]. American Journal of Kidney Diseases2015;65(4):A33. [EMBASE: 71875063]">Fallahzadeh 2015</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0022" title="FallahzadehMK , FaridiP , SarvestaniAK , SaghebMM , BlondinJ , MohagheghzadehA , et al. Effect of senna on reduction of uremic pruritus in hemodialysis patients: a randomized double-blind placebo-controlled trial [abstract]. American Journal of Kidney Diseases2015;65(4):A33. [EMBASE: 71875063]">Fallahzadeh 2015</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evening primrose oil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 2 capsules/day (containing 360 mg of linoleic acid, 50 mg oleic acid and 45 mg of gamma‐linoleic acid) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0089" title="Yoshimoto-FuruieK , YoshimotoK , TanakaT , SaimaS , KikuchiY , ShayJ , et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron1999;81(2):151-9. [MEDLINE: 9933750]">Yoshimoto‐Furuie 1999</a>: none </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0089" title="Yoshimoto-FuruieK , YoshimotoK , TanakaT , SaimaS , KikuchiY , ShayJ , et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron1999;81(2):151-9. [MEDLINE: 9933750]">Yoshimoto‐Furuie 1999</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Activated charcoal versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 6 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0063" title="PedersonJA , MatterBJ , CzerwinskiAW , LlachF . Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Annals of Internal Medicine1980;93(3):446-8. [MEDLINE: 7436164]">Pederson 1980</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0063" title="PedersonJA , MatterBJ , CzerwinskiAW , LlachF . Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Annals of Internal Medicine1980;93(3):446-8. [MEDLINE: 7436164]">Pederson 1980</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Charcoal versus aluminium hydroxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Charcoal: 6 g, 3 times/day</p> <p>Aluminium hydroxide: 30 mL, 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0068" title="ShariatiA , AbbasiA , Mojer LouM , GhorbaniM . Comparison of the effects of oral charcoal capsule with aluminum hydroxide syrup on pruritus in hemodialysis patients. Journal of the Guilan University of Medical Sciences2010;18(72):22-9. ">Shariati 2010</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*when reported</p> </div> </div> <div class="table" id="CD011393-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: dialysis modality</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose/route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High flux/ high permeability/high flow</p> <p>HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) High‐flow HD</p> <p>(b) High‐permeability HD</p> <p>(c) High‐flux HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0003" title="AliasgharpourM , ZabolypourS , AsadinoghabiA , HaghaniH , LesanpezeshkiM . The effect of increasing blood flow rate on severity of uremic pruritus in hemodialysis patients: a single clinical trial. Journal of the National Medical Association2018;110(3):270-5. [MEDLINE: 29778130]">Aliasgharpour 2018</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0017" title="ChenZJ , CaoG , TangWX , LvXY , HuangSM , QinW , et al. A randomized controlled trial of high-permeability haemodialysis against conventional haemodialysis in the treatment of uraemic pruritus. Clinical &amp; Experimental Dermatology2009;34(6):679-83. [MEDLINE: 19175617]">Chen 2009</a> (b): not reported </p> <p><a href="./references#CD011393-bbs2-0033" title="HuiB , MinZ , Cai-lanY , GangL . Effect of high-flux dialysis membrane on uremic pruritus and solute clearance of maintenance hemodialysis patients. Journal of Clinical Rehabilitative Tissue Engineering Research2011;15(29):5493-6. [DOI: 10.3969/j.issn.1673-8225.2011.29.043]">Hui 2011</a> (c): not reported </p> <p><a href="./references#CD011393-bbs2-0034" title="JiangX , JiF , ChenZ , HuangQ . Comparison of high-flux hemodialysis with hemodialysis filtration in treatment of uraemic pruritus: a randomized controlled trial. International Urology &amp; Nephrology2016;48(9):1533-41. [MEDLINE: 27379625]">Jiang 2016</a> (c): not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0003" title="AliasgharpourM , ZabolypourS , AsadinoghabiA , HaghaniH , LesanpezeshkiM . The effect of increasing blood flow rate on severity of uremic pruritus in hemodialysis patients: a single clinical trial. Journal of the National Medical Association2018;110(3):270-5. [MEDLINE: 29778130]">Aliasgharpour 2018</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0017" title="ChenZJ , CaoG , TangWX , LvXY , HuangSM , QinW , et al. A randomized controlled trial of high-permeability haemodialysis against conventional haemodialysis in the treatment of uraemic pruritus. Clinical &amp; Experimental Dermatology2009;34(6):679-83. [MEDLINE: 19175617]">Chen 2009</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0033" title="HuiB , MinZ , Cai-lanY , GangL . Effect of high-flux dialysis membrane on uremic pruritus and solute clearance of maintenance hemodialysis patients. Journal of Clinical Rehabilitative Tissue Engineering Research2011;15(29):5493-6. [DOI: 10.3969/j.issn.1673-8225.2011.29.043]">Hui 2011</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0034" title="JiangX , JiF , ChenZ , HuangQ . Comparison of high-flux hemodialysis with hemodialysis filtration in treatment of uraemic pruritus: a randomized controlled trial. International Urology &amp; Nephrology2016;48(9):1533-41. [MEDLINE: 27379625]">Jiang 2016</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HD with haemoperfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoperfusion</p> <p>HA130‐RHA</p> <p>HA330‐RHA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0039" title="LiWH , YinYM , ChenH , WangXD , YunH , LiH , et al. Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus. Medicine2017;96(12):e6160. [MEDLINE: 28328802]">Li 2017a</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0039" title="LiWH , YinYM , ChenH , WangXD , YunH , LiH , et al. Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus. Medicine2017;96(12):e6160. [MEDLINE: 28328802]">Li 2017a</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoperfusion plus HD versus haemoperfusion plus HDF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoperfusion plus HD</p> <p>Haemoperfusion plus HDF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0092" title="ZhangJ , YuanY , AnX , OuyangC , RenH , YangG , et al. Comparison of combined blood purification techniques in treatment of dialysis patients with uraemic pruritus. International Journal of Clinical &amp; Experimental Medicine2016;9(5):8563-8. [EMBASE: 610545436]">Zhang 2016a</a> </p> <p>Haemoperfusion plus HD: not reported</p> <p>Haemoperfusion plus HDF: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Magnesium‐free HD versus standard HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard HD: 0.85 mmol/L magnesium solution for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0014" title="CarmichaelAJ , DickinsonF , McHughMI , MartinAM , FarrowM . Magnesium free dialysis for uraemic pruritus. BMJ1988;297(6663):1584-5. [MEDLINE: 3147085]CarmichaelAJ . Investigation of a low magnesium dialysate in uraemic pruritus [abstract no: 16]. British Journal of Dermatology1988;119(Suppl 33):50. [CENTRAL: CN-00509120] ">Carmichael 1988</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0014" title="CarmichaelAJ , DickinsonF , McHughMI , MartinAM , FarrowM . Magnesium free dialysis for uraemic pruritus. BMJ1988;297(6663):1584-5. [MEDLINE: 3147085]CarmichaelAJ . Investigation of a low magnesium dialysate in uraemic pruritus [abstract no: 16]. British Journal of Dermatology1988;119(Suppl 33):50. [CENTRAL: CN-00509120] ">Carmichael 1988</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium dialysate HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium concentration</p> <p>1.0 mmol/L</p> <p>1.25 mmol/L</p> <p>1.75 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0037" title="KyriazisJ , GlotsosJ . Dialysate calcium concentration of&lt;/=1.25 mmol/l: is it effective in suppressing uremic pruritus?Nephron2000;84(1):85-6. [MEDLINE: 10644916]">Kyriazis 2000</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0037" title="KyriazisJ , GlotsosJ . Dialysate calcium concentration of&lt;/=1.25 mmol/l: is it effective in suppressing uremic pruritus?Nephron2000;84(1):85-6. [MEDLINE: 10644916]">Kyriazis 2000</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cool versus normal dialysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cool dialysate: 35.5<sup>o</sup>C, 3 times/week </p> <p>Normal dialysate: 37<sup>o</sup>C, 3 time/week </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0066" title="RadM , JaghouriE , SharifipourF , RakhshaniMH . The effects of cool dialysate on pruritus status during hemodialysis of patients with chronic renal failure: a controlled randomized clinical trial. Iranian Red Crescent Medical Journal2017;19(1):e34759. [EMBASE: 614362274]">Rad 2017</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0066" title="RadM , JaghouriE , SharifipourF , RakhshaniMH . The effects of cool dialysate on pruritus status during hemodialysis of patients with chronic renal failure: a controlled randomized clinical trial. Iranian Red Crescent Medical Journal2017;19(1):e34759. [EMBASE: 614362274]">Rad 2017</a>: not reported </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*when reported</p> </div> </div> <div class="table" id="CD011393-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events: other interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose/route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐B exposure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) 0.19 nJ/cm<sup>2</sup>/sec, 3 times/week </p> <p>(b) Minimal erythema dose, twice/week</p> <p>(c) 4.4 watts/m<sup>2</sup>, twice/week </p> <p>(d) 200 mJ/cm<sup>2</sup>, 3 times/week </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0011" title="BlachleyJD , BlankenshipDM , MenterA , Parker TF 3rd, KnochelJP . Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. American Journal of Kidney Diseases1985;5(5):237-41. [MEDLINE: 4003393]">Blachley 1985</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0015" title="ChanCM , LeungCY , LamTY , LoKK , TongKL . Use of phototherapy (UVB) in the treatment uraemic pruritus, a randomized controlled trial [abstract no: OP2-3]. In: 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995:28. [CENTRAL: CN-00460521] ">Chan 1995</a> (b): not reported </p> <p><a href="./references#CD011393-bbs2-0028" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Relief of uremic pruritus with ultraviolet phototherapy. New England Journal of Medicine1977;297(3):136-8. [MEDLINE: 865585]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1977</a> (c): sunburn (3/10), tanning (5/10) </p> <p><a href="./references#CD011393-bbs2-0029" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Annals of Internal Medicine1979;91(1):17-21. [MEDLINE: 464448]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1979</a> (c): mild sunburn and tanning </p> <p><a href="./references#CD011393-bbs2-0035" title="KoMJ , YangJY , WuHY , HuFC , ChenSI , TsaiPJ , et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. British Journal of Dermatology2011;165(3):633-9. [MEDLINE: 21668425]">Ko 2011</a> (d): erythema (2/11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0011" title="BlachleyJD , BlankenshipDM , MenterA , Parker TF 3rd, KnochelJP . Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. American Journal of Kidney Diseases1985;5(5):237-41. [MEDLINE: 4003393]">Blachley 1985</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0015" title="ChanCM , LeungCY , LamTY , LoKK , TongKL . Use of phototherapy (UVB) in the treatment uraemic pruritus, a randomized controlled trial [abstract no: OP2-3]. In: 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995:28. [CENTRAL: CN-00460521] ">Chan 1995</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0028" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Relief of uremic pruritus with ultraviolet phototherapy. New England Journal of Medicine1977;297(3):136-8. [MEDLINE: 865585]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1977</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0029" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Annals of Internal Medicine1979;91(1):17-21. [MEDLINE: 464448]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1979</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0035" title="KoMJ , YangJY , WuHY , HuFC , ChenSI , TsaiPJ , et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. British Journal of Dermatology2011;165(3):633-9. [MEDLINE: 21668425]">Ko 2011</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐A exposure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐A (exposure): 40 min exposure (10, 180 cm 85W UV‐A lamps) 3 times/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0083" title="TaylorR , TaylorAE , DiffeyBL , HindsonTC . A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. Nephron1983;33(1):14-6. [MEDLINE: 6339963]">Taylor 1983</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0083" title="TaylorR , TaylorAE , DiffeyBL , HindsonTC . A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. Nephron1983;33(1):14-6. [MEDLINE: 6339963]">Taylor 1983</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thermal therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40<sup>o</sup>C thermal therapy, twice/week </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0032" title="HsuMC , ChenHW , HwuYJ , ChancCM , LiuCF . Effects of thermal therapy on uremic pruritus and biochemical parameters in patients having haemodialysis. Journal of Advanced Nursing2009;65(11):2397-408. [MEDLINE: 19737321]">Hsu 2009</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0032" title="HsuMC , ChenHW , HwuYJ , ChancCM , LiuCF . Effects of thermal therapy on uremic pruritus and biochemical parameters in patients having haemodialysis. Journal of Advanced Nursing2009;65(11):2397-408. [MEDLINE: 19737321]">Hsu 2009</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐B exposure versus cetirizine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐B</p> <p>Whole body: 200 to 1038 mJ/cm<sup>2</sup> every 3rd day for 15 sessions </p> <p>Cetirizine</p> <p>Oral: 10 mg/day for the same duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0069" title="SherjeenaPB , BinithaMP , RajanU , SreelathaM , SaritaS , NirmalC , et al. A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus. Indian Journal of Dermatology, Venereology &amp; Leprology2017;83(2):247-9. [MEDLINE: 28164894]">Sherjeena 2017</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*when reported</p> </div> </div> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011393-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011393-sec-0045"></div> <section id="CD011393-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD011393-sec-0047"> <h4 class="title">Results of the search</h4> <p>The process of selecting records and studies for inclusion in this systematic review is outlined in <a href="#CD011393-fig-0001">Figure 1</a>. The titles, abstracts, and summaries of 689 records were evaluated from three separate databases and the Specialised Register. Overlap within the database searches resulted in 196 records removed as duplicate records. An additional 312 records were excluded due to failing to meet study design, intervention, participant, or outcome criteria prior to full‐text review. </p> <div class="figure" id="CD011393-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011393-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We contacted 27 authors of papers with conflicting or missing data. Of all authors contacted for further clarification seven responded including Dr. Tol, Dr. Ashmore, Dr. Tarng, Dr. Pornanong Aramwit. Dr. Fleicher, Dr. Peer, and Dr. Haghverdi. Five authors provided supplementary data incorporated into the review. </p> <p>In total we identified 144 studies (181 records). Ninety‐one studies met our inclusion criteria and 42 studies (48 records) were excluded; six non‐RCTs were subsequently deleted. There are seven ongoing studies (<a href="./references#CD011393-bbs2-0133" title="HoltJ , MeyerB . Does evening primrose oil Improve pruritis (itching) in a dialysis population?www.anzctr org au/Trial/Registration/TrialReview.aspx?id=366382 (first received 26 June 2014). ">ACTRN12614000677606</a>; <a href="./references#CD011393-bbs2-0134" title="NevolsJ . Balneum Plus cream for the treatment of itchy skin in renal patients. www.isrctn.com/ISRCTN13971661 (first received 15 January 2015). ">DON'T ITCH 2015</a>; <a href="./references#CD011393-bbs2-0135" title="MortazaviM . Effect of omega-3 on pruritus scale in hemodialysis patients. www.en.irct.ir/trial/2125 (first received 3 October 2016). ">IRCT201311152417N14</a>; <a href="./references#CD011393-bbs2-0136" title="HoseiniAM . The effect of aloe vera gel on pruritus severity of Hemodialysis patients. www.en.irct.ir/trial/12117 (first received 4 May 2016). ">IRCT2015051411940N3</a>; <a href="./references#CD011393-bbs2-0137" title="MenzaghiF . A study to evaluate the safety and efficacy of CR845 in hemodialysis patients with moderate-to-severe pruritus (KALM-1). www.clinicaltrials gov/show/nct03422653 (first received 16 February 2018). ">NCT03422653</a>; <a href="./references#CD011393-bbs2-0138" title="NCT03636269. CR845-CLIN3103: a global study to evaluate the safety and efficacy of CR845 in hemodialysis patients with moderate-to-severe pruritus (KALM-2). www.clinicaltrials.gov/show/nct03636269 (first received 17 August 2018). ">NCT03636269</a>; <a href="./references#CD011393-bbs2-0139" title="KimYC , ParkJY , OhS , ChoJH , ChangJH , ChoiDE , et al. Safety and efficacy of PG102P for the control of pruritus in patients undergoing hemodialysis (SNUG trial): study protocol for a randomized controlled trial. Trials [Electronic Resource]2019;20(1):651. [MEDLINE: 31779697]">SNUG 2019</a> and three studies (<a href="./references#CD011393-bbs2-0130" title="KimSG . Efficacy and safety study of TRK-820 to treat conventional-treatment-resistant pruritus in patients receiving hemodialysis (TRK-820). www.clinicaltrials.gov/show/NCT01513161 (first received 20 January 2012). ">NCT01513161</a>; <a href="./references#CD011393-bbs2-0131" title="NCT02696499. Treatment of uremic pruritus with PA101B. www.clinicaltrials.gov/show/NCT02696499 (first received 2 March 2016). ">NCT02696499</a>; <a href="./references#CD011393-bbs2-0132" title="YuXQ . The effect and safety of hemodialysis and hemoperfusion on severe renal osteopathy and itching in uremia patients. www.clinicaltrials.gov/show/NCT02747979 (first received 22 April 2016). ">NCT02747979</a>) have recently been completed but have yet to report results. These 10 studies will be assessed in a future update of this review. </p> </section> <section id="CD011393-sec-0048"> <h4 class="title">Included studies</h4> <p>Ninety‐two studies (122 records) randomising 4466 participants met our inclusion criteria. All were RCTs that evaluated changes in itch (the primary outcome) associated with CKD before and after an intervention. Almost 90% of all RCTs originated from the USA, UK, Israel, Taiwan, Iran, Germany, or Japan. Translated non‐English study languages included Farsi, French, Mandarin, Turkish, German, and Spanish. </p> <p>The identified RCTs yielded a broad spectrum of different interventions for the treatment of itch associated with different underlying diseases. A total of 78 studies were placebo‐controlled, five studies compared gabapentinoids versus antihistamines or gabapentin versus pregabalin, and nine studies compared different dialysis modalities or dialysis solutions. </p> <p>The most common reason for studies not to be included in this review's quantitative analysis was inadequate reporting that precluded a meaningful comparison (e.g. SD or placebo results not explicitly reported). Thirty additional studies were included in the qualitative analysis. </p> <p>All but 23 studies described adverse effects in at least the intervention group. Just over half of the studies failed to specify adverse effects (or lack thereof) in the control population. A handful of studies also measured QoL, sleep quality, depression, dialysis quality, or patient satisfaction. Two studies with pharmacological interventions measured the interaction of dialysis modality with their intervention. No meaningful qualitative or quantitative analysis could be made from secondary outcomes other than adverse events. </p> <p>For additional information on all included studies see <a href="./references#CD011393-sec-0138" title="">Characteristics of included studies</a>. </p> </section> <section id="CD011393-sec-0049"> <h4 class="title">Excluded studies</h4> <p>Forty‐two studies were excluded from this review after comprehensive full text analysis. The most common reasons for exclusion were not meeting proper criteria for a true RCT, followed by inappropriate intervention. Four studies did not meet our protocol's criteria for the target population. Finally, eight excluded studies appeared to have never been initiated or stopped prematurely without publishing results. </p> <p>Across all searched studies the most common reasons for exclusion were:</p> <p> <ol id="CD011393-list-0012"> <li> <p>Outcome not truly itch‐related (e.g. serum PTH level used as a surrogate monitor)</p> </li> <li> <p>Lack of a true control, self‐control, or comparison group</p> </li> <li> <p>Wrong intervention</p> </li> <li> <p>Selected studies were not truly randomised or pseudo‐randomised.</p> </li> <li> <p>Gross omission of data based on the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD011393-bbs2-0159" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </li> <li> <p>Selected studies include patients without CKD</p> </li> <li> <p>Study was never initiated or stopped prematurely without publishing results.</p> </li> </ol> </p> <p>For additional information on all excluded studies see <a href="./references#CD011393-sec-0139" title="">Characteristics of excluded studies</a> </p> </section> </section> <section id="CD011393-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>All studies included in the meta‐analyses were RCTs, either parallel or cross‐over. Each explicitly reported patients as randomised to an intervention or placebo group. Sensitivity analyses were conducted for each intervention that included both only parallel RCTs versus cross‐over with parallel RCT data. No significant differences in effect size of heterogeneity were observed. See <a href="#CD011393-fig-0002">Figure 2</a>; <a href="#CD011393-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011393-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011393-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011393-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011393-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD011393-sec-0051"> <h4 class="title">Allocation</h4> <section id="CD011393-sec-0052"> <h5 class="title">Random sequence generation</h5> <p>Forty‐two studies reported a specific method of randomisation, either computer‐generated or the use of a random number table. Three studies were judged to be at high risk of bias (<a href="./references#CD011393-bbs2-0025" title="GhaneiE , ZeinaliJ , BorgheiM , HomayouniM . Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial. Iranian Red Crescent Medical Journal2012;14(9):515-22. [MEDLINE: 23115713]">Ghanei 2012</a>; <a href="./references#CD011393-bbs2-0040" title="LinTC , LaiYH , GuoSE , LiuCF , TsaiJC , GuoHR , et al. Baby oil therapy for uremic pruritus in haemodialysis patients. Journal of Clinical Nursing2012;21(1-2):139-48. [MEDLINE: 22093006]">Lin 2012</a>; <a href="./references#CD011393-bbs2-0069" title="SherjeenaPB , BinithaMP , RajanU , SreelathaM , SaritaS , NirmalC , et al. A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus. Indian Journal of Dermatology, Venereology &amp; Leprology2017;83(2):247-9. [MEDLINE: 28164894]">Sherjeena 2017</a>), and the remaining 47 studies were considered to be uncertain risk. </p> </section> <section id="CD011393-sec-0053"> <h5 class="title">Allocation concealment</h5> <p>Nineteen studies were judged to be al low risk of bias for allocation concealment, two were at high risk of bias ((<a href="./references#CD011393-bbs2-0044" title="MarinAR . Gabapentin therapy for pruritus in automated peritoneal dialysis patients: a randomized controlled trial [abstract no: SA-PO936]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):841A. ">Marin 2013</a>; <a href="./references#CD011393-bbs2-0069" title="SherjeenaPB , BinithaMP , RajanU , SreelathaM , SaritaS , NirmalC , et al. A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus. Indian Journal of Dermatology, Venereology &amp; Leprology2017;83(2):247-9. [MEDLINE: 28164894]">Sherjeena 2017</a>), and the remaining 71 studies were considered to be of uncertain risk. </p> </section> </section> <section id="CD011393-sec-0054"> <h4 class="title">Blinding</h4> <p>Two studies (<a href="./references#CD011393-bbs2-0035" title="KoMJ , YangJY , WuHY , HuFC , ChenSI , TsaiPJ , et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. British Journal of Dermatology2011;165(3):633-9. [MEDLINE: 21668425]">Ko 2011</a>; <a href="./references#CD011393-bbs2-0054" title="NasrollahiAR , MiladipourA , GhaneiE , YavariP , HaghverdiF . Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(2):73-7. [MEDLINE: 19363280]">Nasrollahi 2007</a>) only blinded the participants (single blind), and three studies (<a href="./references#CD011393-bbs2-0040" title="LinTC , LaiYH , GuoSE , LiuCF , TsaiJC , GuoHR , et al. Baby oil therapy for uremic pruritus in haemodialysis patients. Journal of Clinical Nursing2012;21(1-2):139-48. [MEDLINE: 22093006]">Lin 2012</a>; <a href="./references#CD011393-bbs2-0044" title="MarinAR . Gabapentin therapy for pruritus in automated peritoneal dialysis patients: a randomized controlled trial [abstract no: SA-PO936]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):841A. ">Marin 2013</a>; <a href="./references#CD011393-bbs2-0058" title="OzaykanS , MansurT , GunduzS , GuneyO . Comparison of ondansetron and cyproheptadine in treatment of uremic pruritus [Uremi kasintisi olan hastalarda ondansetron ve siproheptadinin etkinliginin karsilastirilmasi]. Turkderm Deri Hastaliklari Ve Frengi Arsivi2001;35(2):130-4. [EMBASE: 2001415704]">Ozaykan 2001</a>) were open‐label studies. Complicated equipment for emitting UVB radiation (<a href="./references#CD011393-bbs2-0035" title="KoMJ , YangJY , WuHY , HuFC , ChenSI , TsaiPJ , et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. British Journal of Dermatology2011;165(3):633-9. [MEDLINE: 21668425]">Ko 2011</a>; <a href="./references#CD011393-bbs2-0069" title="SherjeenaPB , BinithaMP , RajanU , SreelathaM , SaritaS , NirmalC , et al. A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus. Indian Journal of Dermatology, Venereology &amp; Leprology2017;83(2):247-9. [MEDLINE: 28164894]">Sherjeena 2017</a>), administering new dialysis modalities (<a href="./references#CD011393-bbs2-0092" title="ZhangJ , YuanY , AnX , OuyangC , RenH , YangG , et al. Comparison of combined blood purification techniques in treatment of dialysis patients with uraemic pruritus. International Journal of Clinical &amp; Experimental Medicine2016;9(5):8563-8. [EMBASE: 610545436]">Zhang 2016a</a>), or the absolute temperature of the intervention (<a href="./references#CD011393-bbs2-0040" title="LinTC , LaiYH , GuoSE , LiuCF , TsaiJC , GuoHR , et al. Baby oil therapy for uremic pruritus in haemodialysis patients. Journal of Clinical Nursing2012;21(1-2):139-48. [MEDLINE: 22093006]">Lin 2012</a>; <a href="./references#CD011393-bbs2-0066" title="RadM , JaghouriE , SharifipourF , RakhshaniMH . The effects of cool dialysate on pruritus status during hemodialysis of patients with chronic renal failure: a controlled randomized clinical trial. Iranian Red Crescent Medical Journal2017;19(1):e34759. [EMBASE: 614362274]">Rad 2017</a>) may have precluded any blinding efforts. The majority of blinded studies utilized unlabelled pills/infusions for oral/IV interventions or a comparable unlabelled vehicle of similar consistency for blinding of a topical agent. </p> <p>For performance bias, 10 studies were judged to be at high risk of bias (<a href="./references#CD011393-bbs2-0001" title="AfrasiabifarA , MehriZ , HosseiniN . Efficacy of topical application of sweet almond oil on reducing uremic pruritus in hemodialysis patients: A randomized clinical trial study. Iranian Red Crescent Medical Journal2017;19(2):e34695. [EMBASE: 614585273]">Afrasiabifar 2017</a>; <a href="./references#CD011393-bbs2-0033" title="HuiB , MinZ , Cai-lanY , GangL . Effect of high-flux dialysis membrane on uremic pruritus and solute clearance of maintenance hemodialysis patients. Journal of Clinical Rehabilitative Tissue Engineering Research2011;15(29):5493-6. [DOI: 10.3969/j.issn.1673-8225.2011.29.043]">Hui 2011</a>; <a href="./references#CD011393-bbs2-0038" title="Legroux-CrespelE , CledesJ , MiseryL . A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology2004;208(4):326-30. [MEDLINE: 15178915]">Legroux‐Crespel 2004</a>; <a href="./references#CD011393-bbs2-0039" title="LiWH , YinYM , ChenH , WangXD , YunH , LiH , et al. Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus. Medicine2017;96(12):e6160. [MEDLINE: 28328802]">Li 2017a</a>; <a href="./references#CD011393-bbs2-0044" title="MarinAR . Gabapentin therapy for pruritus in automated peritoneal dialysis patients: a randomized controlled trial [abstract no: SA-PO936]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):841A. ">Marin 2013</a>; <a href="./references#CD011393-bbs2-0053" title="NakhaeeS , NasiriA , WagheiY , MorshediJ . Comparison of Avena sativa, vinegar, and hydroxyzine for uremic pruritus of hemodialysis patients: a crossover randomized clinical trial. Iranian Journal of Kidney Diseases2015;9(4):316-22. [MEDLINE: 26174460]">Nakhaee 2015</a>; <a href="./references#CD011393-bbs2-0058" title="OzaykanS , MansurT , GunduzS , GuneyO . Comparison of ondansetron and cyproheptadine in treatment of uremic pruritus [Uremi kasintisi olan hastalarda ondansetron ve siproheptadinin etkinliginin karsilastirilmasi]. Turkderm Deri Hastaliklari Ve Frengi Arsivi2001;35(2):130-4. [EMBASE: 2001415704]">Ozaykan 2001</a>; <a href="./references#CD011393-bbs2-0069" title="SherjeenaPB , BinithaMP , RajanU , SreelathaM , SaritaS , NirmalC , et al. A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus. Indian Journal of Dermatology, Venereology &amp; Leprology2017;83(2):247-9. [MEDLINE: 28164894]">Sherjeena 2017</a>; <a href="./references#CD011393-bbs2-0074" title="AtalayH , SolakY , BiyikZ , GaipovA , GuneyF , TurkS . Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clinical Drug Investigation2013;33(6):401-8. [MEDLINE: 23572323]BiyikZ , SolakY , AtalayH , GaipovA , GuneyF , TurkS . Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. International Urology &amp; Nephrology2013;45(3):831-7. [MEDLINE: 22644743]SolakY , BiyikZ , AtalayH , GaipovA , GuneyF , TurkS , et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology2012;17(8):710-7. [MEDLINE: 22909343]">Solak 2012</a>; <a href="./references#CD011393-bbs2-0092" title="ZhangJ , YuanY , AnX , OuyangC , RenH , YangG , et al. Comparison of combined blood purification techniques in treatment of dialysis patients with uraemic pruritus. International Journal of Clinical &amp; Experimental Medicine2016;9(5):8563-8. [EMBASE: 610545436]">Zhang 2016a</a>), 59 studies were at low risk of bias, and the remaining 23 studies were considered to be of uncertain risk. </p> <p>For detection bias, 14 studies were judged to be at high risk of bias (<a href="./references#CD011393-bbs2-0028" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Relief of uremic pruritus with ultraviolet phototherapy. New England Journal of Medicine1977;297(3):136-8. [MEDLINE: 865585]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1977</a>; <a href="./references#CD011393-bbs2-0029" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Annals of Internal Medicine1979;91(1):17-21. [MEDLINE: 464448]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1979</a>; <a href="./references#CD011393-bbs2-0038" title="Legroux-CrespelE , CledesJ , MiseryL . A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology2004;208(4):326-30. [MEDLINE: 15178915]">Legroux‐Crespel 2004</a>; <a href="./references#CD011393-bbs2-0039" title="LiWH , YinYM , ChenH , WangXD , YunH , LiH , et al. Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus. Medicine2017;96(12):e6160. [MEDLINE: 28328802]">Li 2017a</a>; <a href="./references#CD011393-bbs2-0040" title="LinTC , LaiYH , GuoSE , LiuCF , TsaiJC , GuoHR , et al. Baby oil therapy for uremic pruritus in haemodialysis patients. Journal of Clinical Nursing2012;21(1-2):139-48. [MEDLINE: 22093006]">Lin 2012</a>; <a href="./references#CD011393-bbs2-0044" title="MarinAR . Gabapentin therapy for pruritus in automated peritoneal dialysis patients: a randomized controlled trial [abstract no: SA-PO936]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):841A. ">Marin 2013</a>; <a href="./references#CD011393-bbs2-0047" title="MohamedWA , ZakiFM , BekhitWH , SherifIS . Sodium thiosulfate (STS): a new option for hemodialysis patients with uremic pruritus [abstract no: SAP598]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii511-2. [EMBASE: 70766834]">Mohamed 2012</a>; <a href="./references#CD011393-bbs2-0053" title="NakhaeeS , NasiriA , WagheiY , MorshediJ . Comparison of Avena sativa, vinegar, and hydroxyzine for uremic pruritus of hemodialysis patients: a crossover randomized clinical trial. Iranian Journal of Kidney Diseases2015;9(4):316-22. [MEDLINE: 26174460]">Nakhaee 2015</a>; <a href="./references#CD011393-bbs2-0054" title="NasrollahiAR , MiladipourA , GhaneiE , YavariP , HaghverdiF . Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(2):73-7. [MEDLINE: 19363280]">Nasrollahi 2007</a>; <a href="./references#CD011393-bbs2-0058" title="OzaykanS , MansurT , GunduzS , GuneyO . Comparison of ondansetron and cyproheptadine in treatment of uremic pruritus [Uremi kasintisi olan hastalarda ondansetron ve siproheptadinin etkinliginin karsilastirilmasi]. Turkderm Deri Hastaliklari Ve Frengi Arsivi2001;35(2):130-4. [EMBASE: 2001415704]">Ozaykan 2001</a>; <a href="./references#CD011393-bbs2-0069" title="SherjeenaPB , BinithaMP , RajanU , SreelathaM , SaritaS , NirmalC , et al. A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus. Indian Journal of Dermatology, Venereology &amp; Leprology2017;83(2):247-9. [MEDLINE: 28164894]">Sherjeena 2017</a>; <a href="./references#CD011393-bbs2-0074" title="AtalayH , SolakY , BiyikZ , GaipovA , GuneyF , TurkS . Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clinical Drug Investigation2013;33(6):401-8. [MEDLINE: 23572323]BiyikZ , SolakY , AtalayH , GaipovA , GuneyF , TurkS . Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. International Urology &amp; Nephrology2013;45(3):831-7. [MEDLINE: 22644743]SolakY , BiyikZ , AtalayH , GaipovA , GuneyF , TurkS , et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology2012;17(8):710-7. [MEDLINE: 22909343]">Solak 2012</a>; <a href="./references#CD011393-bbs2-0083" title="TaylorR , TaylorAE , DiffeyBL , HindsonTC . A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. Nephron1983;33(1):14-6. [MEDLINE: 6339963]">Taylor 1983</a>; <a href="./references#CD011393-bbs2-0092" title="ZhangJ , YuanY , AnX , OuyangC , RenH , YangG , et al. Comparison of combined blood purification techniques in treatment of dialysis patients with uraemic pruritus. International Journal of Clinical &amp; Experimental Medicine2016;9(5):8563-8. [EMBASE: 610545436]">Zhang 2016a</a>), 47 were at low risk of bias, and the remaining 30 studies were considered to be of uncertain risk. </p> </section> <section id="CD011393-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>Eight studies (<a href="./references#CD011393-bbs2-0014" title="CarmichaelAJ , DickinsonF , McHughMI , MartinAM , FarrowM . Magnesium free dialysis for uraemic pruritus. BMJ1988;297(6663):1584-5. [MEDLINE: 3147085]CarmichaelAJ . Investigation of a low magnesium dialysate in uraemic pruritus [abstract no: 16]. British Journal of Dermatology1988;119(Suppl 33):50. [CENTRAL: CN-00509120] ">Carmichael 1988</a>; <a href="./references#CD011393-bbs2-0029" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Annals of Internal Medicine1979;91(1):17-21. [MEDLINE: 464448]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1979</a>; <a href="./references#CD011393-bbs2-0049" title="MurphyM , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. British Journal of Dermatology2003;148(2):314-7. [MEDLINE: 12588385]MurphyMD , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch [abstract]. British Journal of Dermatology2001;145(Suppl 59):20-1. [CENTRAL: CN-00509373] ">Murphy 2003</a>; <a href="./references#CD011393-bbs2-0062" title="PeckLW , MonsenER , AhmadS . Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. American Journal of Clinical Nutrition1996;64(2):210-4. [MEDLINE: 8694022]">Peck 1996</a>; <a href="./references#CD011393-bbs2-0063" title="PedersonJA , MatterBJ , CzerwinskiAW , LlachF . Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Annals of Internal Medicine1980;93(3):446-8. [MEDLINE: 7436164]">Pederson 1980</a>; <a href="./references#CD011393-bbs2-0071" title="LugonJR , SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF . Thalidomide (TH) as a new perspective for the treatment of uremic pruritus (UP): a crossed randomized double-blind trial [abstract no: 14P]. Journal of the American Society of Nephrology1992;3(3):377. [CENTRAL: CN-00461215] SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF , LugonJR . Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron1994;67(3):270-3. [MEDLINE: 7936015]">Silva 1994</a>; <a href="./references#CD011393-bbs2-0081" title="TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReidenbergMM , et al. Pruritus in dialysis patients treated with parenteral lidocaine. New England Journal of Medicine1977;296(5):261-2. [MEDLINE: 831109]TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReindenbergMM , et al. Treatment of pruritus in dialysis patients with parenteral lidocaine [abstract]. Kidney International1976;10(6):527. [CENTRAL: CN-00583216] ">Tapia 1977</a>; <a href="./references#CD011393-bbs2-0087" title="VessalG , SaghebMM , ShilianS , JafariP , SamaniSM . Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. Nephrology Dialysis Transplantation2010;25(5):1541-7. [MEDLINE: 20007756]">Vessal 2010</a>) had a greater than 10% dropout rate, mainly reflective of low sample sizes. The average post randomisation size of these eight studies was 28 participants. Only one of these studies analysed on an intention‐to‐treat basis. Twenty‐two of the remaining studies were completed with one or more dropouts after randomisation; half were analysed on an intention‐to‐treat basis. </p> <p>For attrition bias, 12 studies were judged to be at high risk of bias (<a href="./references#CD011393-bbs2-0013" title="BrenemanDL , CardoneJS , BlumsackRF , LatherRM , SearleEA , PollackVE . Topical capsaicin for treatment of hemodialysis-related pruritus. Journal of the American Academy of Dermatology1992;26(1):91-4. [MEDLINE: 1732343]">Breneman 1992</a>; <a href="./references#CD011393-bbs2-0014" title="CarmichaelAJ , DickinsonF , McHughMI , MartinAM , FarrowM . Magnesium free dialysis for uraemic pruritus. BMJ1988;297(6663):1584-5. [MEDLINE: 3147085]CarmichaelAJ . Investigation of a low magnesium dialysate in uraemic pruritus [abstract no: 16]. British Journal of Dermatology1988;119(Suppl 33):50. [CENTRAL: CN-00509120] ">Carmichael 1988</a>; <a href="./references#CD011393-bbs2-0028" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Relief of uremic pruritus with ultraviolet phototherapy. New England Journal of Medicine1977;297(3):136-8. [MEDLINE: 865585]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1977</a>; <a href="./references#CD011393-bbs2-0029" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Annals of Internal Medicine1979;91(1):17-21. [MEDLINE: 464448]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1979</a>; <a href="./references#CD011393-bbs2-0049" title="MurphyM , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. British Journal of Dermatology2003;148(2):314-7. [MEDLINE: 12588385]MurphyMD , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch [abstract]. British Journal of Dermatology2001;145(Suppl 59):20-1. [CENTRAL: CN-00509373] ">Murphy 2003</a>; <a href="./references#CD011393-bbs2-0062" title="PeckLW , MonsenER , AhmadS . Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. American Journal of Clinical Nutrition1996;64(2):210-4. [MEDLINE: 8694022]">Peck 1996</a>; <a href="./references#CD011393-bbs2-0063" title="PedersonJA , MatterBJ , CzerwinskiAW , LlachF . Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Annals of Internal Medicine1980;93(3):446-8. [MEDLINE: 7436164]">Pederson 1980</a>; <a href="./references#CD011393-bbs2-0071" title="LugonJR , SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF . Thalidomide (TH) as a new perspective for the treatment of uremic pruritus (UP): a crossed randomized double-blind trial [abstract no: 14P]. Journal of the American Society of Nephrology1992;3(3):377. [CENTRAL: CN-00461215] SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF , LugonJR . Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron1994;67(3):270-3. [MEDLINE: 7936015]">Silva 1994</a>; <a href="./references#CD011393-bbs2-0079" title="TamimiNA , MikhailAI , StevensPE . Role of gamma-linolenic acid in uraemic pruritus. Nephron1999;83(2):170-1. [MEDLINE: 10516500]">Tamimi 1999</a>; <a href="./references#CD011393-bbs2-0081" title="TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReidenbergMM , et al. Pruritus in dialysis patients treated with parenteral lidocaine. New England Journal of Medicine1977;296(5):261-2. [MEDLINE: 831109]TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReindenbergMM , et al. Treatment of pruritus in dialysis patients with parenteral lidocaine [abstract]. Kidney International1976;10(6):527. [CENTRAL: CN-00583216] ">Tapia 1977</a>; <a href="./references#CD011393-bbs2-0087" title="VessalG , SaghebMM , ShilianS , JafariP , SamaniSM . Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. Nephrology Dialysis Transplantation2010;25(5):1541-7. [MEDLINE: 20007756]">Vessal 2010</a>), 52 studies were at low risk of bias, and 28 studies were considered to be of uncertain risk. </p> </section> <section id="CD011393-sec-0056"> <h4 class="title">Selective reporting</h4> <p>Two studies appeared to only report and collect categorical or binary endpoints such as “significant itch reduction” versus “no significant itch reduction (<a href="./references#CD011393-bbs2-0029" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Annals of Internal Medicine1979;91(1):17-21. [MEDLINE: 464448]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1979</a>; <a href="./references#CD011393-bbs2-0081" title="TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReidenbergMM , et al. Pruritus in dialysis patients treated with parenteral lidocaine. New England Journal of Medicine1977;296(5):261-2. [MEDLINE: 831109]TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReindenbergMM , et al. Treatment of pruritus in dialysis patients with parenteral lidocaine [abstract]. Kidney International1976;10(6):527. [CENTRAL: CN-00583216] ">Tapia 1977</a>). <a href="./references#CD011393-bbs2-0071" title="LugonJR , SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF . Thalidomide (TH) as a new perspective for the treatment of uremic pruritus (UP): a crossed randomized double-blind trial [abstract no: 14P]. Journal of the American Society of Nephrology1992;3(3):377. [CENTRAL: CN-00461215] SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF , LugonJR . Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron1994;67(3):270-3. [MEDLINE: 7936015]">Silva 1994</a> clearly collected continuous itch outcomes, but only reported and analysed binomial outcomes. <a href="./references#CD011393-bbs2-0084" title="TolH , AtalayH , GuneyI , GokbelH , AltintepeL , BuyukbasS , et al. The effects of gabapentin therapy on pruritus, quality of life, depression and sleep quality in pruritic hemodialysis patients. Trakya Universitesi Tip Fakultesi Dergisi2010;27(1):1-5. [EMBASE: 2010207038]">Tol 2010</a>, <a href="./references#CD011393-bbs2-0063" title="PedersonJA , MatterBJ , CzerwinskiAW , LlachF . Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Annals of Internal Medicine1980;93(3):446-8. [MEDLINE: 7436164]">Pederson 1980</a>, and <a href="./references#CD011393-bbs2-0082" title="TarngDC , ChoYL , LiuHN , HuangTP . Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron1996;72(4):617-22. [MEDLINE: 8730431]">Tarng 1996</a> did not report placebo results and could not be included in the quantitative analysis. </p> <p>For reporting bias, 25 studies were judged to be at high risk of reporting bias (<a href="./references#CD011393-bbs2-0004" title="AmirkhanlouS , RashediA , TaherianJ , HafeziAA , ParsaeiS . Comparison of gabapentin and ketotifen in treatment of uremic pruritus in hemodialysis patients. Pakistan Journal of Medical Sciences2016;32(1):22-6. [MEDLINE: 27022338]">Amirkhanlou 2016</a>; <a href="./references#CD011393-bbs2-0007" title="AubiaJ , AguileraJ , LlorachI , GarciaC , RiusE , LLoverasJ , et al. Dialysis pruritus: effect of cimetidine. Journal of Dialysis1980;4(4):141-5. [MEDLINE: 7204712]">Aubia 1980</a>; <a href="./references#CD011393-bbs2-0008" title="BaumelouA , MelacM , French Cetirizine in Uraemic Pruritus Multicenter Study Group. Double blind placebo controlled study of cetirizine in the treatment of pruritus in patients receiving maintenance hemodialysis [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:381. ">Baumelou 1993</a>; <a href="./references#CD011393-bbs2-0013" title="BrenemanDL , CardoneJS , BlumsackRF , LatherRM , SearleEA , PollackVE . Topical capsaicin for treatment of hemodialysis-related pruritus. Journal of the American Academy of Dermatology1992;26(1):91-4. [MEDLINE: 1732343]">Breneman 1992</a>; <a href="./references#CD011393-bbs2-0014" title="CarmichaelAJ , DickinsonF , McHughMI , MartinAM , FarrowM . Magnesium free dialysis for uraemic pruritus. BMJ1988;297(6663):1584-5. [MEDLINE: 3147085]CarmichaelAJ . Investigation of a low magnesium dialysate in uraemic pruritus [abstract no: 16]. British Journal of Dermatology1988;119(Suppl 33):50. [CENTRAL: CN-00509120] ">Carmichael 1988</a>; <a href="./references#CD011393-bbs2-0015" title="ChanCM , LeungCY , LamTY , LoKK , TongKL . Use of phototherapy (UVB) in the treatment uraemic pruritus, a randomized controlled trial [abstract no: OP2-3]. In: 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995:28. [CENTRAL: CN-00460521] ">Chan 1995</a>; <a href="./references#CD011393-bbs2-0019" title="De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Effect of erythropoietin therapy on uraemic pruritus [abstract]. Nephrology Dialysis Transplantation1992;7(7):767. [CENTRAL: CN-00260739] De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. New England Journal of Medicine1992;326(15):969-74. [MEDLINE: 1545849]">De Marchi 1992</a>; <a href="./references#CD011393-bbs2-0020" title="DuqueMI , YosipovitchG , Fleischer AB Jr, WillardJ , FreedmanBI . Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. Journal of the American Academy of Dermatology2005;52(3 Pt 1):519-21. [MEDLINE: 15761435]">Duque 2005</a>; <a href="./references#CD011393-bbs2-0028" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Relief of uremic pruritus with ultraviolet phototherapy. New England Journal of Medicine1977;297(3):136-8. [MEDLINE: 865585]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1977</a>; <a href="./references#CD011393-bbs2-0037" title="KyriazisJ , GlotsosJ . Dialysate calcium concentration of&lt;/=1.25 mmol/l: is it effective in suppressing uremic pruritus?Nephron2000;84(1):85-6. [MEDLINE: 10644916]">Kyriazis 2000</a>; <a href="./references#CD011393-bbs2-0038" title="Legroux-CrespelE , CledesJ , MiseryL . A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology2004;208(4):326-30. [MEDLINE: 15178915]">Legroux‐Crespel 2004</a>; <a href="./references#CD011393-bbs2-0047" title="MohamedWA , ZakiFM , BekhitWH , SherifIS . Sodium thiosulfate (STS): a new option for hemodialysis patients with uremic pruritus [abstract no: SAP598]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii511-2. [EMBASE: 70766834]">Mohamed 2012</a>; <a href="./references#CD011393-bbs2-0048" title="MojganM , MasoudM , ShahrzadS , ZahraPH , FirouzehM , JinoosZ , et al. Pruritus-reducing effects of omega-3 fatty acids in hemodialysis patients [abstract no: P106]. Iranian Journal of Kidney Diseases2017;11(Suppl 1):7-8. [EMBASE: 616611409]">Mojgan 2017</a>; <a href="./references#CD011393-bbs2-0053" title="NakhaeeS , NasiriA , WagheiY , MorshediJ . Comparison of Avena sativa, vinegar, and hydroxyzine for uremic pruritus of hemodialysis patients: a crossover randomized clinical trial. Iranian Journal of Kidney Diseases2015;9(4):316-22. [MEDLINE: 26174460]">Nakhaee 2015</a>; <a href="./references#CD011393-bbs2-0063" title="PedersonJA , MatterBJ , CzerwinskiAW , LlachF . Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Annals of Internal Medicine1980;93(3):446-8. [MEDLINE: 7436164]">Pederson 1980</a>; <a href="./references#CD011393-bbs2-0066" title="RadM , JaghouriE , SharifipourF , RakhshaniMH . The effects of cool dialysate on pruritus status during hemodialysis of patients with chronic renal failure: a controlled randomized clinical trial. Iranian Red Crescent Medical Journal2017;19(1):e34759. [EMBASE: 614362274]">Rad 2017</a>; <a href="./references#CD011393-bbs2-0067" title="RivoryJP , MaheutH . Favorable effect of nicergoline on pruritus in chronic hemodialysis patients. Role of a hyper-alpha-adrenergic system? [Effet favorable de la nicergoline sur le prurit des hemodialyses chroniques. Role de l'hyperalpha-adrenergie?]. Presse Medicale1984;13(44):2703. [MEDLINE: 6096843]">Rivory 1984</a>; <a href="./references#CD011393-bbs2-0071" title="LugonJR , SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF . Thalidomide (TH) as a new perspective for the treatment of uremic pruritus (UP): a crossed randomized double-blind trial [abstract no: 14P]. Journal of the American Society of Nephrology1992;3(3):377. [CENTRAL: CN-00461215] SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF , LugonJR . Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron1994;67(3):270-3. [MEDLINE: 7936015]">Silva 1994</a>; <a href="./references#CD011393-bbs2-0076" title="MenzaghiF , MuneraC , OberdickMS , StaufferJW , SpencerRH . Randomized, placebo-controlled study on the efficacy of CR845 in improving the quality of life of hemodialysis patients with CKD- associated pruritus [abstract no: SA-OR032]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):80. MuneraC , VernonMK , StaufferJW , SpencerRH , MenzaghiF . Psychometric validation and meaningful change threshold of the worst itching intensity numerical rating scale for use in hemodialysis patients with pruritus [abstract]. Journal of Investigative Dermatology2018;138(5 Suppl 1):S99. [EMBASE: 622252595]SpencerRH , MuneraC , OberdickMS , StaufferJW , MenzaghiF . Randomized, placebo-controlled study on the efficacy of CR845 in reducing CKD- associated pruritus in hemodialysis patients [abstract no: FR-PO875]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):629. SpencerRH , MuneraC , VernonMK , StaufferJW , MenzaghiF . Clinically meaningful itch reduction by CR845 an 8-week randomized, placebo-controlled study in hemodialysis patients [abstract no: 280]. American Journal of Kidney Diseases2018;71(4):585. [EMBASE: 621596159]">Spencer 2017</a>; <a href="./references#CD011393-bbs2-0079" title="TamimiNA , MikhailAI , StevensPE . Role of gamma-linolenic acid in uraemic pruritus. Nephron1999;83(2):170-1. [MEDLINE: 10516500]">Tamimi 1999</a>; <a href="./references#CD011393-bbs2-0081" title="TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReidenbergMM , et al. Pruritus in dialysis patients treated with parenteral lidocaine. New England Journal of Medicine1977;296(5):261-2. [MEDLINE: 831109]TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReindenbergMM , et al. Treatment of pruritus in dialysis patients with parenteral lidocaine [abstract]. Kidney International1976;10(6):527. [CENTRAL: CN-00583216] ">Tapia 1977</a>; <a href="./references#CD011393-bbs2-0082" title="TarngDC , ChoYL , LiuHN , HuangTP . Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron1996;72(4):617-22. [MEDLINE: 8730431]">Tarng 1996</a>; <a href="./references#CD011393-bbs2-0083" title="TaylorR , TaylorAE , DiffeyBL , HindsonTC . A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. Nephron1983;33(1):14-6. [MEDLINE: 6339963]">Taylor 1983</a>; <a href="./references#CD011393-bbs2-0084" title="TolH , AtalayH , GuneyI , GokbelH , AltintepeL , BuyukbasS , et al. The effects of gabapentin therapy on pruritus, quality of life, depression and sleep quality in pruritic hemodialysis patients. Trakya Universitesi Tip Fakultesi Dergisi2010;27(1):1-5. [EMBASE: 2010207038]">Tol 2010</a>; <a href="./references#CD011393-bbs2-0090" title="FleischerAB , KaurM , ClarkA , YosipovitchG . A controlled comparative study of the efficacy of 1% pramoxine hydrochloride lotion for the treatment of uremic pruritus in adult hemodialysis patients [abstract no: P591]. Journal of the American Academy of Dermatology2007;56(2):AB63. [CENTRAL: CN-00615966] YoungTA , PatelTS , CamachoF , ClarkA , FreedmanBI , KaurM , et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. Journal of Dermatological Treatment2009;20(2):76-81. [MEDLINE: 18821119]">Young 2009</a>), 46 studies were at low risk of bias, and 21 studies were considered to be of uncertain risk. </p> </section> <section id="CD011393-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>In all the included studies, post‐randomisation dropout rates were balanced (no statistically significant difference in dropout rates) between intervention and control with the exception of <a href="./references#CD011393-bbs2-0061" title="Pauli-MagnusC , MikusG , AlscherDM , KirschnerT , NagelW , GugelerN , et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. Journal of the American Society of Nephrology2000;11(3):514-9. [MEDLINE: 10703675]">Pauli‐Magnus 2000</a> which had five dropouts (2.5%) in the intervention group for the indication of opioid pain relief. However, this was anticipated in pretrial planning and the patients were included in the analysis on an intention‐to‐treat basis. </p> <p>The authors of six studies (<a href="./references#CD011393-bbs2-0012" title="BoazM , ShtendikL , OronM , Portugal-CohenM , KohenR , BiroA , et al. A randomized controlled clinical trial comparing the efficacy of dead sea mineral-enriched body lotion versus two types of placebo in the treatment of cutaneous dryness, itching, peeling and tightness in hemodialysis patients (EDIT). Nephron2009;113(3):c169-76. [MEDLINE: 19672115]">Boaz 2009</a>; <a href="./references#CD011393-bbs2-0020" title="DuqueMI , YosipovitchG , Fleischer AB Jr, WillardJ , FreedmanBI . Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. Journal of the American Academy of Dermatology2005;52(3 Pt 1):519-21. [MEDLINE: 15761435]">Duque 2005</a>; <a href="./references#CD011393-bbs2-0075" title="MathurVS , SpencerRH , IllidgeJ , StaufferJW , MuneraC , MenzaghiF . Improvement of quality of life in hemodialysis patients with uremic pruritus as measured by the skindex-10 questionnaire: effect of a novel kappa opiod receptor agonist, CR845 [abstract no: TH-PO1040]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):338A. SpencerR , MathurVS , TumlinJA , StaufferJW , MenzaghiF . CR845, a novel kappa opiod receptor agonist reduces moderate-to-severe pruritus and improves quality of life in chronic kidney disease patients undergoing hemodialysis [abstract no: SA-PO1117]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B9. ">Spencer 2015</a>; <a href="./references#CD011393-bbs2-0076" title="MenzaghiF , MuneraC , OberdickMS , StaufferJW , SpencerRH . Randomized, placebo-controlled study on the efficacy of CR845 in improving the quality of life of hemodialysis patients with CKD- associated pruritus [abstract no: SA-OR032]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):80. MuneraC , VernonMK , StaufferJW , SpencerRH , MenzaghiF . Psychometric validation and meaningful change threshold of the worst itching intensity numerical rating scale for use in hemodialysis patients with pruritus [abstract]. Journal of Investigative Dermatology2018;138(5 Suppl 1):S99. [EMBASE: 622252595]SpencerRH , MuneraC , OberdickMS , StaufferJW , MenzaghiF . Randomized, placebo-controlled study on the efficacy of CR845 in reducing CKD- associated pruritus in hemodialysis patients [abstract no: FR-PO875]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):629. SpencerRH , MuneraC , VernonMK , StaufferJW , MenzaghiF . Clinically meaningful itch reduction by CR845 an 8-week randomized, placebo-controlled study in hemodialysis patients [abstract no: 280]. American Journal of Kidney Diseases2018;71(4):585. [EMBASE: 621596159]">Spencer 2017</a>; <a href="./references#CD011393-bbs2-0085" title="KumarJ , CrawfordP , MathurV , SciasciaT . Nalbuphine ER tablets in hemodialysis patients with severe uremic pruritus: multicenter, randomized, double-blind, placebo-controlled trial [abstract no: 185]. American Journal of Kidney Diseases2016;67(5):A65. [EMBASE: 72313488]MathurVS , GermainMJ , DuncanR , SciasciaT . The rationale for and design of TREVITR02: a multicenter randomized, double-blind, placebo-controlled trial of nalbuphine ER for the treatment of uremic pruritus in hemodialysis patients [abstract no: PUB113]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):912A. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT , TR02 Study Investigators. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. American Journal of Nephrology2017;46(6):450-8. [MEDLINE: 29253847]MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . A multicenter, phase2/3 randomized, double-blind, placebo-controlled tiral of nalbuphine ER tablets for the treatment of uremic pruritus: baseline population characteristics [abstract no: TH-PO956]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):316a. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . Randomized, double-blind, placebo-controlled, parallel, 3-arm study of safety and anti-pruritic efficacy of nalbuphine HCI ER tablets in hemodialysis patients with uremic pruritus [abstract no: HI-OR07]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2. ">TREVITR02 2017</a>; <a href="./references#CD011393-bbs2-0090" title="FleischerAB , KaurM , ClarkA , YosipovitchG . A controlled comparative study of the efficacy of 1% pramoxine hydrochloride lotion for the treatment of uremic pruritus in adult hemodialysis patients [abstract no: P591]. Journal of the American Academy of Dermatology2007;56(2):AB63. [CENTRAL: CN-00615966] YoungTA , PatelTS , CamachoF , ClarkA , FreedmanBI , KaurM , et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. Journal of Dermatological Treatment2009;20(2):76-81. [MEDLINE: 18821119]">Young 2009</a>) had financial backing from the respective pharmaceutical manufacturers. One study (<a href="./references#CD011393-bbs2-0038" title="Legroux-CrespelE , CledesJ , MiseryL . A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology2004;208(4):326-30. [MEDLINE: 15178915]">Legroux‐Crespel 2004</a>) reported conflicting results and used arbitrary definitions of improvement. These seven studies were judged to be at high risk of bias. Sixty studies were judged to be at low risk of bias and 25 studies were considered to of uncertain risk. </p> </section> </section> <section id="CD011393-sec-0058"> <h3 class="title" id="CD011393-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD011393-tbl-0001"><b>Summary of findings 1</b> Pharmacological interventions versus placebo for the relief of itch in people with advanced chronic kidney disease</a>; <a href="./full#CD011393-tbl-0002"><b>Summary of findings 2</b> Topical treatments versus placebo for the relief of itch in people with advanced chronic kidney disease</a>; <a href="./full#CD011393-tbl-0003"><b>Summary of findings 3</b> Supplements, haemodialysis modalities, and other treatments for the relief of itch in people with advanced chronic kidney disease</a> </p> <p>We organised the studies into the following groups:</p> <p> <ol id="CD011393-list-0013"> <li> <p>Pharmacological interventions</p> </li> <li> <p>Topical interventions</p> </li> <li> <p>Oral or IV supplements</p> </li> <li> <p>Dialysis modality</p> </li> <li> <p>All other interventions.</p> </li> </ol> </p> <section id="CD011393-sec-0059"> <h4 class="title">1. Pharmacological interventions</h4> <p>See <a href="./full#CD011393-tbl-0001">summary of findings Table 1</a>; adverse effects <a href="#CD011393-tbl-0004">Table 1</a>. </p> <section id="CD011393-sec-0060"> <h5 class="title">GABA analogues</h5> <p>Twelve studies (<a href="./references#CD011393-bbs2-0004" title="AmirkhanlouS , RashediA , TaherianJ , HafeziAA , ParsaeiS . Comparison of gabapentin and ketotifen in treatment of uremic pruritus in hemodialysis patients. Pakistan Journal of Medical Sciences2016;32(1):22-6. [MEDLINE: 27022338]">Amirkhanlou 2016</a>; <a href="./references#CD011393-bbs2-0024" title="ForoutanN , EtminanA , NikvarzN , Shojai Shahrokh AbadiM . Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial. Hemodialysis International2017;21(1):63-71. [MEDLINE: 27397522]">Foroutan 2017</a>; <a href="./references#CD011393-bbs2-0030" title="Gobo-OliveiraM , PigariVG , OgataMS , MiotHA , PonceD , AbbadeLP . Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial. European Journal of Dermatology2018;28(4):488-95. [MEDLINE: 29976533]">Gobo‐Oliveira 2018</a>; <a href="./references#CD011393-bbs2-0031" title="GunalAI , OzalpG , YoldasTK , GunalSY , KircimanE , CelikerH . Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrology Dialysis Transplantation2004;19(12):3137-9. [MEDLINE: 15575002]">Gunal 2004</a>; <a href="./references#CD011393-bbs2-0044" title="MarinAR . Gabapentin therapy for pruritus in automated peritoneal dialysis patients: a randomized controlled trial [abstract no: SA-PO936]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):841A. ">Marin 2013</a>; <a href="./references#CD011393-bbs2-0050" title="NaghibiM , NazemianF , Mohammad-PoorA , Morovat-DarZ , Javidi-Dasht-BayazA , AzmoodehH . The effect of gabapentin on uremic pruritus in hemodialysis patients [abstract no: FP479]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi181. ">Naghibi 2007</a>; <a href="./references#CD011393-bbs2-0051" title="NainiAE , HarandiAA , KhanbabapourS , ShahidiS , SeirafiyanS , MohseniM . Gabapentin: a promising drug for the treatment of uremic pruritus. Saudi Journal of Kidney Diseases &amp; Transplantation2007;18(3):378-81. [MEDLINE: 17679749]NainiAE , ShahidiS , SeirafianS , AtapoorA , KhanbabapoorS , HarandiAA , et al. Gabapentin: a promising treatment for uremic pruritus [abstract no: SP471]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv174. ">Naini 2007</a>; <a href="./references#CD011393-bbs2-0055" title="NofalE , FaragF , NofalA , EldesoukyF , AlkotR , AbdelkhalikZ . Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2016;27(6):515-9. [MEDLINE: 27043168]SolakB , SolakY . Reply to: Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2017;28(3):280. [MEDLINE: 27687138]">Nofal 2016</a>; <a href="./references#CD011393-bbs2-0056" title="NoshadH . Comparison of gabapentin and antihistamins in treatment of uremic pruritus and its psychological problems [abstract no: P209]. Iranian Journal of Kidney Diseases2011;5(Suppl 2):27-8. [EMBASE: 70673855]">Noshad 2011</a>; <a href="./references#CD011393-bbs2-0074" title="AtalayH , SolakY , BiyikZ , GaipovA , GuneyF , TurkS . Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clinical Drug Investigation2013;33(6):401-8. [MEDLINE: 23572323]BiyikZ , SolakY , AtalayH , GaipovA , GuneyF , TurkS . Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. International Urology &amp; Nephrology2013;45(3):831-7. [MEDLINE: 22644743]SolakY , BiyikZ , AtalayH , GaipovA , GuneyF , TurkS , et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology2012;17(8):710-7. [MEDLINE: 22909343]">Solak 2012</a>; <a href="./references#CD011393-bbs2-0084" title="TolH , AtalayH , GuneyI , GokbelH , AltintepeL , BuyukbasS , et al. The effects of gabapentin therapy on pruritus, quality of life, depression and sleep quality in pruritic hemodialysis patients. Trakya Universitesi Tip Fakultesi Dergisi2010;27(1):1-5. [EMBASE: 2010207038]">Tol 2010</a>; <a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a>) involving 618 patients and 13 comparisons, investigating the effects of either oral gabapentin or pregabalin. Dosing included 300 mg twice weekly oral gabapentin (<a href="./references#CD011393-bbs2-0031" title="GunalAI , OzalpG , YoldasTK , GunalSY , KircimanE , CelikerH . Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrology Dialysis Transplantation2004;19(12):3137-9. [MEDLINE: 15575002]">Gunal 2004</a>; <a href="./references#CD011393-bbs2-0055" title="NofalE , FaragF , NofalA , EldesoukyF , AlkotR , AbdelkhalikZ . Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2016;27(6):515-9. [MEDLINE: 27043168]SolakB , SolakY . Reply to: Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2017;28(3):280. [MEDLINE: 27687138]">Nofal 2016</a>), 400 mg of twice weekly oral gabapentin (<a href="./references#CD011393-bbs2-0051" title="NainiAE , HarandiAA , KhanbabapourS , ShahidiS , SeirafiyanS , MohseniM . Gabapentin: a promising drug for the treatment of uremic pruritus. Saudi Journal of Kidney Diseases &amp; Transplantation2007;18(3):378-81. [MEDLINE: 17679749]NainiAE , ShahidiS , SeirafianS , AtapoorA , KhanbabapoorS , HarandiAA , et al. Gabapentin: a promising treatment for uremic pruritus [abstract no: SP471]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv174. ">Naini 2007</a>) or 75 mg twice weekly oral pregabalin (<a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a>) compared to placebo. <a href="./references#CD011393-bbs2-0050" title="NaghibiM , NazemianF , Mohammad-PoorA , Morovat-DarZ , Javidi-Dasht-BayazA , AzmoodehH . The effect of gabapentin on uremic pruritus in hemodialysis patients [abstract no: FP479]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi181. ">Naghibi 2007</a> did not explicitly state the dose of gabapentin. These five studies all reported itch on a 10 cm VAS. </p> <section id="CD011393-sec-0061"> <h6 class="title">GABA analogues versus placebo</h6> <p>GABA analogues reduced symptoms of uraemic itch compared to placebo (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.1 (5 studies, 297 participants): MD ‐4.95 cm, 95% CI ‐5.46 to ‐4.44 on VAS; I² = 0%; high certainty evidence). The overall certainty of the evidence was high as these results were taken from multiple RCTs with large, homogeneous magnitudes of effect and narrow (%% CI demonstrating precision and efficacy. Risk of bias was uncommon and low overall. </p> <p><a href="./references#CD011393-bbs2-0084" title="TolH , AtalayH , GuneyI , GokbelH , AltintepeL , BuyukbasS , et al. The effects of gabapentin therapy on pruritus, quality of life, depression and sleep quality in pruritic hemodialysis patients. Trakya Universitesi Tip Fakultesi Dergisi2010;27(1):1-5. [EMBASE: 2010207038]">Tol 2010</a>, a placebo controlled cross‐over RCT involving 14 patients taking gabapentin 300 mg/HD session, did not report placebo results and could not be included in the quantitative analysis. <a href="./references#CD011393-bbs2-0084" title="TolH , AtalayH , GuneyI , GokbelH , AltintepeL , BuyukbasS , et al. The effects of gabapentin therapy on pruritus, quality of life, depression and sleep quality in pruritic hemodialysis patients. Trakya Universitesi Tip Fakultesi Dergisi2010;27(1):1-5. [EMBASE: 2010207038]">Tol 2010</a> reported a significant absolute reduction in itch during gabapentin treatment: 6.3 cm (95% CI 3.8 to 8.8) versus baseline in VAS similar to the other gabapentin studies. </p> </section> <section id="CD011393-sec-0062"> <h6 class="title">GABA analogues versus antihistamines</h6> <p>Five studies examined the efficacy of gabapentin versus various antihistamines. <a href="./references#CD011393-bbs2-0044" title="MarinAR . Gabapentin therapy for pruritus in automated peritoneal dialysis patients: a randomized controlled trial [abstract no: SA-PO936]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):841A. ">Marin 2013</a> compared 300 mg gabapentin every two days versus 10 mg oral loratidine every two days; <a href="./references#CD011393-bbs2-0056" title="NoshadH . Comparison of gabapentin and antihistamins in treatment of uremic pruritus and its psychological problems [abstract no: P209]. Iranian Journal of Kidney Diseases2011;5(Suppl 2):27-8. [EMBASE: 70673855]">Noshad 2011</a> studied 100 to 200 gabapentin mg/day versus oral hydroxyzine; <a href="./references#CD011393-bbs2-0004" title="AmirkhanlouS , RashediA , TaherianJ , HafeziAA , ParsaeiS . Comparison of gabapentin and ketotifen in treatment of uremic pruritus in hemodialysis patients. Pakistan Journal of Medical Sciences2016;32(1):22-6. [MEDLINE: 27022338]">Amirkhanlou 2016</a> measured a binary response of itch improvement from gabapentin versus oral ketotifen; <a href="./references#CD011393-bbs2-0030" title="Gobo-OliveiraM , PigariVG , OgataMS , MiotHA , PonceD , AbbadeLP . Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial. European Journal of Dermatology2018;28(4):488-95. [MEDLINE: 29976533]">Gobo‐Oliveira 2018</a> compared 300 mg gabapentin 3 times/week versus 6 mg oral dexchlorpheniramine twice/day; and <a href="./references#CD011393-bbs2-0078" title="SuwanpidokkulP , ChaiprasertA , SupasyndhO , ChoovichianP , LuesuthiviboonL . Effects of gabanpentin and loratadine on uremic pruritus in hemodialysis patients: a randomized controlled trial [abstract no: F-PO896]. Journal of the American Society of Nephrology2007;18(Abstracts):300A. ">Suwanpidokkul 2007</a> studied 100 mg gabapentin/day versus 10 mg loratidine/day. Overall, GABA analogues (gabapentin) may reduce symptoms of uraemic itch (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.2 (5 studies, 220 participants): SMD 0.44 reduction, 95% CI 0.75 to 0.14 lower; I² = 22%; low certainty evidence) compared to antihistamines. </p> <p>While these are four separate independent RCTs, there was low to moderate heterogeneity (the efficacy of oral antihistamines was highly variable), and two studies are at high risk of bias. <a href="./references#CD011393-bbs2-0004" title="AmirkhanlouS , RashediA , TaherianJ , HafeziAA , ParsaeiS . Comparison of gabapentin and ketotifen in treatment of uremic pruritus in hemodialysis patients. Pakistan Journal of Medical Sciences2016;32(1):22-6. [MEDLINE: 27022338]">Amirkhanlou 2016</a> does not report baseline scores and <a href="./references#CD011393-bbs2-0044" title="MarinAR . Gabapentin therapy for pruritus in automated peritoneal dialysis patients: a randomized controlled trial [abstract no: SA-PO936]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):841A. ">Marin 2013</a> was an open‐label study. </p> <p><a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a> (in addition to the placebo comparison above) reported a relative reduction of 4.1 cm (95% CI 1.98 to 6.22) with pregabalin over ondansetron. <a href="./references#CD011393-bbs2-0074" title="AtalayH , SolakY , BiyikZ , GaipovA , GuneyF , TurkS . Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clinical Drug Investigation2013;33(6):401-8. [MEDLINE: 23572323]BiyikZ , SolakY , AtalayH , GaipovA , GuneyF , TurkS . Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. International Urology &amp; Nephrology2013;45(3):831-7. [MEDLINE: 22644743]SolakY , BiyikZ , AtalayH , GaipovA , GuneyF , TurkS , et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology2012;17(8):710-7. [MEDLINE: 22909343]">Solak 2012</a> compared 300 mg gabapentin/day to 75 mg pregabalin/day and reported no significant difference in itch reduction between the two treatments. </p> </section> <section id="CD011393-sec-0063"> <h6 class="title">Adverse effects</h6> <p>Across the studies, few mild adverse effects occurred. Somnolence, dizziness, and fatigue are reported in less than 5% of patients in the intervention groups. No moderate or severe adverse effects are reported. </p> </section> </section> <section id="CD011393-sec-0064"> <h5 class="title">Ondansetron</h5> <section id="CD011393-sec-0065"> <h6 class="title">Ondansetron versus placebo</h6> <p>Three studies (<a href="./references#CD011393-bbs2-0006" title="AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uraemic pruritus in maintenance haemodialysis patients [abstract]. In: 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy. 1998:223. [CENTRAL: CN-00483053] AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uremic pruritus in hemodialysis patients. American Journal of Kidney Diseases2000;35(5):827-31. [MEDLINE: 10793015]">Ashmore 2000</a>; <a href="./references#CD011393-bbs2-0049" title="MurphyM , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. British Journal of Dermatology2003;148(2):314-7. [MEDLINE: 12588385]MurphyMD , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch [abstract]. British Journal of Dermatology2001;145(Suppl 59):20-1. [CENTRAL: CN-00509373] ">Murphy 2003</a>; <a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a>) investigated the effects of 8 mg oral ondansetron 3 times/day. All three studies reported itch on a 10 cm VAS, however <a href="./references#CD011393-bbs2-0006" title="AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uraemic pruritus in maintenance haemodialysis patients [abstract]. In: 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy. 1998:223. [CENTRAL: CN-00483053] AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uremic pruritus in hemodialysis patients. American Journal of Kidney Diseases2000;35(5):827-31. [MEDLINE: 10793015]">Ashmore 2000</a> employed a cross‐over design and reported VAS with only medians and interquartile ranges. This analysis extrapolates means and SDs according to the standard practice recommendations of Cochrane. Based on the inherent variability of these changes, a sensitivity analysis of ondansetron interventions without <a href="./references#CD011393-bbs2-0006" title="AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uraemic pruritus in maintenance haemodialysis patients [abstract]. In: 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy. 1998:223. [CENTRAL: CN-00483053] AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uremic pruritus in hemodialysis patients. American Journal of Kidney Diseases2000;35(5):827-31. [MEDLINE: 10793015]">Ashmore 2000</a> was performed. </p> <p>Ondansetron did not reduce symptoms of uraemic itch (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.3 (3 studies, 183 participants): MD ‐0.38 cm, 95% CI ‐1.04 to 0.27 on VAS; high certainty evidence) compared to placebo. These finding remain valid with the exclusion of <a href="./references#CD011393-bbs2-0006" title="AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uraemic pruritus in maintenance haemodialysis patients [abstract]. In: 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy. 1998:223. [CENTRAL: CN-00483053] AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uremic pruritus in hemodialysis patients. American Journal of Kidney Diseases2000;35(5):827-31. [MEDLINE: 10793015]">Ashmore 2000</a>. The placebo group experienced a non‐significant mean decrease in VAS ranging from 0.1 to 2 cm. </p> </section> <section id="CD011393-sec-0066"> <h6 class="title">Ondansetron versus antihistamine</h6> <p><a href="./references#CD011393-bbs2-0058" title="OzaykanS , MansurT , GunduzS , GuneyO . Comparison of ondansetron and cyproheptadine in treatment of uremic pruritus [Uremi kasintisi olan hastalarda ondansetron ve siproheptadinin etkinliginin karsilastirilmasi]. Turkderm Deri Hastaliklari Ve Frengi Arsivi2001;35(2):130-4. [EMBASE: 2001415704]">Ozaykan 2001</a> compared ondansetron to the antihistamine cyproheptadine. The authors report a slight improvement in itch reduction with ondansetron compared to cyproheptadine. </p> <p><a href="./references#CD011393-bbs2-0077" title="SubachRA , RadabaughRS , WilliamsDK , MarxMA . Ondansetron versus diphenhydramine versus placebo for hemodialysis-associated itching [abstract no: A1790]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):348A. [CENTRAL: CN-00447890] ">Subach 2001</a> and <a href="./references#CD011393-bbs2-0046" title="MirnezamiM . Effect of ondasetron on pruritus in hemodialysis patients. Arak Medical University Journal (AMUJ)2013;16(3):80-4. ">Mirnezami 2013</a> compared ondansetron to diphenhydramine and loratidine, respectively. Neither study found any difference in measured itch. </p> </section> <section id="CD011393-sec-0067"> <h6 class="title">Adverse effects</h6> <p>Nausea and vomiting were reported as uncommon and mild in severity.</p> </section> </section> <section id="CD011393-sec-0068"> <h5 class="title">Kappa‐opioid agonists versus placebo</h5> <p>Six studies investigated the effects of either 5 µg/day or 2.5 µg/day nalfurafine (oral or IV) (<a href="./references#CD011393-bbs2-0010" title="BhaduriS , MathurV , FellmannJ , RosenD , UenoK , UenoY . Nalfurafine (TRK-820) as a treatment for uremic pruritus (UP): patients are responsive independent of baseline itch - data from a multicenter, randomized, placebo controlled trial [abstract no: SA-PO1014]. Journal of the American Society of Nephrology2006;17(Abstracts):787A. BhaduriS , MathurV , FellmannJ , RosenD , UenoK , UenoY . Nalfurafine (TRK-820) as a treatment for uremic pruritus (UP): persistence of effect on dialytic and non-dialytic days - data from a multicenter, randomized, placebo controlled trial [abstract no: SA-PO1015]. Journal of the American Society of Nephrology2006;17(Abstracts):787A. ">Bhaduri 2006</a>; <a href="./references#CD011393-bbs2-0036" title="KumagaiH , EbataT , TakamoriK , MiyasatoK , MuramatsuT , NakamotoH , et al. Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. American Journal of Nephrology2012;36(2):175-83. [MEDLINE: 22868684]KumagaiH , EbataT , TakamoriK , MuramatsuT , NakamotoH , SuzukiH . Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrology Dialysis Transplantation2010;25(4):1251-7. [MEDLINE: 19926718]">Kumagai 2010</a>; <a href="./references#CD011393-bbs2-0088" title="WikstromB , GellertR , LadefogedSD , DandaY , AkaiM , IdeK , et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. Journal of the American Society of Nephrology2005;16(12):3742-7. [MEDLINE: 16251241]">Wikstrom 2005</a> (1); <a href="./references#CD011393-bbs2-0088" title="WikstromB , GellertR , LadefogedSD , DandaY , AkaiM , IdeK , et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. Journal of the American Society of Nephrology2005;16(12):3742-7. [MEDLINE: 16251241]">Wikstrom 2005</a> (2)) and a newly synthesized agent "CR845" (<a href="./references#CD011393-bbs2-0075" title="MathurVS , SpencerRH , IllidgeJ , StaufferJW , MuneraC , MenzaghiF . Improvement of quality of life in hemodialysis patients with uremic pruritus as measured by the skindex-10 questionnaire: effect of a novel kappa opiod receptor agonist, CR845 [abstract no: TH-PO1040]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):338A. SpencerR , MathurVS , TumlinJA , StaufferJW , MenzaghiF . CR845, a novel kappa opiod receptor agonist reduces moderate-to-severe pruritus and improves quality of life in chronic kidney disease patients undergoing hemodialysis [abstract no: SA-PO1117]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B9. ">Spencer 2015</a>; <a href="./references#CD011393-bbs2-0076" title="MenzaghiF , MuneraC , OberdickMS , StaufferJW , SpencerRH . Randomized, placebo-controlled study on the efficacy of CR845 in improving the quality of life of hemodialysis patients with CKD- associated pruritus [abstract no: SA-OR032]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):80. MuneraC , VernonMK , StaufferJW , SpencerRH , MenzaghiF . Psychometric validation and meaningful change threshold of the worst itching intensity numerical rating scale for use in hemodialysis patients with pruritus [abstract]. Journal of Investigative Dermatology2018;138(5 Suppl 1):S99. [EMBASE: 622252595]SpencerRH , MuneraC , OberdickMS , StaufferJW , MenzaghiF . Randomized, placebo-controlled study on the efficacy of CR845 in reducing CKD- associated pruritus in hemodialysis patients [abstract no: FR-PO875]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):629. SpencerRH , MuneraC , VernonMK , StaufferJW , MenzaghiF . Clinically meaningful itch reduction by CR845 an 8-week randomized, placebo-controlled study in hemodialysis patients [abstract no: 280]. American Journal of Kidney Diseases2018;71(4):585. [EMBASE: 621596159]">Spencer 2017</a>) at 0.5, 1.0, and 1.5 µg/kg IV with dialysis. All studies reported itch on a 10 cm VAS. </p> <p>Kappa opioid agonists reduced symptoms of uraemic itch (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.4 (5 studies, 661 participants): MD ‐1.05 cm, 95% CI ‐1.40 to ‐0.71 on VAS; I² = 0%; high certainty evidence). <a href="./references#CD011393-bbs2-0010" title="BhaduriS , MathurV , FellmannJ , RosenD , UenoK , UenoY . Nalfurafine (TRK-820) as a treatment for uremic pruritus (UP): patients are responsive independent of baseline itch - data from a multicenter, randomized, placebo controlled trial [abstract no: SA-PO1014]. Journal of the American Society of Nephrology2006;17(Abstracts):787A. BhaduriS , MathurV , FellmannJ , RosenD , UenoK , UenoY . Nalfurafine (TRK-820) as a treatment for uremic pruritus (UP): persistence of effect on dialytic and non-dialytic days - data from a multicenter, randomized, placebo controlled trial [abstract no: SA-PO1015]. Journal of the American Society of Nephrology2006;17(Abstracts):787A. ">Bhaduri 2006</a> reported no decrease in itch on VAS. </p> <p>Both studies examining CR845 were funded by Cara Therapeutics and were judged to be at high risk of bias. A sensitivity analysis without the CR845 studies yields the similar result. The additional power from these two high risk studies are not required to maintain the high certainty of the evidence. </p> <section id="CD011393-sec-0069"> <h6 class="title">Adverse effects</h6> <p>Adverse effects were common and were mild to moderate in severity. Somnolence, headache, insomnia, diarrhoea, and nausea/vomiting were reported in 2% to 10% of the intervention group. </p> </section> </section> <section id="CD011393-sec-0070"> <h5 class="title">Mu opioid antagonists versus placebo</h5> <p>Two cross‐over studies (<a href="./references#CD011393-bbs2-0061" title="Pauli-MagnusC , MikusG , AlscherDM , KirschnerT , NagelW , GugelerN , et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. Journal of the American Society of Nephrology2000;11(3):514-9. [MEDLINE: 10703675]">Pauli‐Magnus 2000</a>; <a href="./references#CD011393-bbs2-0064" title="PeerG , KivityS , AgamiO , FiremanE , SilverbergD , BlumM , et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet1996;348(9041):1552-4. [MEDLINE: 8950882]PeerG , SilverbergDS , BlumM , KaplanE , IainaA . Naltrexone (NX) an opiate antagonist relieves pruritus in dialysis patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:560. [CENTRAL: CN-00509406] ">Peer 1996</a>) compared 50 mg naltrexone once/day with placebo. Both studies evaluated itch on a 10 cm VAS. </p> <p>Mu opioid antagonists may not improve symptoms of uraemic itch (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.5 (2 studies, 62 participants): MD ‐4.29 cm, 95% CI ‐10.24 to 1.66 on VAS; low certainty evidence). </p> <p><a href="./references#CD011393-bbs2-0061" title="Pauli-MagnusC , MikusG , AlscherDM , KirschnerT , NagelW , GugelerN , et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. Journal of the American Society of Nephrology2000;11(3):514-9. [MEDLINE: 10703675]">Pauli‐Magnus 2000</a> reported interquartile ranges and <a href="./references#CD011393-bbs2-0064" title="PeerG , KivityS , AgamiO , FiremanE , SilverbergD , BlumM , et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet1996;348(9041):1552-4. [MEDLINE: 8950882]PeerG , SilverbergDS , BlumM , KaplanE , IainaA . Naltrexone (NX) an opiate antagonist relieves pruritus in dialysis patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:560. [CENTRAL: CN-00509406] ">Peer 1996</a> reported only percentage changes of VAS. Results are merged according to the standard practice recommendations of Cochrane. Additionally, <a href="./references#CD011393-bbs2-0064" title="PeerG , KivityS , AgamiO , FiremanE , SilverbergD , BlumM , et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet1996;348(9041):1552-4. [MEDLINE: 8950882]PeerG , SilverbergDS , BlumM , KaplanE , IainaA . Naltrexone (NX) an opiate antagonist relieves pruritus in dialysis patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:560. [CENTRAL: CN-00509406] ">Peer 1996</a> evaluated the effect of naltrexone on uraemic itch using Duo scale as well as VAS. There was no significant difference reported between naltrexone and placebo in these studies. </p> <section id="CD011393-sec-0071"> <h6 class="title">Adverse effects</h6> <p>These studies found that the adverse effects of Mu opioid antagonists are both somewhat common and mild to moderate in severity. Symptoms reported included loss of appetite, nausea, heartburn, and other gastrointestinal symptoms in approximately one third of the intervention groups. In addition, patients ceased any opioid medication for the duration of the trial period. Acute pain management became a common reason for cessation of natrexone during the studies resulting in many dropouts post randomisation. </p> </section> </section> <section id="CD011393-sec-0072"> <h5 class="title">Nalbuphine versus placebo</h5> <p><a href="./references#CD011393-bbs2-0085" title="KumarJ , CrawfordP , MathurV , SciasciaT . Nalbuphine ER tablets in hemodialysis patients with severe uremic pruritus: multicenter, randomized, double-blind, placebo-controlled trial [abstract no: 185]. American Journal of Kidney Diseases2016;67(5):A65. [EMBASE: 72313488]MathurVS , GermainMJ , DuncanR , SciasciaT . The rationale for and design of TREVITR02: a multicenter randomized, double-blind, placebo-controlled trial of nalbuphine ER for the treatment of uremic pruritus in hemodialysis patients [abstract no: PUB113]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):912A. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT , TR02 Study Investigators. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. American Journal of Nephrology2017;46(6):450-8. [MEDLINE: 29253847]MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . A multicenter, phase2/3 randomized, double-blind, placebo-controlled tiral of nalbuphine ER tablets for the treatment of uremic pruritus: baseline population characteristics [abstract no: TH-PO956]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):316a. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . Randomized, double-blind, placebo-controlled, parallel, 3-arm study of safety and anti-pruritic efficacy of nalbuphine HCI ER tablets in hemodialysis patients with uremic pruritus [abstract no: HI-OR07]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2. ">TREVITR02 2017</a> compared nalbuphine, a combined kappa‐opioid agonist and mu‐opioid antagonist, to placebo. Nalbuphine may make little or no difference to uraemic itch (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.6 (1 study, 179 participants): MD ‐0.75 cm, 95% CI ‐1.70 to 0.20 on VAS; low certainty evidence). </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0073"> <h5 class="title">Cromolyn versus placebo</h5> <p><a href="./references#CD011393-bbs2-0087" title="VessalG , SaghebMM , ShilianS , JafariP , SamaniSM . Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. Nephrology Dialysis Transplantation2010;25(5):1541-7. [MEDLINE: 20007756]">Vessal 2010</a> reported oral cromolyn may reduce symptoms of uraemic itch compared to placebo (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.7 (1 study, 40 participants): MD ‐4.8 cm, 95% CI ‐7.03 to‐ 2.57; low certainty evidence). </p> <section id="CD011393-sec-0074"> <h6 class="title">Adverse effects</h6> <p>The adverse effects reported were flatulence in one patient in the cromolyn group and three gastrointestinal complaints in the placebo group. </p> </section> </section> <section id="CD011393-sec-0075"> <h5 class="title">Nicotinamide versus placebo</h5> <p>A four‐week study by <a href="./references#CD011393-bbs2-0057" title="OmidianM , KhazaneeA , YaghoobiR , GhorbaniAR , PazyarN , BeladimousaviSS , et al. Therapeutic effect of oral nicotinamide on refractory uremic pruritus: a randomized, double-blind study. Saudi Journal of Kidney Diseases &amp; Transplantation2013;24(5):995-9. [MEDLINE: 24029269]">Omidian 2013</a> evaluated nicotinamide versus placebo. Nicotinamide may make little or no difference to the symptoms of uraemic itch (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.8 (1 study, 50 participants): 0.47 cm, 95% CI ‐0.32 to 1.26; low certainty evidence). </p> <p>No adverse effects were reported in either the nicotinamide to placebo groups.</p> </section> <section id="CD011393-sec-0076"> <h5 class="title">Erythropoietin versus placebo</h5> <p>A four‐week study by <a href="./references#CD011393-bbs2-0019" title="De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Effect of erythropoietin therapy on uraemic pruritus [abstract]. Nephrology Dialysis Transplantation1992;7(7):767. [CENTRAL: CN-00260739] De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. New England Journal of Medicine1992;326(15):969-74. [MEDLINE: 1545849]">De Marchi 1992</a> evaluated erythropoietin versus placebo. Erythropoietin had uncertain effects on the symptoms of uraemic itch (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.9 (1 study, 29 participants): MD ‐14.50, 95% CI ‐38.78 to 9.78 on 40 point Duo score; very low certainty evidence). </p> <p><a href="./references#CD011393-bbs2-0073" title="Sja'baniM , AsdieAH . Effect of erythropoietin on pruritus, anemia and quality of life, in chronic hemodialyzed end stage renal disease patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:501. [CENTRAL: CN-00509480] Sja'baniM , AsdieAH . Effect of erythropoietin on pruritus and quality of life in chronic hemodialyzed end stage renal disease patients [abstract]. Journal of Clinical Epidemiology1997;50(Suppl 1):10S. [CENTRAL: CN-00550491] ">Sja'bani 1997</a> reported that the erythropoietin group experienced a significantly greater mean reduction in itch than the placebo group. However, baseline itch scores are not fully reported to allow for inclusion in the quantitative review. </p> <p>These studies did not report on adverse effects.</p> </section> <section id="CD011393-sec-0077"> <h5 class="title">Cholestyramine versus placebo</h5> <p>Two cross‐over studies (<a href="./references#CD011393-bbs2-0072" title="SilverbergDS , IainaA , ReisinE , RotzakR , EliahouHE . Cholestyramine in uraemic pruritus. BMJ1977;1(6063):752-3. [MEDLINE: 322794]">Silverberg 1977</a>; <a href="./references#CD011393-bbs2-0086" title="vanLeusenR , Kutsch LojengaJC , RubenAT . Is cholestyramine helpful in uraemic pruritus?British Medical Journal1978;1(6117):918-9. [MEDLINE: 346150]">van Leusen 1978</a>) compared cholestyramine and placebo. Cholestyramine may make little or no difference to the symptoms of uraemic itch (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.10 (2 studies, 15 participants): MD 0.00, 95% CI ‐0.49 to 0.49 on a 0 to 3 severity scale; low certainty evidence). </p> <p>These studies did not report on adverse effects.</p> </section> <section id="CD011393-sec-0078"> <h5 class="title">Montelukast versus placebo</h5> <p>One cross‐over study (<a href="./references#CD011393-bbs2-0054" title="NasrollahiAR , MiladipourA , GhaneiE , YavariP , HaghverdiF . Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(2):73-7. [MEDLINE: 19363280]">Nasrollahi 2007</a>) and one parallel study (<a href="./references#CD011393-bbs2-0041" title="MahmudpourM , RouzbehJ , JalaliQA , PakfetratM , ZadeganSE , SaghebMM . Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients. Iranian Journal of Kidney Diseases2017;11(1):50-5. [MEDLINE: 28174353]">Mahmudpour 2017</a>) compared montelukast to placebo. Duo score and VAS were measured, respectively. </p> <p>Montelukast may slightly reduce symptoms of uraemic itch (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.11 (2 studies, 87 participants): SMD ‐1.40, 95% CI ‐1.87 to ‐0.92; moderate certainty evidence). </p> <p>Homogeneity was difficult to assess as the RCTs used well validated but slightly different itch severity scores. </p> <section id="CD011393-sec-0079"> <h6 class="title">Adverse effects</h6> <p>One patient in the intervention group of <a href="./references#CD011393-bbs2-0054" title="NasrollahiAR , MiladipourA , GhaneiE , YavariP , HaghverdiF . Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(2):73-7. [MEDLINE: 19363280]">Nasrollahi 2007</a> developed myelodysplastic syndrome, but this was not considered an adverse effect of Montelukast. In comparison, one patient in the placebo first group developed a myocardial infarction prior to being allocated to Montelukast. No other adverse effects were reported. </p> </section> </section> <section id="CD011393-sec-0080"> <h5 class="title">Sertraline versus placebo</h5> <p><a href="./references#CD011393-bbs2-0060" title="PakfetratM , MalekmakanL , HashemiN , TadayonT . Sertraline can reduce the uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran. Hemodialysis International2018;22(1):103-9. [MEDLINE: 28263039]">Pakfetrat 2018</a> compared sertraline and placebo. Sertraline may make little or no difference to the symptoms of uraemic itch (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.12 (1 study, 46 participants): MD ‐1.80 cm, 95% CI ‐3.65 to 0.05 on VAS; low certainty evidence). </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0081"> <h5 class="title">Lidocaine versus placebo</h5> <p><a href="./references#CD011393-bbs2-0081" title="TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReidenbergMM , et al. Pruritus in dialysis patients treated with parenteral lidocaine. New England Journal of Medicine1977;296(5):261-2. [MEDLINE: 831109]TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReindenbergMM , et al. Treatment of pruritus in dialysis patients with parenteral lidocaine [abstract]. Kidney International1976;10(6):527. [CENTRAL: CN-00583216] ">Tapia 1977</a> compared 600 mg IV lidocaine once/day and placebo. Only acute (15 to 30 minutes) relief of pruritus was included in the analysis. It is unclear whether lidocaine relieved itch (within 30 minutes) compared to placebo due to very low certainty evidence (<a href="./references#CD011393-fig-0004" title="">Analysis 1.1</a>.13 (1 study, 16 participants): MD ‐0.63 cm, 95% CI ‐1.46 to 0.19). Longer term assessment was not reported. Improvement in itch was reported in 8/10 participants receiving lidocaine and 1/6 participants receiving placebo (<a href="./references#CD011393-fig-0005" title="">Analysis 1.2</a>.1); the definition of improvement was not reported. </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0082"> <h5 class="title">Thalidomide versus placebo</h5> <p><a href="./references#CD011393-bbs2-0071" title="LugonJR , SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF . Thalidomide (TH) as a new perspective for the treatment of uremic pruritus (UP): a crossed randomized double-blind trial [abstract no: 14P]. Journal of the American Society of Nephrology1992;3(3):377. [CENTRAL: CN-00461215] SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF , LugonJR . Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron1994;67(3):270-3. [MEDLINE: 7936015]">Silva 1994</a> compared 100 mg thalidomide/day for one week with placebo. Thalidomide may relieve itch following administration (<a href="./references#CD011393-fig-0005" title="">Analysis 1.2</a>.2 (1 study, 18 participants): RR 4.17, 95% CI 1.08 to 16.15) compared to placebo, however, the certainty of the evidence was very low as these results were taken from a single study with a small number of participants, and a high number of dropouts (11). </p> <p>No adverse effects were reported in either the placebo or thalidomide groups.</p> </section> <section id="CD011393-sec-0083"> <h5 class="title">Sodium thiosulfate versus placebo</h5> <p><a href="./references#CD011393-bbs2-0047" title="MohamedWA , ZakiFM , BekhitWH , SherifIS . Sodium thiosulfate (STS): a new option for hemodialysis patients with uremic pruritus [abstract no: SAP598]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii511-2. [EMBASE: 70766834]">Mohamed 2012</a>compared 12.5 mg sodium thiosulfate/dialysis session and placebo. Overall, there was no reported significant difference comparing sodium thiosulfate and placebo. The study was not included in the quantitative analysis due to incomplete reporting of results. </p> <p>The study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0084"> <h5 class="title">Doxepin versus placebo</h5> <p><a href="./references#CD011393-bbs2-0065" title="Pour-Reza-GholiF , NasrollahiA , FirouzanA , NasliEE , FarrokhiF . Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(1):34-7. [MEDLINE: 19357442]Pour Reza GholiF , Reza NasrollahiA , NafarM , FiroozanA , EsfahaniEN , FarrokhiF . A randomized crossover trial: low-dose doxepin reduces pruritus in dialysis patients [abstract no: MP428]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:374. [CENTRAL: CN-00509425] ">Pour‐Reza‐Gholi 2007</a> compared 10 mg doxepin twice/day and placebo in a cross‐over study. Complete improvement was achieved in 58% of participants on doxepin which was significantly higher than placebo (P &gt; 0.001). </p> <section id="CD011393-sec-0085"> <h6 class="title">Adverse effects</h6> <p>Mild drowsiness was a commonly reported complaint and resulted in one dropout. Placebo adverse effects were not reported. </p> </section> </section> <section id="CD011393-sec-0086"> <h5 class="title">Antihistamines</h5> <p><a href="./references#CD011393-bbs2-0007" title="AubiaJ , AguileraJ , LlorachI , GarciaC , RiusE , LLoverasJ , et al. Dialysis pruritus: effect of cimetidine. Journal of Dialysis1980;4(4):141-5. [MEDLINE: 7204712]">Aubia 1980</a>compared 400 mg oral cimetidine once/day (over and up to 1 hour), a different unspecified "classical antihistamine", and placebo. The study found no significant differences between the three groups. No measures of variability (e.g. standard error) were reported. </p> <p>Antihistamines were compared with four other interventions: ondansetron, topically applied dilute vinegar, GABA agonists (gabapentin; see above section on GABA analogues), and Mu opioid antagonists (naltrexone). </p> <p> <ul id="CD011393-list-0014"> <li> <p><a href="./references#CD011393-bbs2-0058" title="OzaykanS , MansurT , GunduzS , GuneyO . Comparison of ondansetron and cyproheptadine in treatment of uremic pruritus [Uremi kasintisi olan hastalarda ondansetron ve siproheptadinin etkinliginin karsilastirilmasi]. Turkderm Deri Hastaliklari Ve Frengi Arsivi2001;35(2):130-4. [EMBASE: 2001415704]">Ozaykan 2001</a> reported the ondansetron group experienced a significantly greater mean reduction: 9 point (95% CI 16.34 to 1.64) compared to cyproheptadine (first generation antihistamine) using Duo pruritus score. </p> </li> <li> <p><a href="./references#CD011393-bbs2-0053" title="NakhaeeS , NasiriA , WagheiY , MorshediJ . Comparison of Avena sativa, vinegar, and hydroxyzine for uremic pruritus of hemodialysis patients: a crossover randomized clinical trial. Iranian Journal of Kidney Diseases2015;9(4):316-22. [MEDLINE: 26174460]">Nakhaee 2015</a> reported no significant difference between hydroxyzine and topically applied dilute vinegar. </p> </li> <li> <p><a href="./references#CD011393-bbs2-0038" title="Legroux-CrespelE , CledesJ , MiseryL . A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology2004;208(4):326-30. [MEDLINE: 15178915]">Legroux‐Crespel 2004</a> reported no significant difference between loratidine and the Mu opioid antagonist naltrexone. </p> </li> <li> <p><a href="./references#CD011393-bbs2-0008" title="BaumelouA , MelacM , French Cetirizine in Uraemic Pruritus Multicenter Study Group. Double blind placebo controlled study of cetirizine in the treatment of pruritus in patients receiving maintenance hemodialysis [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:381. ">Baumelou 1993</a> reported no significant difference between the two antihistamines cetirizine and dexchlorpheniramine. However, both significantly improved itch compared to placebo. </p> </li> </ul> </p> </section> <section id="CD011393-sec-0087"> <h5 class="title">Other therapies</h5> <p>Several isolated interventions could not be included in the quantitative analysis due to insufficient reporting of results. </p> <p> <ul id="CD011393-list-0015"> <li> <p><a href="./references#CD011393-bbs2-0022" title="FallahzadehMK , FaridiP , SarvestaniAK , SaghebMM , BlondinJ , MohagheghzadehA , et al. Effect of senna on reduction of uremic pruritus in hemodialysis patients: a randomized double-blind placebo-controlled trial [abstract]. American Journal of Kidney Diseases2015;65(4):A33. [EMBASE: 71875063]">Fallahzadeh 2015</a> reported a significant improvement with oral senna compared to placebo in patients with uraemic pruritus. </p> </li> <li> <p><a href="./references#CD011393-bbs2-0063" title="PedersonJA , MatterBJ , CzerwinskiAW , LlachF . Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Annals of Internal Medicine1980;93(3):446-8. [MEDLINE: 7436164]">Pederson 1980</a>reported a significant reduction with oral charcoal compared to placebo. </p> </li> <li> <p><a href="./references#CD011393-bbs2-0067" title="RivoryJP , MaheutH . Favorable effect of nicergoline on pruritus in chronic hemodialysis patients. Role of a hyper-alpha-adrenergic system? [Effet favorable de la nicergoline sur le prurit des hemodialyses chroniques. Role de l'hyperalpha-adrenergie?]. Presse Medicale1984;13(44):2703. [MEDLINE: 6096843]">Rivory 1984</a> reported a significant improvement in itch with nicergoline compared to placebo. </p> </li> <li> <p><a href="./references#CD011393-bbs2-0068" title="ShariatiA , AbbasiA , Mojer LouM , GhorbaniM . Comparison of the effects of oral charcoal capsule with aluminum hydroxide syrup on pruritus in hemodialysis patients. Journal of the Guilan University of Medical Sciences2010;18(72):22-9. ">Shariati 2010</a> reported oral charcoal was significantly more effective in reducing VAS in patients with uraemic pruritus than oral aluminium hydroxide. </p> </li> </ul> </p> </section> </section> <section id="CD011393-sec-0088"> <h4 class="title">2. Topical interventions</h4> <p>See <a href="./full#CD011393-tbl-0002">summary of findings Table 2</a>; adverse effects <a href="#CD011393-tbl-0005">Table 2</a>. </p> <section id="CD011393-sec-0089"> <h5 class="title">Capsaicin cream versus vehicle cream</h5> <p>Three studies tested the efficacy of the topical agent capsaicin in treating CKD‐related uraemic pruritus: 0.025% (<a href="./references#CD011393-bbs2-0018" title="ChoYL , LiuHN , HuangTP , TarngDC . Uremic pruritus: roles of parathyroid hormone and substance P. Journal of the American Academy of Dermatology1997;36(4):538-43. [MEDLINE: 9092738]">Cho 1997</a>) or 0.03% (<a href="./references#CD011393-bbs2-0042" title="MakhloughA , AlaS , Haj-HeydariZ , KashiZ , BariA . Topical capsaicin therapy for uremic pruritus in patients on hemodialysis.[Erratum in: Iran J Kidney Dis. 2010 Jul;4(3):273 Note: Ala, Shahram [added]; Haj-Heydari, Zohreh [added]; Kashi, Zahra [added]; Bari, Alireza [added]]. Iranian Journal of Kidney Diseases2010;4(2):137-40. [MEDLINE: 20404425]">Makhlough 2010</a>; <a href="./references#CD011393-bbs2-0082" title="TarngDC , ChoYL , LiuHN , HuangTP . Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron1996;72(4):617-22. [MEDLINE: 8730431]">Tarng 1996</a>) capsaicin cream applied 4 times/day versus vehicle cream (placebo). Evaluation of itch was reported on a 10 cm VAS and a customized 4‐point itch scale (<a href="./references#CD011393-bbs2-0042" title="MakhloughA , AlaS , Haj-HeydariZ , KashiZ , BariA . Topical capsaicin therapy for uremic pruritus in patients on hemodialysis.[Erratum in: Iran J Kidney Dis. 2010 Jul;4(3):273 Note: Ala, Shahram [added]; Haj-Heydari, Zohreh [added]; Kashi, Zahra [added]; Bari, Alireza [added]]. Iranian Journal of Kidney Diseases2010;4(2):137-40. [MEDLINE: 20404425]">Makhlough 2010</a>). Capsaicin cream application probably reduced the symptoms of uraemic itch (<a href="./references#CD011393-fig-0006" title="">Analysis 2.1</a>.1 (2 studies, 112 participants): SMD ‐0.84, 95% CI ‐1.22 to ‐0.45; I<sup>2</sup> = 0%; moderate certainty evidence) than during the vehicle application period. </p> <p><a href="./references#CD011393-bbs2-0082" title="TarngDC , ChoYL , LiuHN , HuangTP . Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron1996;72(4):617-22. [MEDLINE: 8730431]">Tarng 1996</a> did not provide any results for the placebo cross‐over periods and could not be included in the quantitative analysis. Within the intervention group of that study, approximately 80% of patients initially reported moderate to severe pruritus and then none or mild symptoms post‐intervention. </p> <section id="CD011393-sec-0090"> <h6 class="title">Adverse effects</h6> <p>All studies reported mild local burning sensations and cutaneous erythema as adverse effects. </p> </section> </section> <section id="CD011393-sec-0091"> <h5 class="title">Pramoxine cream versus vehicle cream</h5> <p><a href="./references#CD011393-bbs2-0090" title="FleischerAB , KaurM , ClarkA , YosipovitchG . A controlled comparative study of the efficacy of 1% pramoxine hydrochloride lotion for the treatment of uremic pruritus in adult hemodialysis patients [abstract no: P591]. Journal of the American Academy of Dermatology2007;56(2):AB63. [CENTRAL: CN-00615966] YoungTA , PatelTS , CamachoF , ClarkA , FreedmanBI , KaurM , et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. Journal of Dermatological Treatment2009;20(2):76-81. [MEDLINE: 18821119]">Young 2009</a>) compared 1% pramoxine cream twice/day with vehicle cream. It is uncertain whether pramoxine cream decreased uraemic itch (<a href="./references#CD011393-fig-0006" title="">Analysis 2.1</a>.2 (1 study, 28 participants): MD ‐1.97 cm, 95% CI ‐6.06 to 2.12; very low certainty evidence) compared to vehicle. </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0092"> <h5 class="title">Calcineurin inhibitor cream versus vehicle cream</h5> <p>Two studies compared 0.1% tacrolimus (<a href="./references#CD011393-bbs2-0020" title="DuqueMI , YosipovitchG , Fleischer AB Jr, WillardJ , FreedmanBI . Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. Journal of the American Academy of Dermatology2005;52(3 Pt 1):519-21. [MEDLINE: 15761435]">Duque 2005</a>) and 1% pimecrolimus (<a href="./references#CD011393-bbs2-0026" title="GhorbaniAR , FeilyA , KhaliliA , DormaneshB . Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients. Dermatitis2012;22(3):167-8. [MEDLINE: 21569748]">Ghorbani 2012a</a>) with vehicle cream. <a href="./references#CD011393-bbs2-0020" title="DuqueMI , YosipovitchG , Fleischer AB Jr, WillardJ , FreedmanBI . Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. Journal of the American Academy of Dermatology2005;52(3 Pt 1):519-21. [MEDLINE: 15761435]">Duque 2005</a> did not report SD (or any measurement of variability/error) and was not included in the quantitative analysis. <a href="./references#CD011393-bbs2-0020" title="DuqueMI , YosipovitchG , Fleischer AB Jr, WillardJ , FreedmanBI . Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. Journal of the American Academy of Dermatology2005;52(3 Pt 1):519-21. [MEDLINE: 15761435]">Duque 2005</a> reported pimecrolimus cream application resulted in a non‐significant, but greater reduction in VAS compared to the vehicle cream. </p> <p>It is uncertain whether 1% pimecrolimus reduced uraemic itch (<a href="./references#CD011393-fig-0006" title="">Analysis 2.1</a>.3 (1 study, 60 participants): MD 1.2 cm, 95% CI ‐0.36 to 2.76; very low certainty evidence) compared to vehicle. </p> <section id="CD011393-sec-0093"> <h6 class="title">Adverse effects</h6> <p>Adverse effects of the tacrolimus cream included a burning sensation over the area of skin applied with cream. </p> </section> </section> <section id="CD011393-sec-0094"> <h5 class="title">Dead Sea lotion versus vehicle lotion</h5> <p><a href="./references#CD011393-bbs2-0012" title="BoazM , ShtendikL , OronM , Portugal-CohenM , KohenR , BiroA , et al. A randomized controlled clinical trial comparing the efficacy of dead sea mineral-enriched body lotion versus two types of placebo in the treatment of cutaneous dryness, itching, peeling and tightness in hemodialysis patients (EDIT). Nephron2009;113(3):c169-76. [MEDLINE: 19672115]">Boaz 2009</a> compared Dead Sea lotion, containing Dead Sea water and sea silt (Dead Sea mud), and two related vehicle lotion groups. Itch was quantified using a 5‐point itch severity scale. It is uncertain whether Dead Sea lotion reduced uraemic itch (<a href="./references#CD011393-fig-0006" title="">Analysis 2.1</a>.4 (1 study, 41 participants): MD ‐2.00, 95% CI ‐4.31 to 0.31 on 5‐point severity scale; very low certainty evidence) compared to vehicle. </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0095"> <h5 class="title">Cromolyn cream</h5> <section id="CD011393-sec-0096"> <h6 class="title">Cromolyn cream versus vehicle cream</h6> <p><a href="./references#CD011393-bbs2-0023" title="FeilyA , DormaneshB , GhorbaniAR , MoosaviZ , KouchakM , CheraghianB , et al. Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients.[Erratum in: Int J Clin Pharmacol Ther. 2013 Nov;51(11):910]. International Journal of Clinical Pharmacology &amp; Therapeutics2012;50(7):510-3. [MEDLINE: 22732382]">Feily 2012</a> compared 4% cromolyn cream twice/day and vehicle cream. Cromolyn cream may not reduce uraemic itch (<a href="./references#CD011393-fig-0006" title="">Analysis 2.1</a>.5 (1 study, 60 participants): MD 0.8 cm, 95% CI ‐1.98 to 0.38; low certainty evidence) compared to vehicle. </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0097"> <h6 class="title">Cromolyn cream versus calcineurin inhibitor cream</h6> <p><a href="./references#CD011393-bbs2-0027" title="Ghorbani BirganiAR , KhaliliA , ZamaniL . A comparison between the effect of cromolyn sodium gel 4% and pimecrolimus cream 1% in treatment of pruritus of patients with end stage renal disease. Avicenna Journal of Nursing &amp; Midwifery Care2011;19(2):11-22. ">Ghorbani Birgani 2011</a> compared 4% cromolyn cream with 1% pimecrolimus cream. This study reported both interventions significantly reduced pruritus on a VAS with a non‐significant difference between the two. </p> </section> </section> <section id="CD011393-sec-0098"> <h5 class="title">Sericin cream versus vehicle cream</h5> <p><a href="./references#CD011393-bbs2-0005" title="AramwitP , KeongamaroonO , SiritientongT , BangN , SupasyndhO . Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study. BMC Nephrology2012;13:119. [MEDLINE: 23006933]">Aramwit 2012a</a> compared sericin cream and vehicle cream. Itch was reported on a 10 cm VAS. This study reported the sericin cream group experienced a significant absolute mean decrease in itch: 2.8 cm reduction (95% CI 0.5 lower to 5.1 lower) in VAS. Placebo results were not reported and the study could not be included in the quantitative analysis. </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0099"> <h5 class="title">Baby oil versus placebo</h5> <p><a href="./references#CD011393-bbs2-0040" title="LinTC , LaiYH , GuoSE , LiuCF , TsaiJC , GuoHR , et al. Baby oil therapy for uremic pruritus in haemodialysis patients. Journal of Clinical Nursing2012;21(1-2):139-48. [MEDLINE: 22093006]">Lin 2012</a> compared chilled and unchilled baby oil with a common vehicle. Itch was evaluated on with a customized 21‐point itch severity scale that incorporated itching, dryness, peeling, tightness, and sleep disturbances. The itch severity scale does not appear to be well validated unlike VAS or Duo score. The placebo group experienced a 1‐point non‐significant decrease in itch severity scale. </p> <p>Overall, baby oil application may reduce uraemic itch (<a href="./references#CD011393-fig-0006" title="">Analysis 2.1</a>.6 (1 study, 93 participants): MD ‐2.38, 95% CI ‐3.49 to ‐1.27; low certainty evidence) compared to vehicle. </p> <p>The report documented that no adverse effects occurred using either intervention or vehicle. </p> </section> <section id="CD011393-sec-0100"> <h5 class="title">L‐arginine versus vehicle salve</h5> <p><a href="./references#CD011393-bbs2-0021" title="Durrant-FinnU , OstenB , NenoffP . Topical L-arginine hydrochloride ointment improves skin dryness and pruritus in patients under chronic haemodialysis - a vehicle-controlled prospective randomised study [Topisch appliziertes L-argininhydrochlorid verbessert hauttrockenheit und pruritus bei patienten unter chronischer hamodialyse - Eine vehikelkontrollierte prospektive randomisierte studie im halbseitenvergleich]. Aktuelle Dermatologie2008;34(5):175-87. [EMBASE: 2008337532]">Durant‐Finn 2008</a>compared L‐arginine salve and vehicle salve groups. Itch was quantified using a 3‐point itch severity scale. L‐arginine may make little or no difference to uraemic itch (<a href="./references#CD011393-fig-0006" title="">Analysis 2.1</a>.7 (1 study, 48 participants): MD ‐0.58, 95% CI ‐1.86 to 0.7 on 3‐point severity scale; low certainty evidence) compared to vehicle. </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0101"> <h5 class="title">Polyunsaturated fatty acids versus vehicle cream</h5> <p><a href="./references#CD011393-bbs2-0016" title="ChenYC , ChiuWT , WuMS . Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. American Journal of Kidney Diseases2006;48(1):69-76. [MEDLINE: 16797388]">Chen 2006e</a> and <a href="./references#CD011393-bbs2-0001" title="AfrasiabifarA , MehriZ , HosseiniN . Efficacy of topical application of sweet almond oil on reducing uremic pruritus in hemodialysis patients: A randomized clinical trial study. Iranian Red Crescent Medical Journal2017;19(2):e34695. [EMBASE: 614585273]">Afrasiabifar 2017</a> compared topically applied polyunsaturated fatty acids of varying concentrations and quantity with vehicle cream. Itch was reported with a 10 cm VAS in both studies. </p> <p>Topically applied polyunsaturated fatty acids may make little or no difference to uraemic itch (<a href="./references#CD011393-fig-0006" title="">Analysis 2.1</a>.8 (2 studies, 78 participants): SMD ‐0.91, 95% CI ‐1.99 to 0.17; I<sup>2</sup> = 88% low certainty evidence) compared to vehicle. </p> <p>These studies did not report on adverse effects.</p> </section> <section id="CD011393-sec-0102"> <h5 class="title">Eurax cream versus Sarna lotion</h5> <p><a href="./references#CD011393-bbs2-0080" title="TanCC , WongKS , ThirumoorthyT , LeeE , WooK . A randomized, crossover trial of sarna and eurax lotions in the treatment of haemodialysis patients with uraemic pruritus. Journal of Dermatological Treatment1990;1(5):235-8. [EMBASE: 1991052418]">Tan 1990</a> compared Eurax cream with Sarna lotion and reported a statistically significant reduction of uraemic itch for both the Eurax cream and Sarna lotion periods. </p> <p>This study did not report on adverse effects.</p> </section> </section> <section id="CD011393-sec-0103"> <h4 class="title">3. Oral or IV supplements</h4> <p>See <a href="./full#CD011393-tbl-0003">summary of findings Table 3</a>; adverse effects <a href="#CD011393-tbl-0006">Table 3</a>. </p> <section id="CD011393-sec-0104"> <h5 class="title">Oral polyunsaturated fatty acids versus placebo</h5> <p>Three studies (<a href="./references#CD011393-bbs2-0025" title="GhaneiE , ZeinaliJ , BorgheiM , HomayouniM . Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial. Iranian Red Crescent Medical Journal2012;14(9):515-22. [MEDLINE: 23115713]">Ghanei 2012</a>; <a href="./references#CD011393-bbs2-0062" title="PeckLW , MonsenER , AhmadS . Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. American Journal of Clinical Nutrition1996;64(2):210-4. [MEDLINE: 8694022]">Peck 1996</a>; <a href="./references#CD011393-bbs2-0089" title="Yoshimoto-FuruieK , YoshimotoK , TanakaT , SaimaS , KikuchiY , ShayJ , et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron1999;81(2):151-9. [MEDLINE: 9933750]">Yoshimoto‐Furuie 1999</a>) tested the efficacy of 1 g polyunsaturated fatty acids 3 time/day versus placebo. Itch was evaluated with a customized 5‐point itch scale with continuous or binary results reported. Only <a href="./references#CD011393-bbs2-0025" title="GhaneiE , ZeinaliJ , BorgheiM , HomayouniM . Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial. Iranian Red Crescent Medical Journal2012;14(9):515-22. [MEDLINE: 23115713]">Ghanei 2012</a> also reported complete placebo results. </p> <p><a href="./references#CD011393-bbs2-0025" title="GhaneiE , ZeinaliJ , BorgheiM , HomayouniM . Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial. Iranian Red Crescent Medical Journal2012;14(9):515-22. [MEDLINE: 23115713]">Ghanei 2012</a> reported oral polyunsaturated fatty acids may decrease uraemic itch (<a href="./references#CD011393-fig-0007" title="">Analysis 3.1</a>.1 (1 study, 22 participants): MD ‐11.30%, 95% CI ‐19.01% to ‐3.59%; low certainty evidence) compared to placebo. Two additional studies (<a href="./references#CD011393-bbs2-0062" title="PeckLW , MonsenER , AhmadS . Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. American Journal of Clinical Nutrition1996;64(2):210-4. [MEDLINE: 8694022]">Peck 1996</a>; <a href="./references#CD011393-bbs2-0089" title="Yoshimoto-FuruieK , YoshimotoK , TanakaT , SaimaS , KikuchiY , ShayJ , et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron1999;81(2):151-9. [MEDLINE: 9933750]">Yoshimoto‐Furuie 1999</a>) also reported reductions in itch scores versus baseline, but did not include sufficient reporting of placebo results. </p> <p><a href="./references#CD011393-bbs2-0048" title="MojganM , MasoudM , ShahrzadS , ZahraPH , FirouzehM , JinoosZ , et al. Pruritus-reducing effects of omega-3 fatty acids in hemodialysis patients [abstract no: P106]. Iranian Journal of Kidney Diseases2017;11(Suppl 1):7-8. [EMBASE: 616611409]">Mojgan 2017</a> examined fish oil supplements versus placebo and reported a small but significant benefit versus placebo; neither CIs nor SDs were reported. </p> <p><a href="./references#CD011393-bbs2-0009" title="BegumR , BeluryMA , BurgessJR , PeckLW . Supplementation with n-3 and n-6 polyunsaturated fatty acids: effects on lipoxygenase activity and clinical symptoms of pruritus in hemodialysis patients. Journal of Renal Nutrition2004;14(4):233-41. [MEDLINE: 15483784]">Begum 2004</a> compared fish oil and safflower oil (both polyunsaturated fatty acids) and found neither significantly reduced itch on a VAS. </p> <p>These studies did not report on adverse effects.</p> </section> <section id="CD011393-sec-0105"> <h5 class="title">IV L‐carnitine versus placebo</h5> <p><a href="./references#CD011393-bbs2-0045" title="MettangT , ThomasS , KuhlmannU . L-carnitine does not alleviate uremic pruritus in hemodialysis patients. Nephron1997;75(3):372. [MEDLINE: 9069470]ThomasS , FischerFP , MettangT , Pauli-MagnusC , WeberJ , KuhlmannU . Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: a double-blind randomized trial. American Journal of Kidney Diseases1999;34(4):678-87. [MEDLINE: 10516349]">Mettang 1997</a> compared 10 mg IV L‐carnitine/kg and IV placebo once/dialysis session. Evaluation of itch used a 10 cm VAS. IV L‐carnitine may make little or no difference to uraemic itch (<a href="./references#CD011393-fig-0007" title="">Analysis 3.1</a>.2 (1 study, 12 participants): MD ‐0.26 cm, 95% CI ‐2.85 to 2.43 on VAS; low certainty evidence) compared to IV placebo. </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0106"> <h5 class="title">Oral zinc sulfate versus placebo</h5> <p>Two studies (<a href="./references#CD011393-bbs2-0043" title="MaparMA , PazyarN , SiahpooshA , LatifiSM , Beladi MousaviSS , KhazaneeA . Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: a pilot randomized, triple-blind study. Giornale Italiano di Dermatologia e Venereologia2015;150(4):351-5. [MEDLINE: 24825404]">Mapar 2015</a>; <a href="./references#CD011393-bbs2-0052" title="MortazaviM , FaghihiG , NaeiniAE , MonghadM , HosseiniSM . Zinc sulfate for the relief of pruritus in patients on maintenance hemodialysis [abstract no: SA590]. NDT Plus2010;3(Suppl 3):iii241. [EMBASE: 70484056]NajafabadiMM , FaghihiG , EmamiA , MonghadM , MoeenzadehF , SharifN , et al. Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis. Therapeutic Apheresis &amp; Dialysis2012;16(2):142-5. [MEDLINE: 22458392]">Najafabadi 2012</a>) compared 220 mg oral zinc sulfate twice/day and placebo. Evaluation of itch was reported on a 10 cm VAS. Zinc sulfate probably reduces uraemic itch (<a href="./references#CD011393-fig-0007" title="">Analysis 3.1</a>.3 (2 studies, 76 participants): MD ‐1.77 cm, 95% CI ‐2.88 to ‐0.66 on VAS; moderate certainty evidence) compared to placebo. </p> <section id="CD011393-sec-0107"> <h6 class="title">Adverse effects</h6> <p><a href="./references#CD011393-bbs2-0043" title="MaparMA , PazyarN , SiahpooshA , LatifiSM , Beladi MousaviSS , KhazaneeA . Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: a pilot randomized, triple-blind study. Giornale Italiano di Dermatologia e Venereologia2015;150(4):351-5. [MEDLINE: 24825404]">Mapar 2015</a> reported vomiting in one participant in the placebo group and <a href="./references#CD011393-bbs2-0052" title="MortazaviM , FaghihiG , NaeiniAE , MonghadM , HosseiniSM . Zinc sulfate for the relief of pruritus in patients on maintenance hemodialysis [abstract no: SA590]. NDT Plus2010;3(Suppl 3):iii241. [EMBASE: 70484056]NajafabadiMM , FaghihiG , EmamiA , MonghadM , MoeenzadehF , SharifN , et al. Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis. Therapeutic Apheresis &amp; Dialysis2012;16(2):142-5. [MEDLINE: 22458392]">Najafabadi 2012</a> did not specify exact adverse effects, only that none were "attributable to zinc sulfate". </p> </section> </section> <section id="CD011393-sec-0108"> <h5 class="title">Oral ergocalciferol versus placebo</h5> <p><a href="./references#CD011393-bbs2-0070" title="ShirazianS , KlineM , SakhiyaV , SchanlerM , MoledinaD , PatelC , et al. Longitudinal predictors of uremic pruritus. Journal of Renal Nutrition2013;23(6):428-31. [MEDLINE: 24209894]ShirazianS , SchanlerM , DrakakisJ , MiyawakiNB , FishbaneS . The effect of vitamin D insufficiency on uremic pruritis [abstract no: PUB388]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):982A. ShirazianS , SchanlerM , ShastryS , DwivediS , KumarM , RiceK , et al. The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial. Journal of Renal Nutrition2013;23(4):308-14. [MEDLINE: 23453391]">Shirazian 2013</a> compared 50,000 IU oral ergocalciferol/week and placebo. Itch was reported with the results of a 21‐point customised itch questionnaire. Ergocalciferol may make little or no difference to uraemic itch (<a href="./references#CD011393-fig-0007" title="">Analysis 3.1</a>.4 (1 study, 50 participants): MD 0.40, 95% CI ‐2.48 to 3.28; low certainty evidence) compared to placebo. </p> <p>No adverse effects were reported in the ergocalciferol group.</p> </section> <section id="CD011393-sec-0109"> <h5 class="title">Oral turmeric versus placebo</h5> <p><a href="./references#CD011393-bbs2-0059" title="PakfetratM , BasiriF , MalekmakanL , RoozbehJ . Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. Journal of Nephrology2014;27(2):203-7. [EMBASE: 2014347658]">Pakfetrat 2014</a>compared 22 mg oral turmeric 3 times/day and placebo. Itch was evaluated with a 40‐point modified Duo scale. Turmeric probably reduces uraemic itch (<a href="./references#CD011393-fig-0007" title="">Analysis 3.1</a>.5 (1 study, 100 participants): MD ‐6.40, 95% CI ‐7.42 to ‐5.38 on modified Duo scale; moderate certainty evidence) compared to placebo. </p> <p>No adverse effects are reported in the intervention group.</p> </section> <section id="CD011393-sec-0110"> <h5 class="title">Oral Fumaria parviflora versus placebo</h5> <p><a href="./references#CD011393-bbs2-0002" title="AkramiR , HashempurMH , TavakoliA , NimrouziM , SayadiM , RoodakiM , et al. Effects of Fumaria parviflora L on uremic pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled trial. Jundishapur Journal of Natural Pharmaceutical Products2017;12(3 Suppl):e39744. [EMBASE: 621978284]">Akrami 2017</a> compared 1 g oral Fumaria parviflora 3 times/day of with placebo. Itch was evaluated on a 10 cm VAS. Fumaria parviflora may reduce uraemic itch (<a href="./references#CD011393-fig-0007" title="">Analysis 3.1</a>.6 (1 study, 63 participants): MD ‐3.90 cm, 95% CI ‐5.04 to ‐2.76 on modified Duo scale; low certainty evidence) compared to placebo. </p> <p>A few mild abdominal symptoms were observed in both the Fumaria parviflora and placebo groups. </p> </section> </section> <section id="CD011393-sec-0111"> <h4 class="title">4. Dialysis modality</h4> <p>See <a href="./full#CD011393-tbl-0003">summary of findings Table 3</a>; adverse effects <a href="#CD011393-tbl-0007">Table 4</a>. </p> <section id="CD011393-sec-0112"> <h5 class="title">High flux/permeability haemodialysis versus conventional haemodialysis</h5> <p>Three studies (<a href="./references#CD011393-bbs2-0017" title="ChenZJ , CaoG , TangWX , LvXY , HuangSM , QinW , et al. A randomized controlled trial of high-permeability haemodialysis against conventional haemodialysis in the treatment of uraemic pruritus. Clinical &amp; Experimental Dermatology2009;34(6):679-83. [MEDLINE: 19175617]">Chen 2009</a>; <a href="./references#CD011393-bbs2-0033" title="HuiB , MinZ , Cai-lanY , GangL . Effect of high-flux dialysis membrane on uremic pruritus and solute clearance of maintenance hemodialysis patients. Journal of Clinical Rehabilitative Tissue Engineering Research2011;15(29):5493-6. [DOI: 10.3969/j.issn.1673-8225.2011.29.043]">Hui 2011</a>; <a href="./references#CD011393-bbs2-0034" title="JiangX , JiF , ChenZ , HuangQ . Comparison of high-flux hemodialysis with hemodialysis filtration in treatment of uraemic pruritus: a randomized controlled trial. International Urology &amp; Nephrology2016;48(9):1533-41. [MEDLINE: 27379625]">Jiang 2016</a>) compared high flux/permeability HD to conventional HD. Evaluation of itch used a 10 cm VAS. High flux/permeability HD may decrease uraemic itch (<a href="./references#CD011393-fig-0008" title="">Analysis 4.1</a>.1 (3 studies, 202 participants): MD ‐2.62 cm, 95% CI ‐3.72 to ‐1.52; I<sup>2</sup> = 67%; low certainty evidence) compared to conventional HD. </p> <p>These studies did not report on adverse effects.</p> </section> <section id="CD011393-sec-0113"> <h5 class="title">Haemodialysis with haemoperfusion versus conventional haemodialysis</h5> <p><a href="./references#CD011393-bbs2-0039" title="LiWH , YinYM , ChenH , WangXD , YunH , LiH , et al. Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus. Medicine2017;96(12):e6160. [MEDLINE: 28328802]">Li 2017a</a> compared conventional HD with HD using neutral macroporous resin haemoperfusion with one of two different resin perfusers. Evaluation of itch used a 10 cm VAS. HD with haemoperfusion therapy may decrease uraemic itch (<a href="./references#CD011393-fig-0008" title="">Analysis 4.1</a>.2 (1 study, 202 participants): MD ‐2.37 cm, 95% CI ‐2.89 to ‐1.85; low certainty evidence) compared to conventional HD </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0114"> <h5 class="title">Haemodiafiltration with haemoperfusion against high‐flux haemodialysis</h5> <p><a href="./references#CD011393-bbs2-0092" title="ZhangJ , YuanY , AnX , OuyangC , RenH , YangG , et al. Comparison of combined blood purification techniques in treatment of dialysis patients with uraemic pruritus. International Journal of Clinical &amp; Experimental Medicine2016;9(5):8563-8. [EMBASE: 610545436]">Zhang 2016a</a> compared haemodiafiltration with haemoperfusion to high‐flux HD. They reported that haemodiafiltration with haemoperfusion was significantly more effective in relieving itch than high‐flux HD measured on a VAS. </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0115"> <h5 class="title">High‐flow versus conventional flow haemodialysis</h5> <p><a href="./references#CD011393-bbs2-0003" title="AliasgharpourM , ZabolypourS , AsadinoghabiA , HaghaniH , LesanpezeshkiM . The effect of increasing blood flow rate on severity of uremic pruritus in hemodialysis patients: a single clinical trial. Journal of the National Medical Association2018;110(3):270-5. [MEDLINE: 29778130]">Aliasgharpour 2018</a> compared high‐flow HD with conventional flow HD. They reported a significant reduction in severity in itch with high‐flow HD measured on a 4‐point VAS. </p> <p>This study did not report on adverse effects.</p> </section> <section id="CD011393-sec-0116"> <h5 class="title">Haemodialysis solutions</h5> <p><a href="./references#CD011393-bbs2-0014" title="CarmichaelAJ , DickinsonF , McHughMI , MartinAM , FarrowM . Magnesium free dialysis for uraemic pruritus. BMJ1988;297(6663):1584-5. [MEDLINE: 3147085]CarmichaelAJ . Investigation of a low magnesium dialysate in uraemic pruritus [abstract no: 16]. British Journal of Dermatology1988;119(Suppl 33):50. [CENTRAL: CN-00509120] ">Carmichael 1988</a> compared magnesium‐free dialysate with conventional dialysate containing magnesium. They reported no significant itch reduction on a VAS. </p> <p><a href="./references#CD011393-bbs2-0066" title="RadM , JaghouriE , SharifipourF , RakhshaniMH . The effects of cool dialysate on pruritus status during hemodialysis of patients with chronic renal failure: a controlled randomized clinical trial. Iranian Red Crescent Medical Journal2017;19(1):e34759. [EMBASE: 614362274]">Rad 2017</a> compared cool dialysate with conventional dialysate at a normal temperature. They reported cool dialysate was significantly more effective in relieving uraemic pruritus. </p> <p><a href="./references#CD011393-bbs2-0037" title="KyriazisJ , GlotsosJ . Dialysate calcium concentration of&lt;/=1.25 mmol/l: is it effective in suppressing uremic pruritus?Nephron2000;84(1):85-6. [MEDLINE: 10644916]">Kyriazis 2000</a> crossed over four patients with variable concentrations of calcium in their dialysate and reported a non‐significant trend towards lower calcium concentrations reducing uraemic itch. </p> </section> </section> <section id="CD011393-sec-0117"> <h4 class="title">5. Other interventions</h4> <p>See <a href="./full#CD011393-tbl-0003">summary of findings Table 3</a>; adverse effects <a href="#CD011393-tbl-0008">Table 5</a>. </p> <section id="CD011393-sec-0118"> <h5 class="title">UV‐B radiation</h5> <p>Four studies (<a href="./references#CD011393-bbs2-0011" title="BlachleyJD , BlankenshipDM , MenterA , Parker TF 3rd, KnochelJP . Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. American Journal of Kidney Diseases1985;5(5):237-41. [MEDLINE: 4003393]">Blachley 1985</a>; <a href="./references#CD011393-bbs2-0029" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Annals of Internal Medicine1979;91(1):17-21. [MEDLINE: 464448]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1979</a>; <a href="./references#CD011393-bbs2-0035" title="KoMJ , YangJY , WuHY , HuFC , ChenSI , TsaiPJ , et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. British Journal of Dermatology2011;165(3):633-9. [MEDLINE: 21668425]">Ko 2011</a>; <a href="./references#CD011393-bbs2-0069" title="SherjeenaPB , BinithaMP , RajanU , SreelathaM , SaritaS , NirmalC , et al. A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus. Indian Journal of Dermatology, Venereology &amp; Leprology2017;83(2):247-9. [MEDLINE: 28164894]">Sherjeena 2017</a>) compared UV‐B radiation versus placebo (typically UV‐A) exposure 3 times/week for the reduction of CKD‐related uraemic pruritus. Due to the mechanism of the intervention there was often inherent difficulties in blinding the administrators and patients. Outcomes included both Duo score and percent of patients experiencing absolute relief. </p> <p>UV‐B radiation may make little or no difference to uraemic itch (<a href="./references#CD011393-fig-0009" title="">Analysis 5.1</a>.1 (4 studies, 86 participants): SMD ‐2.49, 95% CI ‐4.62 to ‐0.41; I<sup>2</sup> = 93%; low certainty evidence) compared to UV‐A/placebo </p> <p>UV‐A radiation was not originally included in this systemic review as an intervention category. During the 1980s some RCTs (including <a href="./references#CD011393-bbs2-0122" title="SanchezHG . Comparison of UVA and PUVA in pruritis due to renal failure. Actas Dermo Sifiliograficas1986;77(10):621-4. [CENTRAL: CN-00550484] ">Sanchez 1986</a> and <a href="./references#CD011393-bbs2-0083" title="TaylorR , TaylorAE , DiffeyBL , HindsonTC . A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. Nephron1983;33(1):14-6. [MEDLINE: 6339963]">Taylor 1983</a>) investigated UV‐A and found that it likely does not decrease uraemic itch. UV‐A has been commonly used as a placebo in RCTs of analogous interventions. </p> <p><a href="./references#CD011393-bbs2-0015" title="ChanCM , LeungCY , LamTY , LoKK , TongKL . Use of phototherapy (UVB) in the treatment uraemic pruritus, a randomized controlled trial [abstract no: OP2-3]. In: 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995:28. [CENTRAL: CN-00460521] ">Chan 1995</a> reported a significant reduction in itch in the UV‐B group but did not report the results of the placebo intervention. </p> <p>Common adverse effects across all studies included sunburn and tanning; these were also seen in the control UV exposures. </p> </section> <section id="CD011393-sec-0119"> <h5 class="title">Thermal therapy</h5> <p><a href="./references#CD011393-bbs2-0032" title="HsuMC , ChenHW , HwuYJ , ChancCM , LiuCF . Effects of thermal therapy on uremic pruritus and biochemical parameters in patients having haemodialysis. Journal of Advanced Nursing2009;65(11):2397-408. [MEDLINE: 19737321]">Hsu 2009</a> compared thermal (warming) therapy with a placebo patch. Evaluation of itch used a 10 cm VAS. Thermal therapy may make little or no difference to uraemic itch (<a href="./references#CD011393-fig-0009" title="">Analysis 5.1</a>.2 (1 study, 42 participants): MD ‐2.06 cm, 95% CI ‐6.54 to 2.42; low certainty evidence) compared to the placebo patch. </p> <p>This study did not report on adverse effects.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011393-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011393-sec-0120"></div> <section id="CD011393-sec-0121"> <h3 class="title" id="CD011393-sec-0121">Summary of main results</h3> <p>This systematic review assesses 92 RCTs evaluating 43 different interventions. Evidence for most interventions include only a single placebo controlled trial, often underpowered. However, the number of studies, participants, statistical power, and evidence quality significantly improves for several interventions. Less often, one intervention was compared to another allowing for some informal indirect comparisons between treatments. Fortunately, the majority of interventions include studies reporting itch with a well‐validated VAS or Duo’s scores aiding in the interpretation of the results. These results allowed reporting as MD or SMD with most interventions. </p> <p>The results are reported in <a href="./full#CD011393-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD011393-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011393-tbl-0003">summary of findings Table 3</a>. The grouping of the GABA analogues, kappa opioid agonists, Mu opioid antagonists, polyunsaturated fatty acids, and UV‐B radiation assumed their class effect corroborated by previous studies on their effectiveness in uraemic pruritus, non‐specified pruritus, and related pathophysiology such as pain. For instance pregabalin and gabapentin, known to have similar and highly correlative downstream effects, are studied together for their classed effect on uraemic pruritus (<a href="./references#CD011393-bbs2-0168" title="MatsudaKM , SharmaD , SchonfeldAR , KwatraSG . Gabapentin and pregabalin for the treatment of chronic pruritus. American Academy of Dermatology2016;75(3):619-25. [MEDLINE: 27206757]">Matsuda 2016</a>). They have also been shown through a head‐to‐head RCT to have similar efficacy in treating uraemic pruritus (<a href="./references#CD011393-bbs2-0074" title="AtalayH , SolakY , BiyikZ , GaipovA , GuneyF , TurkS . Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clinical Drug Investigation2013;33(6):401-8. [MEDLINE: 23572323]BiyikZ , SolakY , AtalayH , GaipovA , GuneyF , TurkS . Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. International Urology &amp; Nephrology2013;45(3):831-7. [MEDLINE: 22644743]SolakY , BiyikZ , AtalayH , GaipovA , GuneyF , TurkS , et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology2012;17(8):710-7. [MEDLINE: 22909343]">Solak 2012</a>). Finally, the results of this review's placebo‐controlled gabapentin and pregabalin RCTs are homogeneous, again supporting this classification. </p> <p>Five interventions included multiple and/or larger studies with a combined sample size of over 100 participants: GABA analogues, kappa opioid agonists, ondansetron, capsaicin cream, and turmeric. Each of these has no identified major sources of bias limiting their interpretation. Of the five, only ondansetron was not found to be associated with a reduction in uraemic itch versus placebo. GABA analogues achieved the largest effect size of all interventions. The effect size of kappa opioid agonists and capsaicin cream are both modest in comparison. One direct comparison (GABA analogues versus. Ondansetron) was consistent with above with similar effect size to those of the GABA analogue versus placebo RCTs. Supplementing this data on gabapentin and pregabalin are five mixed quality RCTs favouring gabapentin in direct comparison to various antihistamines. </p> <p>The small sample sizes and often significant sources of bias limit the conclusions drawn from the majority of this review's other interventions. No meaningful quantitative analysis can be drawn from the adverse effects of the interventions due to insufficient and disorganised reporting. As a global assessment, adverse effects of nearly all antipruritic interventions are somewhat uncommon and non severe. One exception may be kappa opioid agonists where adverse effects were slightly more common. </p> <p>While most studies provided adequate data to contribute to an analysis of itch reduction, few reported on any of the secondary outcomes (e.g. sleep, QoL) described by our protocol. Of the secondary data reported, the conclusions are limited by heterogeneous outcomes and low individual study quality. </p> </section> <section id="CD011393-sec-0122"> <h3 class="title" id="CD011393-sec-0122">Overall completeness and applicability of evidence</h3> <p>Recruited patients included only those already on HD or those with an expectation to begin shortly. All studies outlined prolonged and ongoing significant itch coinciding with CKD as inclusion criteria. Nearly every RCT also outlined exclusion criteria to exclude patients with pathology that potentially otherwise explains their itch symptoms (e.g. dermatological or liver disease). The applicability of the evidence derived from this meta‐analysis may be weaker in populations who have potential non‐renal causes to their itch pathology. This was notable as many patients living with CKD do not have the disease in isolation. </p> <p>Given the diversity of the interventions and relatively modest number of studies per intervention, it was not possible to make comparisons on the effectiveness of all interventions. For instance, <a href="./references#CD011393-bbs2-0074" title="AtalayH , SolakY , BiyikZ , GaipovA , GuneyF , TurkS . Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clinical Drug Investigation2013;33(6):401-8. [MEDLINE: 23572323]BiyikZ , SolakY , AtalayH , GaipovA , GuneyF , TurkS . Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. International Urology &amp; Nephrology2013;45(3):831-7. [MEDLINE: 22644743]SolakY , BiyikZ , AtalayH , GaipovA , GuneyF , TurkS , et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology2012;17(8):710-7. [MEDLINE: 22909343]">Solak 2012</a> found both gabapentin and pregabalin to be equally and highly efficacious in reducing uraemic itch. Missing data and inconsistent reporting did not allow us to include data from all studies in the quantitative meta‐analyses. Approximately 70% of all participants (in studies that met protocol inclusion criteria) contributed to our meta‐analyses and the remainder were qualitatively analysed. Patient characteristics in the quantitative and qualitative analyses are very similar. </p> <p>Multiple studies noted that recruited patients had already failed one anti‐itch treatment prior to being randomised. The most common previous treatment was an antihistamine despite the lack of substantial evidence for its use for uraemic itch. It is unclear if prior antihistamine treatment could be a confounding factor. </p> <p>Some interventions that are yet to be studied via an RCT are currently recommended by guidelines and authorities for uraemic itch. Often, they are also routinely used in clinical practice. Without at least one placebo‐controlled RCT it is beyond the scope of this systematic review to assess this evidence in a quantitative manner. </p> <p>There have not been sufficient RCTs using different dosing regimens to give definitive recommendations about the doses of specific interventions. The populations included in the RCT’s tend to be younger than the typical population with CKD. The elderly may be more susceptible to side effects from these drugs. In the case of GABA analogues, evidence from <a href="./references#CD011393-bbs2-0056" title="NoshadH . Comparison of gabapentin and antihistamins in treatment of uremic pruritus and its psychological problems [abstract no: P209]. Iranian Journal of Kidney Diseases2011;5(Suppl 2):27-8. [EMBASE: 70673855]">Noshad 2011</a> and <a href="./references#CD011393-bbs2-0179" title="RaynerH , BaharaniJ , SmithS , SureshV , DasguptaI . Uraemic pruritus: Relief of itching by gabapentin and pregabalin. Nephron Clinical Practice2012;122:75-79. [DOI: 10.1159/000349943]">Rayner 2012</a> suggest that a low dose of gabapentin (100 mg/day) or pregabalin (25 mg/day) should be used initially and then titrated up. </p> <p>This systematic review's recommendation on individual interventions as monotherapy are generalisable to patients with CKD and chronic itching with no other obvious cause. Thus, there is strong external validity extending to this review's outlined population (patients with stage 4 and 5 CKD and established CKD‐related itch). </p> </section> <section id="CD011393-sec-0123"> <h3 class="title" id="CD011393-sec-0123">Quality of the evidence</h3> <p>Certainty of the evidence varied widely. High quality evidence exists for GABA analogues, kappa opioid agonists, and ondansetron. These interventions draw conclusions from multiple independent well‐powered RCTs with no significant biases identified. There was moderate quality evidence for several other inventions <a href="./full#CD011393-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD011393-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011393-tbl-0003">summary of findings Table 3</a>. The most common factor limiting the certainty of the evidence was the reliance on a single underpowered RCT. Many of these studies are clearly underpowered with limited participants and large standard error. Other common reasons include the use of a non‐validated itch severity outcome measures, insignificant magnitude of effect, and other significant sources of bias. </p> <p>Most studies had low or unclear risk of bias across the majority of domains (<a href="#CD011393-fig-0002">Figure 2</a> and <a href="#CD011393-fig-0003">Figure 3</a>), however results of this review should be interpreted with caution. Increased risk of bias appears correlated with earlier dates of publication. In this review, underpowered interventions often had increased risk across most of the bias categories. This aside, there are many interventions (both of small and large sample sizes) with low overall risk of bias profiles <a href="#CD011393-fig-0002">Figure 2</a>. </p> </section> <section id="CD011393-sec-0124"> <h3 class="title" id="CD011393-sec-0124">Potential biases in the review process</h3> <p>Several intervention are grouped (most notably GABA analogues, Kappa agonists, Mu antagonists, and antihistamines) within the quantitative and qualitative analysis. Opioids, GABA analogues, and antihistamines all have a body of literature externally supporting this "class effect". Additionally, within this systematic review, consistent effects sizes, standard error, and adverse effects provide strong internal validity to this categorisation. However, this inevitably poses a potential for bias and warrants highlighting. </p> <p>Several cross‐over studies within this review reported results consistent with parallel RCTs. This approach gives rise to a unit‐of‐analysis error with CIs that are likely to be too wide, and the study would receive too little weight, with the possible consequence of disguising clinically important heterogeneity. This was somewhat mitigated by verifying that our calculated results match those that are partially reported and also by an overall sensitivity analysis targeting these "approximated" studies. </p> <p>This review only examined RCTs. All included studies, save one, were blinded. Chilled baby, some UV‐B, and some HD modality interventions are unlikely to have been able to blind their participants due to the inherent nature of the intervention. Six studies included significant statements of declaration; all declared significant financial conflicts of interest relating to the pharmaceutical manufacturers of those interventions. However, these were unlikely to bias the major findings of this review. </p> <p>This systematic review addressed a clear research questions and used predefined inclusion criteria to select and appraise studies. We conducted extensive and sensitive searches but the possibility of publication bias remains. This was especially true for interventions with only one RCT identified. Our protocol did not include exhaustive exclusion criteria for patients potentially with pathology associated with non‐uraemic itch. It should be noted that the majority of RCTs in this review excluded such patients. </p> <p>The review did not impose language restrictions. Seven studies were translated prior to data extraction. </p> <p>A comprehensive search of the literature was performed by searching multiple databases and well as handsearching for potential RCTs in the grey literature. All possible relevant data was extracted and whenever studies’ reporting proved insufficient the relevant author(s) were contacted or studies were cross checked in the relevant clinical trials registry. Approximately half of all such cases recovered additional original data. Registers of ongoing trials and available conference proceedings were also searched. </p> <p>Of the studies qualifying for this review, many did not, or only superficially, reported on adverse effects. Overall, the adverse effects reported were somewhat uncommon and generally mild in nature. Often no adverse effects occurred. It was possible that in some studies the authors did not bother to report the lack of adverse effects occurring, however this was not helpful for drawing accurate conclusions. Other secondary outcomes investigated were rarely reported. Significant results of either adverse effects or important secondary outcomes that go unreported may bias the results of this review. </p> </section> <section id="CD011393-sec-0125"> <h3 class="title" id="CD011393-sec-0125">Agreements and disagreements with other studies or reviews</h3> <p>This systematic review found similar results relative to other reviews on the treatment uraemic pruritus. Our search revealed three recent reviews on pathological itch in general. Two are specifically CKD‐related. </p> <p><a href="./references#CD011393-bbs2-0185" title="SiemensW , XanderC , MeerpohlJJ , BurohS , AntesG , SchwarzerG , et al. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD008320. [DOI: 10.1002/14651858.CD008320.pub3]">Siemens 2016</a> examined 947 CKD participants in 36 trials. The review included all patients in the palliative care setting, did not focus on non‐pharmacological interventions, and excluded trials comparing interventions. The review did not exclusively focus on patients with CKD. Additionally, substantial new evidence on GABA analogues, ondansetron, and new pharmacological interventions have been published since their search. This new evidence and our review is consistent with the overall findings of <a href="./references#CD011393-bbs2-0185" title="SiemensW , XanderC , MeerpohlJJ , BurohS , AntesG , SchwarzerG , et al. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD008320. [DOI: 10.1002/14651858.CD008320.pub3]">Siemens 2016</a>, but notably provided increase power to the positive findings on GABA analogues, kappa opioid agonists, and the non‐efficacy of ondansetron. </p> <p><a href="./references#CD011393-bbs2-0178" title="PongcharoenP , Fleischer AB Jr. An evidence-based review of systemic treatments for itch. European Journal of Pain2016;20(1):24-31. [MEDLINE: 26416344]">Pongcharoen 2015</a> examined participants in 26 trials in a quasi‐systematic review of all systemic anti‐itch treatments. Again, this review did not exclusively focus on patients with CKD. Less than half of all trials involved patients with CKD. </p> <p><a href="./references#CD011393-bbs2-0186" title="SimonsenE , KomendaP , LernerB , AskinN , BohmC , ShawJ , et al. Treatment of uremic pruritus: a systematic review. American Journal of Kidney Diseases2017;70(5):638-55. [MEDLINE: 28720208]">Simonsen 2017</a> examined participants in 44 trials examining pharmacological, alternative, and adjunctive interventions. These included interventions such as acupuncture which was not included in our review. The limited number and degree of heterogeneity of the studies did not permit formal meta‐analysis. While the authors did not comment on kappa agonists and ondansetron their results on gabapentin are consistent with the findings of our review. </p> <p>Other more focused reviews examined the effect of the GABA analogue gabapentin (<a href="./references#CD011393-bbs2-0164" title="LauT , LeungS , LauW . Gabapentin for uremic pruritus in hemodialysis patients: a qualitative systematic review. Canadian Journal of Kidney Health &amp; Disease2016;3:14. [MEDLINE: 27022475]">Lau 2016</a>), opioid receptor antagonist (<a href="./references#CD011393-bbs2-0176" title="PhanNQ , BernhardJD , LugerTA , StänderS . Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. Journal of the American Academy of Dermatology2010;63(4):680-8. [MEDLINE: 20462660]">Phan 2010</a>), and topical capsaicin (<a href="./references#CD011393-bbs2-0152" title="GoodingSM , CanterPH , CoelhoHF , BoddyK , ErnstE . Systematic review of topical capsaicin in the treatment of pruritus. International Journal of Dermatology2010;49(8):858-65. [MEDLINE: 21128913]">Gooding 2010</a>) on uraemic pruritus. Again, the results of this systematic review are consistent with these reviews. Of note, this is the first quantitative meta‐analysis of uraemic pruritus on this scale. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011393-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/urn:x-wiley:14651858:media:CD011393:CD011393-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011393-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_t/tCD011393-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011393-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/urn:x-wiley:14651858:media:CD011393:CD011393-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011393-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_t/tCD011393-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011393-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/urn:x-wiley:14651858:media:CD011393:CD011393-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011393-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_t/tCD011393-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011393-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/urn:x-wiley:14651858:media:CD011393:CD011393-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pharmacological interventions (oral or IV), Outcome 1: Itch" data-id="CD011393-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_t/tCD011393-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Pharmacological interventions (oral or IV), Outcome 1: Itch</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011393-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/urn:x-wiley:14651858:media:CD011393:CD011393-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Pharmacological interventions (oral or IV), Outcome 2: Itch (dichotomous)" data-id="CD011393-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_t/tCD011393-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Pharmacological interventions (oral or IV), Outcome 2: Itch (dichotomous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011393-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/urn:x-wiley:14651858:media:CD011393:CD011393-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical interventions, Outcome 1: Itch" data-id="CD011393-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_t/tCD011393-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Topical interventions, Outcome 1: Itch</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011393-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/urn:x-wiley:14651858:media:CD011393:CD011393-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral or IV supplements, Outcome 1: Itch" data-id="CD011393-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_t/tCD011393-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Oral or IV supplements, Outcome 1: Itch</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011393-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/urn:x-wiley:14651858:media:CD011393:CD011393-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Haemodialysis modality, Outcome 1: Itch" data-id="CD011393-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_t/tCD011393-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Haemodialysis modality, Outcome 1: Itch</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011393-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/urn:x-wiley:14651858:media:CD011393:CD011393-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Other interventions, Outcome 1: Itch" data-id="CD011393-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_t/tCD011393-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Other interventions, Outcome 1: Itch</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011393-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/urn:x-wiley:14651858:media:CD011393:CD011393-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Cross‐over studies with paired data, Outcome 1: Cholestyramine" data-id="CD011393-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_t/tCD011393-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Cross‐over studies with paired data, Outcome 1: Cholestyramine</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/media/CDSR/CD011393/image_n/nCD011393-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011393-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Pharmacological interventions versus placebo for the relief of itch in people with advanced chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pharmacological interventions versus placebo for the relief of itch in people with advanced chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> uraemic pruritus </p> <p><b>Settings:</b> outpatient and multi‐centre </p> <p><b>Intervention:</b> pharmacological treatments </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative Effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk of placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk with pharmacological interventions</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GABA analogue</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group ranged from <b>0.8 to 2 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the GABA analogue group was <b>4.95 cm lower</b> (5.46 to 4.44 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p>HIGH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ondansetron</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group ranged from <b>0.1 to 2 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the ondansetron agonist group was <b>0.38 cm lower</b> (1.04 lower to 0.27 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p>HIGH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kappa‐opioid agonist</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group ranged from <b>1.3 to 1.9 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the kappa‐opioid agonist group was <b>1.05 cm lower</b> (1.40 to 0.70 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p>HIGH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mu‐opioid antagonist</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group ranged from <b>0.5 to 1 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the mu‐opioid antagonist group was <b>4.29 cm lower</b> (10.24 lower to 1.66 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nalbuphine</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of the placebo group was <b>3.2 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The <b>mean reduction</b> in VAS score of the nalbuphine group was <b>0.75 cm lower</b> (1.70 lower to 0.20 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cromolyn</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group was <b>3 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the cromolyn group was <b>4.8 cm lower</b> (7.03 to 2.57 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nicotinamide</p> <p><b>VAS</b> <b>(0 to 5 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of the placebo group was <b>1.7 cm lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The <b>mean reduction</b> in VAS score of the nicotinamide group was <b>0.47 cm higher</b> (0.32 lower to 1.26 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPO</p> <p><b>Duo score</b> <b>(0 to 40)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Duo score of the placebo group was <b>1.5 lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The <b>mean reduction</b> in Duo score of the EPO group was <b>14.5 lower</b> (38.78 lower to 9.78 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cholestyramine</p> <p><b>0 to 3 severity scale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean itch score of the placebo group ranged from <b>1.3 to 0.7 lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the cholestyramine group was <b>0.24 higher</b> (0.38 lower to 0.86 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Montelukast</p> <p><b>Duo score (0 to 81) and VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Duo score and VAS of the placebo group was <b>7 points and 0.5 cm lower</b> (respectively) than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The<b>SMD reduction</b> of the montelukast group was <b>1.4 lower</b> (1.87 to 0.92 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sertraline</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VAS score of the placebo group was <b>3.7 lower</b> than pretreatment scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The <b>mean reduction</b> in VAS score of the sertraline group was <b>1.8 cm lower</b> (3.65 lower to 0.05 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lidocaine</p> <p>Itch relief</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>800 per 1000</b><br/>(221 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.80</b><br/>(0.78 to 29.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sodium thalidomide</p> <p>Itch relief</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>133 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>556 per 1000</b><br/>(177 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.17</b><br/>(1.08 to 16.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxepin</p> <p>Itch relief</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>875 per 1000</b> </p> <p>(396 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.20</p> <p>(1.90 to 9.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>The reduction of risk of pharmacological versus placebo (column 3) is the additional risk reduction in addition to the benefit provided by the placebo. "Lower" indicates a reduction or negative numerical change versus baseline. </p> <p><b>CI:</b> Confidence interval; <b>SMD</b> : standardised mean difference; <b>RR:</b> Risk Ratio; <b>VAS</b>: visual analogues scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Evidence of certainty was downgraded one level because of the reliance of the estimated effect on a small number of participants </p> <p><sup>2</sup>Evidence of certainty was downgraded one level because of the imprecise treatment estimate </p> <p><sup>3</sup>Evidence of certainty was downgraded one level because of study risks of bias </p> <p><sup>4</sup>Evidence of certainty was downgraded one level because heterogeneous results utilizing nonvalidated itch scoring methods </p> <p><sup>5</sup>Evidence of certainty was downgraded one level as homogeneity was difficult to assess (due to well validated but different itch scoring methods) and that the analysis would benefit from a greater number of participants </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Pharmacological interventions versus placebo for the relief of itch in people with advanced chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011393-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical treatments versus placebo for the relief of itch in people with advanced chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Topical treatments versus placebo for the relief of itch in people with advanced chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> uraemic pruritus </p> <p><b>Settings:</b> outpatient and multi‐centre </p> <p><b>Intervention:</b> topical treatments </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk of placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk with topical treatments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capsaicin cream</p> <p><b>VAS and Duo’s score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS and Duo score of this vehicle group was <b>1.7 cm and 13.4 lower</b> (respectively) than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The SMD of the capsaicin group was <b>0.84 lower</b> (1.22 to 0.45 lower) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pramoxine lotion</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this vehicle group was <b>1.4 cm lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the pramoxine lotion group was <b>1.97 lower</b> (6.06 lower to 2.12 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW<sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcineurin inhibitor</p> <p><b>VAS</b> <b>(0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this vehicle group was <b>7.1 cm lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the calcineurin inhibitor group was <b>1.2 higher</b> (0.36 lower to 2.76 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW<sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dead Sea lotion</p> <p><b>1 to 5 severity score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean severity score of this vehicle group was <b>3 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in severity score of the Dead Sea Lotion group was <b>2 lower</b> (4.31 lower to 0.31 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p>VERY LOW<sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cromolyn cream</p> <p><b>VAS (0 to 5 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this vehicle group was <b>1.4 cm lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the cromolyn cream group was <b>0.8 cm lower</b> (1.98 lower to 0.38 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baby oil</p> <p><b>Itch Severity Scale</b> <b>(0 to 21)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Itch Severity Scale of this vehicle group was <b>1 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in Itch Severity Scale of the baby oil group was <b>2.36 lower</b> (3.29 to 1.44 lower) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐arginine salve</p> <p><b>0 to 3 severity score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean severity score of this vehicle group was <b>3.4 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in severity score of the L‐arginine salve group was <b>0.58 lower</b> (1.86 lower to 0.7 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polyunsaturated fatty acids</p> <p><b>VAS (0 to 10 cm)</b> </p> <p><b>Duo score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS and Duo score of this vehicle group was <b>1 cm lower and 5 points higher</b> (respectively) than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The SMD of the polyunsaturated fatty acids group was <b>0.91 lower</b> (1.99 lower to 0.17 higher) than vehicle </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>2,6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>The reduction of risk of pharmacological versus placebo (column 3) is the additional risk reduction in addition to the benefit provided by the placebo. "Lower" indicates a reduction or negative numerical change versus baseline. </p> <p><b>CI:</b> Confidence interval; <b>SMD</b> : standardised mean difference; <b>VAS</b>: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Evidence of certainty was downgraded one level as homogeneity was difficult to assess (due to well validated but different itch scoring methods) and that the analysis would benefit from a greater number of participants </p> <p><sup>2</sup>Evidence of certainty was downgraded one level because of the reliance of the estimated effect on a small number of participants </p> <p><sup>3</sup>Evidence of certainty was downgraded one level because of the imprecise treatment estimate </p> <p><sup>4</sup>Evidence of certainty was downgraded one level because of study risks of bias </p> <p><sup>5</sup>Evidence of certainty was downgraded two levels because of study risks of bias and use of a non‐validated itch scoring method. </p> <p><sup>6</sup>Evidence of certainty was downgraded one level because of the imprecise and small treatment estimate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical treatments versus placebo for the relief of itch in people with advanced chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011393-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Supplements, haemodialysis modalities, and other treatments for the relief of itch in people with advanced chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Supplements, HD modalities, and other treatments for the relief of itch in people with advanced chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> uraemic pruritus </p> <p><b>Settings:</b> outpatient and multi‐centre </p> <p><b>Intervention:</b> supplements, HD modalities, and other treatments </p> <p><b>Comparison:</b> placebo; other HD comparators </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p>A<b>nticipated absolute effects<sup>*</sup> </b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk of comparator</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reduction of risk with supplements, HD modalities, and other treatments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polyunsaturated fatty acids</p> <p><b>0 to 5</b> <b>severity score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean severity score of this placebo group was <b>1.6% lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in 0 to 5 severity score of the polyunsaturated fatty acids group was <b>11.3% lower</b> (9.0 to 3.6 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine</p> <p><b>VAS (0 to 6 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this placebo group was <b>0.2 higher</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the L‐carnitine group was <b>0.26 lower</b> (2.85 lower to 2.43 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zinc sulfate</p> <p><b>VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS and Duo score of this vehicle group was <b>4.3</b> <b>cm and 6.1 lower</b> (respectively) than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction of the zinc sulfate group was <b>1.77 lower</b> (2.88 to 0.66 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ergocalciferol</p> <p><b>21 point scale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score of this vehicle group was <b>6.1 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the ergocalciferol group was <b>0.4 higher</b> (2.52 lower to 3.32 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turmeric</p> <p><b>Duo score (5 to 40)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Duo’s score of this vehicle group was <b>2 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the turmeric group was <b>6.4 lower*</b> (7.42 to 5.38 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fumaria parviflora</p> <p><b>VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this vehicle group was 2.2<b>lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the Fumaria parviflora group was 3.90<b>lower</b> (5.04 to 2.76 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High flux/permeability</p> <p>dialysis</p> <p><b>VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this control group ranged from <b>0.6 cm to 5.6 cm lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the high flow/permeability group was <b>2.60 cm lower</b> (3.22 to 1.97 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HD with haemoperfusion</p> <p><b>VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this control group was <b>0.6 cm lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the HD with haemoperfusion group was <b>2.37 cm lower</b> (2.89 to 1.85 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐B</p> <p><b>Duo score,</b> </p> <p><b>VAS, and %improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Duo score and VAS of this control group was <b>2.2 points and 0.3 cm lower</b> (respectively) than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The SMD of the UV‐B group was <b>2.49 lower</b> (4.62 to 0.36 lower) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thermal therapy</p> <p><b>VAS (0 to 10 cm)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean VAS score of this control group was <b>5.8 lower</b> than pretreatment scores. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean reduction in VAS score of the thermal therapy group was <b>2.06 lower</b> (6.98 lower to 2.84 higher) than placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>The reduction of risk of pharmacological versus placebo (column 3) is the additional risk reduction in addition to the benefit provided by the placebo. "Lower" indicates a reduction or negative numerical change versus baseline. </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>SMD</b> : standardised mean difference; <b>VAS</b>: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Evidence of certainty was downgraded one level because of the reliance of the estimated effect on a small number of participants </p> <p><sup>2</sup>Evidence of certainty was downgraded one level because of the imprecise treatment estimate </p> <p><sup>3</sup>Evidence of certainty was downgraded one level because of study risks of bias </p> <p><sup>4</sup>Evidence of certainty was downgraded one level because heterogeneity between studies </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Supplements, haemodialysis modalities, and other treatments for the relief of itch in people with advanced chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011393-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events: pharmacological interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Route/dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GABA analogue</p> <p>(pregabalin or</p> <p>gabapentin) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pregabalin</p> <p>(a) Oral: 75 mg, twice/week</p> <p>Gabapentin</p> <p>(b) Oral: 400 mg, twice/week</p> <p>(c) Oral: 300 mg, 3 times/week</p> <p>(d) Oral: 300 mg/day</p> <p>(e) Oral: dose not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0031" title="GunalAI , OzalpG , YoldasTK , GunalSY , KircimanE , CelikerH . Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrology Dialysis Transplantation2004;19(12):3137-9. [MEDLINE: 15575002]">Gunal 2004</a> (c): somnolence, dizziness, fatigue </p> <p><a href="./references#CD011393-bbs2-0050" title="NaghibiM , NazemianF , Mohammad-PoorA , Morovat-DarZ , Javidi-Dasht-BayazA , AzmoodehH . The effect of gabapentin on uremic pruritus in hemodialysis patients [abstract no: FP479]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi181. ">Naghibi 2007</a> (e): somnolence </p> <p><a href="./references#CD011393-bbs2-0051" title="NainiAE , HarandiAA , KhanbabapourS , ShahidiS , SeirafiyanS , MohseniM . Gabapentin: a promising drug for the treatment of uremic pruritus. Saudi Journal of Kidney Diseases &amp; Transplantation2007;18(3):378-81. [MEDLINE: 17679749]NainiAE , ShahidiS , SeirafianS , AtapoorA , KhanbabapoorS , HarandiAA , et al. Gabapentin: a promising treatment for uremic pruritus [abstract no: SP471]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv174. ">Naini 2007</a> (b): somnolence, dizziness, nausea </p> <p><a href="./references#CD011393-bbs2-0055" title="NofalE , FaragF , NofalA , EldesoukyF , AlkotR , AbdelkhalikZ . Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2016;27(6):515-9. [MEDLINE: 27043168]SolakB , SolakY . Reply to: Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2017;28(3):280. [MEDLINE: 27687138]">Nofal 2016</a> (d): somnolence (9/27), dizziness (5/27) </p> <p><a href="./references#CD011393-bbs2-0084" title="TolH , AtalayH , GuneyI , GokbelH , AltintepeL , BuyukbasS , et al. The effects of gabapentin therapy on pruritus, quality of life, depression and sleep quality in pruritic hemodialysis patients. Trakya Universitesi Tip Fakultesi Dergisi2010;27(1):1-5. [EMBASE: 2010207038]">Tol 2010</a> (c): not reported </p> <p><a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a> (a): somnolence (3/67), loss of balance (2/67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0031" title="GunalAI , OzalpG , YoldasTK , GunalSY , KircimanE , CelikerH . Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrology Dialysis Transplantation2004;19(12):3137-9. [MEDLINE: 15575002]">Gunal 2004</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0050" title="NaghibiM , NazemianF , Mohammad-PoorA , Morovat-DarZ , Javidi-Dasht-BayazA , AzmoodehH . The effect of gabapentin on uremic pruritus in hemodialysis patients [abstract no: FP479]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi181. ">Naghibi 2007</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0051" title="NainiAE , HarandiAA , KhanbabapourS , ShahidiS , SeirafiyanS , MohseniM . Gabapentin: a promising drug for the treatment of uremic pruritus. Saudi Journal of Kidney Diseases &amp; Transplantation2007;18(3):378-81. [MEDLINE: 17679749]NainiAE , ShahidiS , SeirafianS , AtapoorA , KhanbabapoorS , HarandiAA , et al. Gabapentin: a promising treatment for uremic pruritus [abstract no: SP471]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv174. ">Naini 2007</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0055" title="NofalE , FaragF , NofalA , EldesoukyF , AlkotR , AbdelkhalikZ . Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2016;27(6):515-9. [MEDLINE: 27043168]SolakB , SolakY . Reply to: Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. Journal of Dermatological Treatment2017;28(3):280. [MEDLINE: 27687138]">Nofal 2016</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0084" title="TolH , AtalayH , GuneyI , GokbelH , AltintepeL , BuyukbasS , et al. The effects of gabapentin therapy on pruritus, quality of life, depression and sleep quality in pruritic hemodialysis patients. Trakya Universitesi Tip Fakultesi Dergisi2010;27(1):1-5. [EMBASE: 2010207038]">Tol 2010</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ondansetron versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>161 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) Oral: 8 mg, 3 times/day</p> <p>(b) Oral: 8 mg, once/day</p> <p>(c) Oral: 8 mg, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0006" title="AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uraemic pruritus in maintenance haemodialysis patients [abstract]. In: 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy. 1998:223. [CENTRAL: CN-00483053] AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uremic pruritus in hemodialysis patients. American Journal of Kidney Diseases2000;35(5):827-31. [MEDLINE: 10793015]">Ashmore 2000</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0049" title="MurphyM , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. British Journal of Dermatology2003;148(2):314-7. [MEDLINE: 12588385]MurphyMD , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch [abstract]. British Journal of Dermatology2001;145(Suppl 59):20-1. [CENTRAL: CN-00509373] ">Murphy 2003</a> (b): constipation (1/14), ischaemic stroke (1/18), line sepsis (1/17) </p> <p><a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a> (c): nausea and vomiting (2/64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0006" title="AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uraemic pruritus in maintenance haemodialysis patients [abstract]. In: 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy. 1998:223. [CENTRAL: CN-00483053] AshmoreSD , JonesCH , NewsteadCG , DalyMJ , ChrystynH . Ondansetron therapy for uremic pruritus in hemodialysis patients. American Journal of Kidney Diseases2000;35(5):827-31. [MEDLINE: 10793015]">Ashmore 2000</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0049" title="MurphyM , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. British Journal of Dermatology2003;148(2):314-7. [MEDLINE: 12588385]MurphyMD , ReaichD , PaiP , FinnP , CarmichaelAJ . A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch [abstract]. British Journal of Dermatology2001;145(Suppl 59):20-1. [CENTRAL: CN-00509373] ">Murphy 2003</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kappa opioid agonists versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>626 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nalfurafine</p> <p>(a) Oral: 2.5 µg once/day</p> <p>(b) Oral: 5 µg once/day</p> <p>(c) IV: 5 µg, 3 times/week</p> <p>(d) IV: 2.5, 5 µg with dialysis</p> <p>CR845</p> <p>(e) IV: 0.5 to 1.5 µg/kg with dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0036" title="KumagaiH , EbataT , TakamoriK , MiyasatoK , MuramatsuT , NakamotoH , et al. Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. American Journal of Nephrology2012;36(2):175-83. [MEDLINE: 22868684]KumagaiH , EbataT , TakamoriK , MuramatsuT , NakamotoH , SuzukiH . Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrology Dialysis Transplantation2010;25(4):1251-7. [MEDLINE: 19926718]">Kumagai 2010</a> (a, b) </p> <p>2.5 µg (oral): somnolence (4.5%); insomnia (7.1%), diarrhoea (4.5%), nasopharyngitis (8.0%) </p> <p>5 µg (oral): constipation (7.9%), somnolence (3.5%), insomnia (14.9%), nasopharyngitis (12.3%) </p> <p><a href="./references#CD011393-bbs2-0075" title="MathurVS , SpencerRH , IllidgeJ , StaufferJW , MuneraC , MenzaghiF . Improvement of quality of life in hemodialysis patients with uremic pruritus as measured by the skindex-10 questionnaire: effect of a novel kappa opiod receptor agonist, CR845 [abstract no: TH-PO1040]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):338A. SpencerR , MathurVS , TumlinJA , StaufferJW , MenzaghiF . CR845, a novel kappa opiod receptor agonist reduces moderate-to-severe pruritus and improves quality of life in chronic kidney disease patients undergoing hemodialysis [abstract no: SA-PO1117]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B9. ">Spencer 2015</a> (e): not reported </p> <p><a href="./references#CD011393-bbs2-0076" title="MenzaghiF , MuneraC , OberdickMS , StaufferJW , SpencerRH . Randomized, placebo-controlled study on the efficacy of CR845 in improving the quality of life of hemodialysis patients with CKD- associated pruritus [abstract no: SA-OR032]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):80. MuneraC , VernonMK , StaufferJW , SpencerRH , MenzaghiF . Psychometric validation and meaningful change threshold of the worst itching intensity numerical rating scale for use in hemodialysis patients with pruritus [abstract]. Journal of Investigative Dermatology2018;138(5 Suppl 1):S99. [EMBASE: 622252595]SpencerRH , MuneraC , OberdickMS , StaufferJW , MenzaghiF . Randomized, placebo-controlled study on the efficacy of CR845 in reducing CKD- associated pruritus in hemodialysis patients [abstract no: FR-PO875]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):629. SpencerRH , MuneraC , VernonMK , StaufferJW , MenzaghiF . Clinically meaningful itch reduction by CR845 an 8-week randomized, placebo-controlled study in hemodialysis patients [abstract no: 280]. American Journal of Kidney Diseases2018;71(4):585. [EMBASE: 621596159]">Spencer 2017</a> (e) (0.5 to 1.5 µg/kg): somnolence (9/129), dizziness (12/129), headache (5/129), diarrhoea (16/129), nausea (11/129) </p> <p><a href="./references#CD011393-bbs2-0010" title="BhaduriS , MathurV , FellmannJ , RosenD , UenoK , UenoY . Nalfurafine (TRK-820) as a treatment for uremic pruritus (UP): patients are responsive independent of baseline itch - data from a multicenter, randomized, placebo controlled trial [abstract no: SA-PO1014]. Journal of the American Society of Nephrology2006;17(Abstracts):787A. BhaduriS , MathurV , FellmannJ , RosenD , UenoK , UenoY . Nalfurafine (TRK-820) as a treatment for uremic pruritus (UP): persistence of effect on dialytic and non-dialytic days - data from a multicenter, randomized, placebo controlled trial [abstract no: SA-PO1015]. Journal of the American Society of Nephrology2006;17(Abstracts):787A. ">Bhaduri 2006</a> (d): not reported </p> <p><a href="./references#CD011393-bbs2-0088" title="WikstromB , GellertR , LadefogedSD , DandaY , AkaiM , IdeK , et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. Journal of the American Society of Nephrology2005;16(12):3742-7. [MEDLINE: 16251241]">Wikstrom 2005</a> (c): headache (3/26), nausea (3/26), vomiting (2/26), insomnia (2/26), vertigo (2/26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0036" title="KumagaiH , EbataT , TakamoriK , MiyasatoK , MuramatsuT , NakamotoH , et al. Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. American Journal of Nephrology2012;36(2):175-83. [MEDLINE: 22868684]KumagaiH , EbataT , TakamoriK , MuramatsuT , NakamotoH , SuzukiH . Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrology Dialysis Transplantation2010;25(4):1251-7. [MEDLINE: 19926718]">Kumagai 2010</a>: nasopharyngitis (17.1%), headache (3.6%), vomiting (3.6%) </p> <p><a href="./references#CD011393-bbs2-0075" title="MathurVS , SpencerRH , IllidgeJ , StaufferJW , MuneraC , MenzaghiF . Improvement of quality of life in hemodialysis patients with uremic pruritus as measured by the skindex-10 questionnaire: effect of a novel kappa opiod receptor agonist, CR845 [abstract no: TH-PO1040]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):338A. SpencerR , MathurVS , TumlinJA , StaufferJW , MenzaghiF . CR845, a novel kappa opiod receptor agonist reduces moderate-to-severe pruritus and improves quality of life in chronic kidney disease patients undergoing hemodialysis [abstract no: SA-PO1117]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B9. ">Spencer 2015</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0076" title="MenzaghiF , MuneraC , OberdickMS , StaufferJW , SpencerRH . Randomized, placebo-controlled study on the efficacy of CR845 in improving the quality of life of hemodialysis patients with CKD- associated pruritus [abstract no: SA-OR032]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):80. MuneraC , VernonMK , StaufferJW , SpencerRH , MenzaghiF . Psychometric validation and meaningful change threshold of the worst itching intensity numerical rating scale for use in hemodialysis patients with pruritus [abstract]. Journal of Investigative Dermatology2018;138(5 Suppl 1):S99. [EMBASE: 622252595]SpencerRH , MuneraC , OberdickMS , StaufferJW , MenzaghiF . Randomized, placebo-controlled study on the efficacy of CR845 in reducing CKD- associated pruritus in hemodialysis patients [abstract no: FR-PO875]. Journal of the American Society of Nephrology2017;28(Abstract Suppl):629. SpencerRH , MuneraC , VernonMK , StaufferJW , MenzaghiF . Clinically meaningful itch reduction by CR845 an 8-week randomized, placebo-controlled study in hemodialysis patients [abstract no: 280]. American Journal of Kidney Diseases2018;71(4):585. [EMBASE: 621596159]">Spencer 2017</a>: somnolence (1/45), dizziness (2/45), headache (1/45), diarrhoea (0/45) </p> <p><a href="./references#CD011393-bbs2-0088" title="WikstromB , GellertR , LadefogedSD , DandaY , AkaiM , IdeK , et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. Journal of the American Society of Nephrology2005;16(12):3742-7. [MEDLINE: 16251241]">Wikstrom 2005</a>: 13/25 (type not reported) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mu opioid antagonists versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 50 mg once/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0061" title="Pauli-MagnusC , MikusG , AlscherDM , KirschnerT , NagelW , GugelerN , et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. Journal of the American Society of Nephrology2000;11(3):514-9. [MEDLINE: 10703675]">Pauli‐Magnus 2000</a>: loss of appetite and nausea (9) </p> <p><a href="./references#CD011393-bbs2-0064" title="PeerG , KivityS , AgamiO , FiremanE , SilverbergD , BlumM , et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet1996;348(9041):1552-4. [MEDLINE: 8950882]PeerG , SilverbergDS , BlumM , KaplanE , IainaA . Naltrexone (NX) an opiate antagonist relieves pruritus in dialysis patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:560. [CENTRAL: CN-00509406] ">Peer 1996</a>: heartburn (2), abdominal discomfort (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0061" title="Pauli-MagnusC , MikusG , AlscherDM , KirschnerT , NagelW , GugelerN , et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. Journal of the American Society of Nephrology2000;11(3):514-9. [MEDLINE: 10703675]">Pauli‐Magnus 2000</a>: nausea (1) </p> <p><a href="./references#CD011393-bbs2-0064" title="PeerG , KivityS , AgamiO , FiremanE , SilverbergD , BlumM , et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet1996;348(9041):1552-4. [MEDLINE: 8950882]PeerG , SilverbergDS , BlumM , KaplanE , IainaA . Naltrexone (NX) an opiate antagonist relieves pruritus in dialysis patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:560. [CENTRAL: CN-00509406] ">Peer 1996</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nalbuphine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>373 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 60 or 120 mg, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0085" title="KumarJ , CrawfordP , MathurV , SciasciaT . Nalbuphine ER tablets in hemodialysis patients with severe uremic pruritus: multicenter, randomized, double-blind, placebo-controlled trial [abstract no: 185]. American Journal of Kidney Diseases2016;67(5):A65. [EMBASE: 72313488]MathurVS , GermainMJ , DuncanR , SciasciaT . The rationale for and design of TREVITR02: a multicenter randomized, double-blind, placebo-controlled trial of nalbuphine ER for the treatment of uremic pruritus in hemodialysis patients [abstract no: PUB113]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):912A. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT , TR02 Study Investigators. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. American Journal of Nephrology2017;46(6):450-8. [MEDLINE: 29253847]MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . A multicenter, phase2/3 randomized, double-blind, placebo-controlled tiral of nalbuphine ER tablets for the treatment of uremic pruritus: baseline population characteristics [abstract no: TH-PO956]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):316a. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . Randomized, double-blind, placebo-controlled, parallel, 3-arm study of safety and anti-pruritic efficacy of nalbuphine HCI ER tablets in hemodialysis patients with uremic pruritus [abstract no: HI-OR07]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2. ">TREVITR02 2017</a> </p> <p>60 mg: serious adverse events (12.7%), adverse events leading to discontinuation (33/128)</p> <p>120 mg: serious adverse events (6.7%), adverse events leading to discontinuation (27/120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0085" title="KumarJ , CrawfordP , MathurV , SciasciaT . Nalbuphine ER tablets in hemodialysis patients with severe uremic pruritus: multicenter, randomized, double-blind, placebo-controlled trial [abstract no: 185]. American Journal of Kidney Diseases2016;67(5):A65. [EMBASE: 72313488]MathurVS , GermainMJ , DuncanR , SciasciaT . The rationale for and design of TREVITR02: a multicenter randomized, double-blind, placebo-controlled trial of nalbuphine ER for the treatment of uremic pruritus in hemodialysis patients [abstract no: PUB113]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):912A. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT , TR02 Study Investigators. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. American Journal of Nephrology2017;46(6):450-8. [MEDLINE: 29253847]MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . A multicenter, phase2/3 randomized, double-blind, placebo-controlled tiral of nalbuphine ER tablets for the treatment of uremic pruritus: baseline population characteristics [abstract no: TH-PO956]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):316a. MathurVS , KumarJ , CrawfordPW , HaitH , SciasciaT . Randomized, double-blind, placebo-controlled, parallel, 3-arm study of safety and anti-pruritic efficacy of nalbuphine HCI ER tablets in hemodialysis patients with uremic pruritus [abstract no: HI-OR07]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2. ">TREVITR02 2017</a>: serious adverse events (15.4%), adverse events leading to discontinuation (7/123) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPO versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) IV: 36 U/kg/dialysis</p> <p>(b) SC: 2000 IU twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0019" title="De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Effect of erythropoietin therapy on uraemic pruritus [abstract]. Nephrology Dialysis Transplantation1992;7(7):767. [CENTRAL: CN-00260739] De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. New England Journal of Medicine1992;326(15):969-74. [MEDLINE: 1545849]">De Marchi 1992</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0073" title="Sja'baniM , AsdieAH . Effect of erythropoietin on pruritus, anemia and quality of life, in chronic hemodialyzed end stage renal disease patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:501. [CENTRAL: CN-00509480] Sja'baniM , AsdieAH . Effect of erythropoietin on pruritus and quality of life in chronic hemodialyzed end stage renal disease patients [abstract]. Journal of Clinical Epidemiology1997;50(Suppl 1):10S. [CENTRAL: CN-00550491] ">Sja'bani 1997</a> (b): not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0019" title="De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Effect of erythropoietin therapy on uraemic pruritus [abstract]. Nephrology Dialysis Transplantation1992;7(7):767. [CENTRAL: CN-00260739] De MarchiS , CecchinE , VillaltaD , SepiacciG , SantiniG , BartoliE . Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. New England Journal of Medicine1992;326(15):969-74. [MEDLINE: 1545849]">De Marchi 1992</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0073" title="Sja'baniM , AsdieAH . Effect of erythropoietin on pruritus, anemia and quality of life, in chronic hemodialyzed end stage renal disease patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:501. [CENTRAL: CN-00509480] Sja'baniM , AsdieAH . Effect of erythropoietin on pruritus and quality of life in chronic hemodialyzed end stage renal disease patients [abstract]. Journal of Clinical Epidemiology1997;50(Suppl 1):10S. [CENTRAL: CN-00550491] ">Sja'bani 1997</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nicotinamide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 500 mg twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0057" title="OmidianM , KhazaneeA , YaghoobiR , GhorbaniAR , PazyarN , BeladimousaviSS , et al. Therapeutic effect of oral nicotinamide on refractory uremic pruritus: a randomized, double-blind study. Saudi Journal of Kidney Diseases &amp; Transplantation2013;24(5):995-9. [MEDLINE: 24029269]">Omidian 2013</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0057" title="OmidianM , KhazaneeA , YaghoobiR , GhorbaniAR , PazyarN , BeladimousaviSS , et al. Therapeutic effect of oral nicotinamide on refractory uremic pruritus: a randomized, double-blind study. Saudi Journal of Kidney Diseases &amp; Transplantation2013;24(5):995-9. [MEDLINE: 24029269]">Omidian 2013</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lidocaine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV: 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0081" title="TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReidenbergMM , et al. Pruritus in dialysis patients treated with parenteral lidocaine. New England Journal of Medicine1977;296(5):261-2. [MEDLINE: 831109]TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReindenbergMM , et al. Treatment of pruritus in dialysis patients with parenteral lidocaine [abstract]. Kidney International1976;10(6):527. [CENTRAL: CN-00583216] ">Tapia 1977</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0081" title="TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReidenbergMM , et al. Pruritus in dialysis patients treated with parenteral lidocaine. New England Journal of Medicine1977;296(5):261-2. [MEDLINE: 831109]TapiaL , CheighJS , DavidDS , SullivanJF , SaalS , ReindenbergMM , et al. Treatment of pruritus in dialysis patients with parenteral lidocaine [abstract]. Kidney International1976;10(6):527. [CENTRAL: CN-00583216] ">Tapia 1977</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholestyramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 5 mg, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0072" title="SilverbergDS , IainaA , ReisinE , RotzakR , EliahouHE . Cholestyramine in uraemic pruritus. BMJ1977;1(6063):752-3. [MEDLINE: 322794]">Silverberg 1977</a>: constipation (1/5), nausea (1/5) </p> <p><a href="./references#CD011393-bbs2-0086" title="vanLeusenR , Kutsch LojengaJC , RubenAT . Is cholestyramine helpful in uraemic pruritus?British Medical Journal1978;1(6117):918-9. [MEDLINE: 346150]">van Leusen 1978</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0072" title="SilverbergDS , IainaA , ReisinE , RotzakR , EliahouHE . Cholestyramine in uraemic pruritus. BMJ1977;1(6063):752-3. [MEDLINE: 322794]">Silverberg 1977</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0086" title="vanLeusenR , Kutsch LojengaJC , RubenAT . Is cholestyramine helpful in uraemic pruritus?British Medical Journal1978;1(6117):918-9. [MEDLINE: 346150]">van Leusen 1978</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Montelukast versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0041" title="MahmudpourM , RouzbehJ , JalaliQA , PakfetratM , ZadeganSE , SaghebMM . Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients. Iranian Journal of Kidney Diseases2017;11(1):50-5. [MEDLINE: 28174353]">Mahmudpour 2017</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0054" title="NasrollahiAR , MiladipourA , GhaneiE , YavariP , HaghverdiF . Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(2):73-7. [MEDLINE: 19363280]">Nasrollahi 2007</a>: myelodysplastic syndrome (1/8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0041" title="MahmudpourM , RouzbehJ , JalaliQA , PakfetratM , ZadeganSE , SaghebMM . Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients. Iranian Journal of Kidney Diseases2017;11(1):50-5. [MEDLINE: 28174353]">Mahmudpour 2017</a>: Not reported </p> <p><a href="./references#CD011393-bbs2-0054" title="NasrollahiAR , MiladipourA , GhaneiE , YavariP , HaghverdiF . Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(2):73-7. [MEDLINE: 19363280]">Nasrollahi 2007</a>: myocardial infarction (1/8) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sertraline versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 50 mg twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0060" title="PakfetratM , MalekmakanL , HashemiN , TadayonT . Sertraline can reduce the uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran. Hemodialysis International2018;22(1):103-9. [MEDLINE: 28263039]">Pakfetrat 2018</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0060" title="PakfetratM , MalekmakanL , HashemiN , TadayonT . Sertraline can reduce the uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran. Hemodialysis International2018;22(1):103-9. [MEDLINE: 28263039]">Pakfetrat 2018</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sodium thiosulfate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV: 12.5 mg/dialysis session</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0047" title="MohamedWA , ZakiFM , BekhitWH , SherifIS . Sodium thiosulfate (STS): a new option for hemodialysis patients with uremic pruritus [abstract no: SAP598]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii511-2. [EMBASE: 70766834]">Mohamed 2012</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0047" title="MohamedWA , ZakiFM , BekhitWH , SherifIS . Sodium thiosulfate (STS): a new option for hemodialysis patients with uremic pruritus [abstract no: SAP598]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii511-2. [EMBASE: 70766834]">Mohamed 2012</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxepin versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 10 mg, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0065" title="Pour-Reza-GholiF , NasrollahiA , FirouzanA , NasliEE , FarrokhiF . Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(1):34-7. [MEDLINE: 19357442]Pour Reza GholiF , Reza NasrollahiA , NafarM , FiroozanA , EsfahaniEN , FarrokhiF . A randomized crossover trial: low-dose doxepin reduces pruritus in dialysis patients [abstract no: MP428]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:374. [CENTRAL: CN-00509425] ">Pour‐Reza‐Gholi 2007</a>: drowsiness (12/24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0065" title="Pour-Reza-GholiF , NasrollahiA , FirouzanA , NasliEE , FarrokhiF . Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iranian Journal of Kidney Diseases2007;1(1):34-7. [MEDLINE: 19357442]Pour Reza GholiF , Reza NasrollahiA , NafarM , FiroozanA , EsfahaniEN , FarrokhiF . A randomized crossover trial: low-dose doxepin reduces pruritus in dialysis patients [abstract no: MP428]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:374. [CENTRAL: CN-00509425] ">Pour‐Reza‐Gholi 2007</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thalidomide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0071" title="LugonJR , SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF . Thalidomide (TH) as a new perspective for the treatment of uremic pruritus (UP): a crossed randomized double-blind trial [abstract no: 14P]. Journal of the American Society of Nephrology1992;3(3):377. [CENTRAL: CN-00461215] SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF , LugonJR . Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron1994;67(3):270-3. [MEDLINE: 7936015]">Silva 1994</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0071" title="LugonJR , SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF . Thalidomide (TH) as a new perspective for the treatment of uremic pruritus (UP): a crossed randomized double-blind trial [abstract no: 14P]. Journal of the American Society of Nephrology1992;3(3):377. [CENTRAL: CN-00461215] SilvaSR , VianaPC , LugonNV , HoetteM , RuzanyF , LugonJR . Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron1994;67(3):270-3. [MEDLINE: 7936015]">Silva 1994</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cimetidine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 600 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0007" title="AubiaJ , AguileraJ , LlorachI , GarciaC , RiusE , LLoverasJ , et al. Dialysis pruritus: effect of cimetidine. Journal of Dialysis1980;4(4):141-5. [MEDLINE: 7204712]">Aubia 1980</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0007" title="AubiaJ , AguileraJ , LlorachI , GarciaC , RiusE , LLoverasJ , et al. Dialysis pruritus: effect of cimetidine. Journal of Dialysis1980;4(4):141-5. [MEDLINE: 7204712]">Aubia 1980</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cromolyn versus</p> <p>placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 135 mg, 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0087" title="VessalG , SaghebMM , ShilianS , JafariP , SamaniSM . Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. Nephrology Dialysis Transplantation2010;25(5):1541-7. [MEDLINE: 20007756]">Vessal 2010</a>: flatulence (1/32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0087" title="VessalG , SaghebMM , ShilianS , JafariP , SamaniSM . Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. Nephrology Dialysis Transplantation2010;25(5):1541-7. [MEDLINE: 20007756]">Vessal 2010</a>: nausea (5/30), diarrhoea (4/30) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gabapentin versus pregabalin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral gabapentin (300 mg, once/day) versus oral pregabalin (75 mg, once/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0074" title="AtalayH , SolakY , BiyikZ , GaipovA , GuneyF , TurkS . Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clinical Drug Investigation2013;33(6):401-8. [MEDLINE: 23572323]BiyikZ , SolakY , AtalayH , GaipovA , GuneyF , TurkS . Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. International Urology &amp; Nephrology2013;45(3):831-7. [MEDLINE: 22644743]SolakY , BiyikZ , AtalayH , GaipovA , GuneyF , TurkS , et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology2012;17(8):710-7. [MEDLINE: 22909343]">Solak 2012</a> </p> <p>Gabapentin: not reported</p> <p>Pregabalin: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GADA versus ondansetron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral pregabalin (75 mg twice/week) versus oral ondansetron (8 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0091" title="YueJ , JiaoS , XiaoY , RenW , ZhaoT , MengJ . Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. International Journal of Urology &amp; Nephrology2015;47(1):161-7. [MEDLINE: 25099523]">Yue 2015</a> </p> <p>Pregabalin: somnolence (3/67), loss of balance (2/67)</p> <p>Ondansetron: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GABA analogue versus doxepin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral pregabalin (50 mg every other night) versus oral doxepin (10 mg/night)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0024" title="ForoutanN , EtminanA , NikvarzN , Shojai Shahrokh AbadiM . Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial. Hemodialysis International2017;21(1):63-71. [MEDLINE: 27397522]">Foroutan 2017</a> </p> <p>Pregabalin: intolerable adverse events (3/46), somnolence (6/37), oedema (3/37), drowsiness (3/27), imbalance (1/37), numbness (1/37) </p> <p>Doxepin: intolerable adverse events (1/44), nervousness (1/35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GABA analogue versus antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>212 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) Oral gabapentin (100 mg/day) versus oral ketotifen (1 mg, twice/day)</p> <p>(b) Oral gabapentin (300 mg, 3 times/week) versus oral dexchlorpheniramine (6 mg, 3 times/week) </p> <p>(c) Oral gabapentin (300 mg/day) versus oral loratadine (10 mg/day)</p> <p>(d) Oral gabapentin (100 to 200 mg/day) versus oral hydroxyzine (10 mg/day)</p> <p>(e) Oral gabapentin (100 mg/day) versus oral hydroxyzine (10 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0004" title="AmirkhanlouS , RashediA , TaherianJ , HafeziAA , ParsaeiS . Comparison of gabapentin and ketotifen in treatment of uremic pruritus in hemodialysis patients. Pakistan Journal of Medical Sciences2016;32(1):22-6. [MEDLINE: 27022338]">Amirkhanlou 2016</a> (a) </p> <p>Gabapentin: drowsiness (4/26), dizziness (1/26)</p> <p>Ketotifen: drowsiness (4/26), dizziness (1/26)</p> <p><a href="./references#CD011393-bbs2-0030" title="Gobo-OliveiraM , PigariVG , OgataMS , MiotHA , PonceD , AbbadeLP . Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial. European Journal of Dermatology2018;28(4):488-95. [MEDLINE: 29976533]">Gobo‐Oliveira 2018</a> (b) </p> <p>Gabapentin: total (11/30), drowsiness (17%)</p> <p>Dexchlorpheniramine: total (8/30), drowsiness (1/30)</p> <p><a href="./references#CD011393-bbs2-0044" title="MarinAR . Gabapentin therapy for pruritus in automated peritoneal dialysis patients: a randomized controlled trial [abstract no: SA-PO936]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):841A. ">Marin 2013</a> (c) </p> <p>Gabapentin: somnolence (8/30)</p> <p>Loratadine: none reported</p> <p><a href="./references#CD011393-bbs2-0056" title="NoshadH . Comparison of gabapentin and antihistamins in treatment of uremic pruritus and its psychological problems [abstract no: P209]. Iranian Journal of Kidney Diseases2011;5(Suppl 2):27-8. [EMBASE: 70673855]">Noshad 2011</a> (d) </p> <p>Gabapentin: complications (7/20)</p> <p>Hydroxyzine: complications (10/20)</p> <p><a href="./references#CD011393-bbs2-0078" title="SuwanpidokkulP , ChaiprasertA , SupasyndhO , ChoovichianP , LuesuthiviboonL . Effects of gabanpentin and loratadine on uremic pruritus in hemodialysis patients: a randomized controlled trial [abstract no: F-PO896]. Journal of the American Society of Nephrology2007;18(Abstracts):300A. ">Suwanpidokkul 2007</a> (e) </p> <p>Gabapentin: (9/18)</p> <p>Loratadine: (4/16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mu opioid antagonists versus antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral naltrexone (50 mg/day) versus oral loratadine (10 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0038" title="Legroux-CrespelE , CledesJ , MiseryL . A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology2004;208(4):326-30. [MEDLINE: 15178915]">Legroux‐Crespel 2004</a> </p> <p>Naltrexone (26): vomiting (2), nausea (9), anorexia (1), abdominal distention (1), malaise (1), cramps (2), sleep disturbances (5), vertigo (5), headache (2), somnolence (1), paraesthesia (1), withdrawn (10) </p> <p>Loratadine (26): vomiting (2), malaise (1), withdrawn from study (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ondansetron versus antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) Ondansetron tablet (8 mg/day) versus cyproheptadine</p> <p>syrup (8 mg/day)</p> <p>(b) "3 doses ondansetron 8mg" versus "diphenhydramine 25mg"</p> <p>(c) Oral ondansetron (8 mg, 3 times/day) versus oral loratadine (10 mg twice/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0058" title="OzaykanS , MansurT , GunduzS , GuneyO . Comparison of ondansetron and cyproheptadine in treatment of uremic pruritus [Uremi kasintisi olan hastalarda ondansetron ve siproheptadinin etkinliginin karsilastirilmasi]. Turkderm Deri Hastaliklari Ve Frengi Arsivi2001;35(2):130-4. [EMBASE: 2001415704]">Ozaykan 2001</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0077" title="SubachRA , RadabaughRS , WilliamsDK , MarxMA . Ondansetron versus diphenhydramine versus placebo for hemodialysis-associated itching [abstract no: A1790]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):348A. [CENTRAL: CN-00447890] ">Subach 2001</a> (b): not reported </p> <p><a href="./references#CD011393-bbs2-0046" title="MirnezamiM . Effect of ondasetron on pruritus in hemodialysis patients. Arak Medical University Journal (AMUJ)2013;16(3):80-4. ">Mirnezami 2013</a> (c): not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*when reported</p> <p>GABA ‐ gamma‐aminobutyric acid</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events: pharmacological interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011393-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events: topical interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Route/dose</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cromolyn cream versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4% cream</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0023" title="FeilyA , DormaneshB , GhorbaniAR , MoosaviZ , KouchakM , CheraghianB , et al. Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients.[Erratum in: Int J Clin Pharmacol Ther. 2013 Nov;51(11):910]. International Journal of Clinical Pharmacology &amp; Therapeutics2012;50(7):510-3. [MEDLINE: 22732382]">Feily 2012</a>: burning sensation (6/30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0023" title="FeilyA , DormaneshB , GhorbaniAR , MoosaviZ , KouchakM , CheraghianB , et al. Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients.[Erratum in: Int J Clin Pharmacol Ther. 2013 Nov;51(11):910]. International Journal of Clinical Pharmacology &amp; Therapeutics2012;50(7):510-3. [MEDLINE: 22732382]">Feily 2012</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capsaicin cream versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) 0.025%, 4 times/day</p> <p>(b) 0.03%, 4 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0013" title="BrenemanDL , CardoneJS , BlumsackRF , LatherRM , SearleEA , PollackVE . Topical capsaicin for treatment of hemodialysis-related pruritus. Journal of the American Academy of Dermatology1992;26(1):91-4. [MEDLINE: 1732343]">Breneman 1992</a> (a): burning and stinging sensation (5), decrease in xerosis (3), dryness (2) </p> <p><a href="./references#CD011393-bbs2-0018" title="ChoYL , LiuHN , HuangTP , TarngDC . Uremic pruritus: roles of parathyroid hormone and substance P. Journal of the American Academy of Dermatology1997;36(4):538-43. [MEDLINE: 9092738]">Cho 1997</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0042" title="MakhloughA , AlaS , Haj-HeydariZ , KashiZ , BariA . Topical capsaicin therapy for uremic pruritus in patients on hemodialysis.[Erratum in: Iran J Kidney Dis. 2010 Jul;4(3):273 Note: Ala, Shahram [added]; Haj-Heydari, Zohreh [added]; Kashi, Zahra [added]; Bari, Alireza [added]]. Iranian Journal of Kidney Diseases2010;4(2):137-40. [MEDLINE: 20404425]">Makhlough 2010</a> (b): skin burning </p> <p><a href="./references#CD011393-bbs2-0082" title="TarngDC , ChoYL , LiuHN , HuangTP . Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron1996;72(4):617-22. [MEDLINE: 8730431]">Tarng 1996</a> (a): local burning and/or stinging sensations </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0013" title="BrenemanDL , CardoneJS , BlumsackRF , LatherRM , SearleEA , PollackVE . Topical capsaicin for treatment of hemodialysis-related pruritus. Journal of the American Academy of Dermatology1992;26(1):91-4. [MEDLINE: 1732343]">Breneman 1992</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0018" title="ChoYL , LiuHN , HuangTP , TarngDC . Uremic pruritus: roles of parathyroid hormone and substance P. Journal of the American Academy of Dermatology1997;36(4):538-43. [MEDLINE: 9092738]">Cho 1997</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0042" title="MakhloughA , AlaS , Haj-HeydariZ , KashiZ , BariA . Topical capsaicin therapy for uremic pruritus in patients on hemodialysis.[Erratum in: Iran J Kidney Dis. 2010 Jul;4(3):273 Note: Ala, Shahram [added]; Haj-Heydari, Zohreh [added]; Kashi, Zahra [added]; Bari, Alireza [added]]. Iranian Journal of Kidney Diseases2010;4(2):137-40. [MEDLINE: 20404425]">Makhlough 2010</a>: none </p> <p><a href="./references#CD011393-bbs2-0082" title="TarngDC , ChoYL , LiuHN , HuangTP . Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron1996;72(4):617-22. [MEDLINE: 8730431]">Tarng 1996</a>: local burning and/or stinging sensations </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pramoxine lotion versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0% twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0090" title="FleischerAB , KaurM , ClarkA , YosipovitchG . A controlled comparative study of the efficacy of 1% pramoxine hydrochloride lotion for the treatment of uremic pruritus in adult hemodialysis patients [abstract no: P591]. Journal of the American Academy of Dermatology2007;56(2):AB63. [CENTRAL: CN-00615966] YoungTA , PatelTS , CamachoF , ClarkA , FreedmanBI , KaurM , et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. Journal of Dermatological Treatment2009;20(2):76-81. [MEDLINE: 18821119]">Young 2009</a>: none </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0090" title="FleischerAB , KaurM , ClarkA , YosipovitchG . A controlled comparative study of the efficacy of 1% pramoxine hydrochloride lotion for the treatment of uremic pruritus in adult hemodialysis patients [abstract no: P591]. Journal of the American Academy of Dermatology2007;56(2):AB63. [CENTRAL: CN-00615966] YoungTA , PatelTS , CamachoF , ClarkA , FreedmanBI , KaurM , et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. Journal of Dermatological Treatment2009;20(2):76-81. [MEDLINE: 18821119]">Young 2009</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baby oil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chilled and unchilled 15 min application at least once/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0040" title="LinTC , LaiYH , GuoSE , LiuCF , TsaiJC , GuoHR , et al. Baby oil therapy for uremic pruritus in haemodialysis patients. Journal of Clinical Nursing2012;21(1-2):139-48. [MEDLINE: 22093006]">Lin 2012</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0040" title="LinTC , LaiYH , GuoSE , LiuCF , TsaiJC , GuoHR , et al. Baby oil therapy for uremic pruritus in haemodialysis patients. Journal of Clinical Nursing2012;21(1-2):139-48. [MEDLINE: 22093006]">Lin 2012</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dead Sea lotion versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Entire body, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0012" title="BoazM , ShtendikL , OronM , Portugal-CohenM , KohenR , BiroA , et al. A randomized controlled clinical trial comparing the efficacy of dead sea mineral-enriched body lotion versus two types of placebo in the treatment of cutaneous dryness, itching, peeling and tightness in hemodialysis patients (EDIT). Nephron2009;113(3):c169-76. [MEDLINE: 19672115]">Boaz 2009</a>: total adverse events (2/25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0012" title="BoazM , ShtendikL , OronM , Portugal-CohenM , KohenR , BiroA , et al. A randomized controlled clinical trial comparing the efficacy of dead sea mineral-enriched body lotion versus two types of placebo in the treatment of cutaneous dryness, itching, peeling and tightness in hemodialysis patients (EDIT). Nephron2009;113(3):c169-76. [MEDLINE: 19672115]">Boaz 2009</a>: total adverse events (3/25) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sericin cream versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 g, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0005" title="AramwitP , KeongamaroonO , SiritientongT , BangN , SupasyndhO . Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study. BMC Nephrology2012;13:119. [MEDLINE: 23006933]">Aramwit 2012a</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0005" title="AramwitP , KeongamaroonO , SiritientongT , BangN , SupasyndhO . Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study. BMC Nephrology2012;13:119. [MEDLINE: 23006933]">Aramwit 2012a</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐arginine salve versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 µg/2.5 cm<sup>2</sup> twice/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0021" title="Durrant-FinnU , OstenB , NenoffP . Topical L-arginine hydrochloride ointment improves skin dryness and pruritus in patients under chronic haemodialysis - a vehicle-controlled prospective randomised study [Topisch appliziertes L-argininhydrochlorid verbessert hauttrockenheit und pruritus bei patienten unter chronischer hamodialyse - Eine vehikelkontrollierte prospektive randomisierte studie im halbseitenvergleich]. Aktuelle Dermatologie2008;34(5):175-87. [EMBASE: 2008337532]">Durant‐Finn 2008</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0021" title="Durrant-FinnU , OstenB , NenoffP . Topical L-arginine hydrochloride ointment improves skin dryness and pruritus in patients under chronic haemodialysis - a vehicle-controlled prospective randomised study [Topisch appliziertes L-argininhydrochlorid verbessert hauttrockenheit und pruritus bei patienten unter chronischer hamodialyse - Eine vehikelkontrollierte prospektive randomisierte studie im halbseitenvergleich]. Aktuelle Dermatologie2008;34(5):175-87. [EMBASE: 2008337532]">Durant‐Finn 2008</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcineurin inhibitors versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TAC: 0.1% twice/day</p> <p>Pimecrolimus: 1.0% twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0020" title="DuqueMI , YosipovitchG , Fleischer AB Jr, WillardJ , FreedmanBI . Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. Journal of the American Academy of Dermatology2005;52(3 Pt 1):519-21. [MEDLINE: 15761435]">Duque 2005</a>: warmth sensation (6/12) </p> <p><a href="./references#CD011393-bbs2-0026" title="GhorbaniAR , FeilyA , KhaliliA , DormaneshB . Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients. Dermatitis2012;22(3):167-8. [MEDLINE: 21569748]">Ghorbani 2012a</a>: burning sensation which disappeared by the end of 8 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0020" title="DuqueMI , YosipovitchG , Fleischer AB Jr, WillardJ , FreedmanBI . Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. Journal of the American Academy of Dermatology2005;52(3 Pt 1):519-21. [MEDLINE: 15761435]">Duque 2005</a>: warmth sensation (3/8) </p> <p><a href="./references#CD011393-bbs2-0026" title="GhorbaniAR , FeilyA , KhaliliA , DormaneshB . Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients. Dermatitis2012;22(3):167-8. [MEDLINE: 21569748]">Ghorbani 2012a</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweet almond oil versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0001" title="AfrasiabifarA , MehriZ , HosseiniN . Efficacy of topical application of sweet almond oil on reducing uremic pruritus in hemodialysis patients: A randomized clinical trial study. Iranian Red Crescent Medical Journal2017;19(2):e34695. [EMBASE: 614585273]">Afrasiabifar 2017</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0001" title="AfrasiabifarA , MehriZ , HosseiniN . Efficacy of topical application of sweet almond oil on reducing uremic pruritus in hemodialysis patients: A randomized clinical trial study. Iranian Red Crescent Medical Journal2017;19(2):e34695. [EMBASE: 614585273]">Afrasiabifar 2017</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gamma‐linoleic acid versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2%, 30 mL/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0016" title="ChenYC , ChiuWT , WuMS . Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. American Journal of Kidney Diseases2006;48(1):69-76. [MEDLINE: 16797388]">Chen 2006e</a>: allergic reaction (1/8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0016" title="ChenYC , ChiuWT , WuMS . Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. American Journal of Kidney Diseases2006;48(1):69-76. [MEDLINE: 16797388]">Chen 2006e</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcineurin inhibitors versus cromolyn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pimecrolimus: 2% twice/day</p> <p>Cromolyn: 4%, twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0027" title="Ghorbani BirganiAR , KhaliliA , ZamaniL . A comparison between the effect of cromolyn sodium gel 4% and pimecrolimus cream 1% in treatment of pruritus of patients with end stage renal disease. Avicenna Journal of Nursing &amp; Midwifery Care2011;19(2):11-22. ">Ghorbani Birgani 2011</a>: unknown </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0027" title="Ghorbani BirganiAR , KhaliliA , ZamaniL . A comparison between the effect of cromolyn sodium gel 4% and pimecrolimus cream 1% in treatment of pruritus of patients with end stage renal disease. Avicenna Journal of Nursing &amp; Midwifery Care2011;19(2):11-22. ">Ghorbani Birgani 2011</a>: unknown </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avena sativa versus diluted vinegar versus hydroxyzine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avena sativa: variable dose, twice/day</p> <p>Dilute vinegar: 30 mL twice/day</p> <p>Oral hydroxyzine: 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0053" title="NakhaeeS , NasiriA , WagheiY , MorshediJ . Comparison of Avena sativa, vinegar, and hydroxyzine for uremic pruritus of hemodialysis patients: a crossover randomized clinical trial. Iranian Journal of Kidney Diseases2015;9(4):316-22. [MEDLINE: 26174460]">Nakhaee 2015</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sarna versus eurax</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sarna: 0.5% each of camphor, menthol, and phenol "as required" for 7 days</p> <p>Eurax: 10% crotamiton "as required" for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0080" title="TanCC , WongKS , ThirumoorthyT , LeeE , WooK . A randomized, crossover trial of sarna and eurax lotions in the treatment of haemodialysis patients with uraemic pruritus. Journal of Dermatological Treatment1990;1(5):235-8. [EMBASE: 1991052418]">Tan 1990</a> </p> <p>Sarna: none</p> <p>Eurax: rash (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*when reported</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events: topical interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011393-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: oral and IV supplements</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose/route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polyunsaturated fatty acids versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fish oil</p> <p>(a) Oral: 6 g/day</p> <p>(b) Oral: 3 g/day</p> <p>Omega‐3 fatty acids</p> <p>(c) Oral: 3 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0009" title="BegumR , BeluryMA , BurgessJR , PeckLW . Supplementation with n-3 and n-6 polyunsaturated fatty acids: effects on lipoxygenase activity and clinical symptoms of pruritus in hemodialysis patients. Journal of Renal Nutrition2004;14(4):233-41. [MEDLINE: 15483784]">Begum 2004</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0025" title="GhaneiE , ZeinaliJ , BorgheiM , HomayouniM . Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial. Iranian Red Crescent Medical Journal2012;14(9):515-22. [MEDLINE: 23115713]">Ghanei 2012</a> (c): not reported </p> <p><a href="./references#CD011393-bbs2-0048" title="MojganM , MasoudM , ShahrzadS , ZahraPH , FirouzehM , JinoosZ , et al. Pruritus-reducing effects of omega-3 fatty acids in hemodialysis patients [abstract no: P106]. Iranian Journal of Kidney Diseases2017;11(Suppl 1):7-8. [EMBASE: 616611409]">Mojgan 2017</a> (b): not reported </p> <p><a href="./references#CD011393-bbs2-0062" title="PeckLW , MonsenER , AhmadS . Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. American Journal of Clinical Nutrition1996;64(2):210-4. [MEDLINE: 8694022]">Peck 1996</a> (a): not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0009" title="BegumR , BeluryMA , BurgessJR , PeckLW . Supplementation with n-3 and n-6 polyunsaturated fatty acids: effects on lipoxygenase activity and clinical symptoms of pruritus in hemodialysis patients. Journal of Renal Nutrition2004;14(4):233-41. [MEDLINE: 15483784]">Begum 2004</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0025" title="GhaneiE , ZeinaliJ , BorgheiM , HomayouniM . Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial. Iranian Red Crescent Medical Journal2012;14(9):515-22. [MEDLINE: 23115713]">Ghanei 2012</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0048" title="MojganM , MasoudM , ShahrzadS , ZahraPH , FirouzehM , JinoosZ , et al. Pruritus-reducing effects of omega-3 fatty acids in hemodialysis patients [abstract no: P106]. Iranian Journal of Kidney Diseases2017;11(Suppl 1):7-8. [EMBASE: 616611409]">Mojgan 2017</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0062" title="PeckLW , MonsenER , AhmadS . Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. American Journal of Clinical Nutrition1996;64(2):210-4. [MEDLINE: 8694022]">Peck 1996</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV: 10 mg/kg, once/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0045" title="MettangT , ThomasS , KuhlmannU . L-carnitine does not alleviate uremic pruritus in hemodialysis patients. Nephron1997;75(3):372. [MEDLINE: 9069470]ThomasS , FischerFP , MettangT , Pauli-MagnusC , WeberJ , KuhlmannU . Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: a double-blind randomized trial. American Journal of Kidney Diseases1999;34(4):678-87. [MEDLINE: 10516349]">Mettang 1997</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0045" title="MettangT , ThomasS , KuhlmannU . L-carnitine does not alleviate uremic pruritus in hemodialysis patients. Nephron1997;75(3):372. [MEDLINE: 9069470]ThomasS , FischerFP , MettangT , Pauli-MagnusC , WeberJ , KuhlmannU . Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: a double-blind randomized trial. American Journal of Kidney Diseases1999;34(4):678-87. [MEDLINE: 10516349]">Mettang 1997</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zinc sulfate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) Oral: 220 mg/day</p> <p>(b) Oral: 200 mg twice/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0043" title="MaparMA , PazyarN , SiahpooshA , LatifiSM , Beladi MousaviSS , KhazaneeA . Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: a pilot randomized, triple-blind study. Giornale Italiano di Dermatologia e Venereologia2015;150(4):351-5. [MEDLINE: 24825404]">Mapar 2015</a> (a): none </p> <p><a href="./references#CD011393-bbs2-0052" title="MortazaviM , FaghihiG , NaeiniAE , MonghadM , HosseiniSM . Zinc sulfate for the relief of pruritus in patients on maintenance hemodialysis [abstract no: SA590]. NDT Plus2010;3(Suppl 3):iii241. [EMBASE: 70484056]NajafabadiMM , FaghihiG , EmamiA , MonghadM , MoeenzadehF , SharifN , et al. Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis. Therapeutic Apheresis &amp; Dialysis2012;16(2):142-5. [MEDLINE: 22458392]">Najafabadi 2012</a> (b): none “attributable to zinc sulfate” </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0043" title="MaparMA , PazyarN , SiahpooshA , LatifiSM , Beladi MousaviSS , KhazaneeA . Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: a pilot randomized, triple-blind study. Giornale Italiano di Dermatologia e Venereologia2015;150(4):351-5. [MEDLINE: 24825404]">Mapar 2015</a>: vomiting (1/20) </p> <p><a href="./references#CD011393-bbs2-0052" title="MortazaviM , FaghihiG , NaeiniAE , MonghadM , HosseiniSM . Zinc sulfate for the relief of pruritus in patients on maintenance hemodialysis [abstract no: SA590]. NDT Plus2010;3(Suppl 3):iii241. [EMBASE: 70484056]NajafabadiMM , FaghihiG , EmamiA , MonghadM , MoeenzadehF , SharifN , et al. Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis. Therapeutic Apheresis &amp; Dialysis2012;16(2):142-5. [MEDLINE: 22458392]">Najafabadi 2012</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ergocalciferol versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 50,000 IU/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0070" title="ShirazianS , KlineM , SakhiyaV , SchanlerM , MoledinaD , PatelC , et al. Longitudinal predictors of uremic pruritus. Journal of Renal Nutrition2013;23(6):428-31. [MEDLINE: 24209894]ShirazianS , SchanlerM , DrakakisJ , MiyawakiNB , FishbaneS . The effect of vitamin D insufficiency on uremic pruritis [abstract no: PUB388]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):982A. ShirazianS , SchanlerM , ShastryS , DwivediS , KumarM , RiceK , et al. The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial. Journal of Renal Nutrition2013;23(4):308-14. [MEDLINE: 23453391]">Shirazian 2013</a>: none </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0070" title="ShirazianS , KlineM , SakhiyaV , SchanlerM , MoledinaD , PatelC , et al. Longitudinal predictors of uremic pruritus. Journal of Renal Nutrition2013;23(6):428-31. [MEDLINE: 24209894]ShirazianS , SchanlerM , DrakakisJ , MiyawakiNB , FishbaneS . The effect of vitamin D insufficiency on uremic pruritis [abstract no: PUB388]. Journal of the American Society of Nephrology2012;23(Abstract Suppl):982A. ShirazianS , SchanlerM , ShastryS , DwivediS , KumarM , RiceK , et al. The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial. Journal of Renal Nutrition2013;23(4):308-14. [MEDLINE: 23453391]">Shirazian 2013</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turmeric (curcumin) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 500 mg (22.1 mg), 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0059" title="PakfetratM , BasiriF , MalekmakanL , RoozbehJ . Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. Journal of Nephrology2014;27(2):203-7. [EMBASE: 2014347658]">Pakfetrat 2014</a>: none </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0059" title="PakfetratM , BasiriF , MalekmakanL , RoozbehJ . Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. Journal of Nephrology2014;27(2):203-7. [EMBASE: 2014347658]">Pakfetrat 2014</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fumaria parviflora versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 1000 mg, 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0002" title="AkramiR , HashempurMH , TavakoliA , NimrouziM , SayadiM , RoodakiM , et al. Effects of Fumaria parviflora L on uremic pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled trial. Jundishapur Journal of Natural Pharmaceutical Products2017;12(3 Suppl):e39744. [EMBASE: 621978284]">Akrami 2017</a>: Gastric pain (4/39), rash (1/39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0002" title="AkramiR , HashempurMH , TavakoliA , NimrouziM , SayadiM , RoodakiM , et al. Effects of Fumaria parviflora L on uremic pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled trial. Jundishapur Journal of Natural Pharmaceutical Products2017;12(3 Suppl):e39744. [EMBASE: 621978284]">Akrami 2017</a>: abdominal pain (1/40), constipation (1/40) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Senna versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: dose and frequency not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0022" title="FallahzadehMK , FaridiP , SarvestaniAK , SaghebMM , BlondinJ , MohagheghzadehA , et al. Effect of senna on reduction of uremic pruritus in hemodialysis patients: a randomized double-blind placebo-controlled trial [abstract]. American Journal of Kidney Diseases2015;65(4):A33. [EMBASE: 71875063]">Fallahzadeh 2015</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0022" title="FallahzadehMK , FaridiP , SarvestaniAK , SaghebMM , BlondinJ , MohagheghzadehA , et al. Effect of senna on reduction of uremic pruritus in hemodialysis patients: a randomized double-blind placebo-controlled trial [abstract]. American Journal of Kidney Diseases2015;65(4):A33. [EMBASE: 71875063]">Fallahzadeh 2015</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evening primrose oil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 2 capsules/day (containing 360 mg of linoleic acid, 50 mg oleic acid and 45 mg of gamma‐linoleic acid) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0089" title="Yoshimoto-FuruieK , YoshimotoK , TanakaT , SaimaS , KikuchiY , ShayJ , et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron1999;81(2):151-9. [MEDLINE: 9933750]">Yoshimoto‐Furuie 1999</a>: none </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0089" title="Yoshimoto-FuruieK , YoshimotoK , TanakaT , SaimaS , KikuchiY , ShayJ , et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron1999;81(2):151-9. [MEDLINE: 9933750]">Yoshimoto‐Furuie 1999</a>: none </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Activated charcoal versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral: 6 g/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0063" title="PedersonJA , MatterBJ , CzerwinskiAW , LlachF . Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Annals of Internal Medicine1980;93(3):446-8. [MEDLINE: 7436164]">Pederson 1980</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0063" title="PedersonJA , MatterBJ , CzerwinskiAW , LlachF . Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Annals of Internal Medicine1980;93(3):446-8. [MEDLINE: 7436164]">Pederson 1980</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Charcoal versus aluminium hydroxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Charcoal: 6 g, 3 times/day</p> <p>Aluminium hydroxide: 30 mL, 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0068" title="ShariatiA , AbbasiA , Mojer LouM , GhorbaniM . Comparison of the effects of oral charcoal capsule with aluminum hydroxide syrup on pruritus in hemodialysis patients. Journal of the Guilan University of Medical Sciences2010;18(72):22-9. ">Shariati 2010</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*when reported</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: oral and IV supplements</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011393-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: dialysis modality</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose/route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High flux/ high permeability/high flow</p> <p>HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) High‐flow HD</p> <p>(b) High‐permeability HD</p> <p>(c) High‐flux HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0003" title="AliasgharpourM , ZabolypourS , AsadinoghabiA , HaghaniH , LesanpezeshkiM . The effect of increasing blood flow rate on severity of uremic pruritus in hemodialysis patients: a single clinical trial. Journal of the National Medical Association2018;110(3):270-5. [MEDLINE: 29778130]">Aliasgharpour 2018</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0017" title="ChenZJ , CaoG , TangWX , LvXY , HuangSM , QinW , et al. A randomized controlled trial of high-permeability haemodialysis against conventional haemodialysis in the treatment of uraemic pruritus. Clinical &amp; Experimental Dermatology2009;34(6):679-83. [MEDLINE: 19175617]">Chen 2009</a> (b): not reported </p> <p><a href="./references#CD011393-bbs2-0033" title="HuiB , MinZ , Cai-lanY , GangL . Effect of high-flux dialysis membrane on uremic pruritus and solute clearance of maintenance hemodialysis patients. Journal of Clinical Rehabilitative Tissue Engineering Research2011;15(29):5493-6. [DOI: 10.3969/j.issn.1673-8225.2011.29.043]">Hui 2011</a> (c): not reported </p> <p><a href="./references#CD011393-bbs2-0034" title="JiangX , JiF , ChenZ , HuangQ . Comparison of high-flux hemodialysis with hemodialysis filtration in treatment of uraemic pruritus: a randomized controlled trial. International Urology &amp; Nephrology2016;48(9):1533-41. [MEDLINE: 27379625]">Jiang 2016</a> (c): not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0003" title="AliasgharpourM , ZabolypourS , AsadinoghabiA , HaghaniH , LesanpezeshkiM . The effect of increasing blood flow rate on severity of uremic pruritus in hemodialysis patients: a single clinical trial. Journal of the National Medical Association2018;110(3):270-5. [MEDLINE: 29778130]">Aliasgharpour 2018</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0017" title="ChenZJ , CaoG , TangWX , LvXY , HuangSM , QinW , et al. A randomized controlled trial of high-permeability haemodialysis against conventional haemodialysis in the treatment of uraemic pruritus. Clinical &amp; Experimental Dermatology2009;34(6):679-83. [MEDLINE: 19175617]">Chen 2009</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0033" title="HuiB , MinZ , Cai-lanY , GangL . Effect of high-flux dialysis membrane on uremic pruritus and solute clearance of maintenance hemodialysis patients. Journal of Clinical Rehabilitative Tissue Engineering Research2011;15(29):5493-6. [DOI: 10.3969/j.issn.1673-8225.2011.29.043]">Hui 2011</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0034" title="JiangX , JiF , ChenZ , HuangQ . Comparison of high-flux hemodialysis with hemodialysis filtration in treatment of uraemic pruritus: a randomized controlled trial. International Urology &amp; Nephrology2016;48(9):1533-41. [MEDLINE: 27379625]">Jiang 2016</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HD with haemoperfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoperfusion</p> <p>HA130‐RHA</p> <p>HA330‐RHA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0039" title="LiWH , YinYM , ChenH , WangXD , YunH , LiH , et al. Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus. Medicine2017;96(12):e6160. [MEDLINE: 28328802]">Li 2017a</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0039" title="LiWH , YinYM , ChenH , WangXD , YunH , LiH , et al. Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus. Medicine2017;96(12):e6160. [MEDLINE: 28328802]">Li 2017a</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoperfusion plus HD versus haemoperfusion plus HDF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoperfusion plus HD</p> <p>Haemoperfusion plus HDF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0092" title="ZhangJ , YuanY , AnX , OuyangC , RenH , YangG , et al. Comparison of combined blood purification techniques in treatment of dialysis patients with uraemic pruritus. International Journal of Clinical &amp; Experimental Medicine2016;9(5):8563-8. [EMBASE: 610545436]">Zhang 2016a</a> </p> <p>Haemoperfusion plus HD: not reported</p> <p>Haemoperfusion plus HDF: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Magnesium‐free HD versus standard HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard HD: 0.85 mmol/L magnesium solution for 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0014" title="CarmichaelAJ , DickinsonF , McHughMI , MartinAM , FarrowM . Magnesium free dialysis for uraemic pruritus. BMJ1988;297(6663):1584-5. [MEDLINE: 3147085]CarmichaelAJ . Investigation of a low magnesium dialysate in uraemic pruritus [abstract no: 16]. British Journal of Dermatology1988;119(Suppl 33):50. [CENTRAL: CN-00509120] ">Carmichael 1988</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0014" title="CarmichaelAJ , DickinsonF , McHughMI , MartinAM , FarrowM . Magnesium free dialysis for uraemic pruritus. BMJ1988;297(6663):1584-5. [MEDLINE: 3147085]CarmichaelAJ . Investigation of a low magnesium dialysate in uraemic pruritus [abstract no: 16]. British Journal of Dermatology1988;119(Suppl 33):50. [CENTRAL: CN-00509120] ">Carmichael 1988</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium dialysate HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium concentration</p> <p>1.0 mmol/L</p> <p>1.25 mmol/L</p> <p>1.75 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0037" title="KyriazisJ , GlotsosJ . Dialysate calcium concentration of&lt;/=1.25 mmol/l: is it effective in suppressing uremic pruritus?Nephron2000;84(1):85-6. [MEDLINE: 10644916]">Kyriazis 2000</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0037" title="KyriazisJ , GlotsosJ . Dialysate calcium concentration of&lt;/=1.25 mmol/l: is it effective in suppressing uremic pruritus?Nephron2000;84(1):85-6. [MEDLINE: 10644916]">Kyriazis 2000</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cool versus normal dialysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cool dialysate: 35.5<sup>o</sup>C, 3 times/week </p> <p>Normal dialysate: 37<sup>o</sup>C, 3 time/week </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0066" title="RadM , JaghouriE , SharifipourF , RakhshaniMH . The effects of cool dialysate on pruritus status during hemodialysis of patients with chronic renal failure: a controlled randomized clinical trial. Iranian Red Crescent Medical Journal2017;19(1):e34759. [EMBASE: 614362274]">Rad 2017</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0066" title="RadM , JaghouriE , SharifipourF , RakhshaniMH . The effects of cool dialysate on pruritus status during hemodialysis of patients with chronic renal failure: a controlled randomized clinical trial. Iranian Red Crescent Medical Journal2017;19(1):e34759. [EMBASE: 614362274]">Rad 2017</a>: not reported </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*when reported</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: dialysis modality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011393-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events: other interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose/route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control adverse effects</b> <br/><b>(dropouts/participants)*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐B exposure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(a) 0.19 nJ/cm<sup>2</sup>/sec, 3 times/week </p> <p>(b) Minimal erythema dose, twice/week</p> <p>(c) 4.4 watts/m<sup>2</sup>, twice/week </p> <p>(d) 200 mJ/cm<sup>2</sup>, 3 times/week </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0011" title="BlachleyJD , BlankenshipDM , MenterA , Parker TF 3rd, KnochelJP . Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. American Journal of Kidney Diseases1985;5(5):237-41. [MEDLINE: 4003393]">Blachley 1985</a> (a): not reported </p> <p><a href="./references#CD011393-bbs2-0015" title="ChanCM , LeungCY , LamTY , LoKK , TongKL . Use of phototherapy (UVB) in the treatment uraemic pruritus, a randomized controlled trial [abstract no: OP2-3]. In: 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995:28. [CENTRAL: CN-00460521] ">Chan 1995</a> (b): not reported </p> <p><a href="./references#CD011393-bbs2-0028" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Relief of uremic pruritus with ultraviolet phototherapy. New England Journal of Medicine1977;297(3):136-8. [MEDLINE: 865585]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1977</a> (c): sunburn (3/10), tanning (5/10) </p> <p><a href="./references#CD011393-bbs2-0029" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Annals of Internal Medicine1979;91(1):17-21. [MEDLINE: 464448]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1979</a> (c): mild sunburn and tanning </p> <p><a href="./references#CD011393-bbs2-0035" title="KoMJ , YangJY , WuHY , HuFC , ChenSI , TsaiPJ , et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. British Journal of Dermatology2011;165(3):633-9. [MEDLINE: 21668425]">Ko 2011</a> (d): erythema (2/11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0011" title="BlachleyJD , BlankenshipDM , MenterA , Parker TF 3rd, KnochelJP . Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. American Journal of Kidney Diseases1985;5(5):237-41. [MEDLINE: 4003393]">Blachley 1985</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0015" title="ChanCM , LeungCY , LamTY , LoKK , TongKL . Use of phototherapy (UVB) in the treatment uraemic pruritus, a randomized controlled trial [abstract no: OP2-3]. In: 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995:28. [CENTRAL: CN-00460521] ">Chan 1995</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0028" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Relief of uremic pruritus with ultraviolet phototherapy. New England Journal of Medicine1977;297(3):136-8. [MEDLINE: 865585]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1977</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0029" title="GilchrestBA , RoweJW , BrownRS , SteinmanTI , ArndtKA . Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Annals of Internal Medicine1979;91(1):17-21. [MEDLINE: 464448]GilchrestBA . Ultraviolet phototherapy of uremic pruritus. International Journal of Dermatology1979;18(9):741-8. [MEDLINE: 511436]">Gilchrest 1979</a>: not reported </p> <p><a href="./references#CD011393-bbs2-0035" title="KoMJ , YangJY , WuHY , HuFC , ChenSI , TsaiPJ , et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. British Journal of Dermatology2011;165(3):633-9. [MEDLINE: 21668425]">Ko 2011</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐A exposure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐A (exposure): 40 min exposure (10, 180 cm 85W UV‐A lamps) 3 times/week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0083" title="TaylorR , TaylorAE , DiffeyBL , HindsonTC . A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. Nephron1983;33(1):14-6. [MEDLINE: 6339963]">Taylor 1983</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0083" title="TaylorR , TaylorAE , DiffeyBL , HindsonTC . A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. Nephron1983;33(1):14-6. [MEDLINE: 6339963]">Taylor 1983</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thermal therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40<sup>o</sup>C thermal therapy, twice/week </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0032" title="HsuMC , ChenHW , HwuYJ , ChancCM , LiuCF . Effects of thermal therapy on uremic pruritus and biochemical parameters in patients having haemodialysis. Journal of Advanced Nursing2009;65(11):2397-408. [MEDLINE: 19737321]">Hsu 2009</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0032" title="HsuMC , ChenHW , HwuYJ , ChancCM , LiuCF . Effects of thermal therapy on uremic pruritus and biochemical parameters in patients having haemodialysis. Journal of Advanced Nursing2009;65(11):2397-408. [MEDLINE: 19737321]">Hsu 2009</a>: not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐B exposure versus cetirizine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UV‐B</p> <p>Whole body: 200 to 1038 mJ/cm<sup>2</sup> every 3rd day for 15 sessions </p> <p>Cetirizine</p> <p>Oral: 10 mg/day for the same duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011393-bbs2-0069" title="SherjeenaPB , BinithaMP , RajanU , SreelathaM , SaritaS , NirmalC , et al. A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus. Indian Journal of Dermatology, Venereology &amp; Leprology2017;83(2):247-9. [MEDLINE: 28164894]">Sherjeena 2017</a>: not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*when reported</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events: other interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/full#CD011393-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011393-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pharmacological interventions (oral or IV)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Itch <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 GABA analogues</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.14 [‐2.43, ‐1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 GABA analogues versus antihistamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐0.75, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Ondansetron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.49, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Kappa‐opioid agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.60, ‐0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 Mu‐opioid antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.10 [‐11.05, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.6 Nalbuphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.54, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.7 Cromolyn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.31 [‐2.00, ‐0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.8 Nicotinamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [‐0.23, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.9 EPO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.39, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.10 Cholestyramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.89, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.11 Montelukast</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐1.87, ‐0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.12 Sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐1.15, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.13 Lidocaine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐1.87, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.14 Gabapentin versus pregabalin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.61, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.15 GABA analogues versus doxepin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.84 [‐1.33, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Itch (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Lidocaine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Thalidomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Doxepin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pharmacological interventions (oral or IV)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011393-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical interventions</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Itch <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Capsaicin cream</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.84 [‐1.22, ‐0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Pramoxine cream</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐1.11, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Calcineurin Inhibitor cream</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [‐0.13, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Dead Sea lotion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐1.14, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 Cromolyn cream</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐0.85, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.6 Baby oil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.87 [‐1.32, ‐0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.7 L‐arginine salve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.82, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.8 Polyunsaturated fatty acids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.91 [‐1.99, 0.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011393-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral or IV supplements</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Itch <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Polyunsaturated fatty acids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.30 [‐19.01, ‐3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 L‐carnitine (IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐2.85, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Zinc sulfate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.77 [‐2.88, ‐0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Ergocalciferol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐2.48, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 Turmeric</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.40 [‐7.42, ‐5.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.6 Fumaria parviflora</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.90 [‐5.04, ‐2.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral or IV supplements</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011393-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Haemodialysis modality</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Itch <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 High flux or permeability HD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.62 [‐3.72, ‐1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 NMR haemoperfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.37 [‐2.89, ‐1.85]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Haemodialysis modality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011393-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Other interventions</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Itch <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 UV‐B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.06 [‐8.40, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Thermal therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.06 [‐6.54, 2.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Other interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011393-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Cross‐over studies with paired data</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Cholestyramine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.86, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Cross‐over studies with paired data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011393.pub2/references#CD011393-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011393.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011393-note-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011393-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011393-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011393-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD011393-note-0013">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011393-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD011393-note-0014">ภาษาไทย</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011393\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011393\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011393\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011393\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011393\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011393.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011393.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011393.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011393.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011393.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728536853"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011393.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728536857"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011393.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec6dff8b0f431',t:'MTc0MDcyODUzNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 